<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Medical methods for first trimester abortion - Zhang, J - 2022 | Cochrane Library</title> <meta content="Medical methods for first trimester abortion - Zhang, J - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002855.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Medical methods for first trimester abortion - Zhang, J - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002855.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002855.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Medical methods for first trimester abortion" name="citation_title"/> <meta content="Jing Zhang" name="citation_author"/> <meta content="Kunyan Zhou" name="citation_author"/> <meta content="zhoukunyan2006@126.com" name="citation_author_email"/> <meta content="Dan Shan" name="citation_author"/> <meta content="Xiaoyan Luo" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD002855.pub5" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002855.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002855.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002855.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Abortifacient Agents, Nonsteroidal [adverse effects]; *Abortion, Spontaneous [chemically induced]; Diarrhea [chemically induced]; Drug Therapy, Combination; Estradiol; Letrozole; Methotrexate; Mifepristone [adverse effects]; *Misoprostol; *Oxytocics; Pregnancy Trimester, First; Prostaglandins; Tamoxifen" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002855.pub5&amp;doi=10.1002/14651858.CD002855.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="QO4KtYGW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002855\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002855\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","ja","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002855.pub5",title:"Medical methods for first trimester abortion",firstPublishedDate:"May 24, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Fertility Regulation Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002855.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002855.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002855.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002855.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002855.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002855.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002855.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002855.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002855.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002855.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>304505 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002855.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/appendices#CD002855-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/table_n/CD002855StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/table_n/CD002855StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Medical methods for first trimester abortion</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information#CD002855-cr-0004">Jing Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information#CD002855-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Kunyan Zhou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information#CD002855-cr-0006">Dan Shan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information#CD002855-cr-0007">Xiaoyan Luo</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information/en#CD002855-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002855.pub5">https://doi.org/10.1002/14651858.CD002855.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002855-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002855-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002855-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002855-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD002855-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002855-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002855-abs-0001" lang="en"> <section id="CD002855-sec-0001"> <h3 class="title" id="CD002855-sec-0001">Background</h3> <p>Medical abortion became an alternative method of pregnancy termination following the development of prostaglandins and antiprogesterone in the 1970s and 1980s. Recently, synthesis inhibitors of oestrogen (such as letrozole) have also been used to enhance efficacy. The most widely researched drugs are prostaglandins (such as misoprostol, which has a strong uterotonic effect), mifepristone, mifepristone with prostaglandins, and letrozole with prostaglandins. More evidence is needed to identify the best dosage, regimen, and route of administration to optimise patient outcomes. This is an update of a review last published in 2011. </p> </section> <section id="CD002855-sec-0002"> <h3 class="title" id="CD002855-sec-0002">Objectives</h3> <p>To compare the effectiveness and side effects of different medical methods for first trimester abortion. </p> </section> <section id="CD002855-sec-0003"> <h3 class="title" id="CD002855-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, Global Health, and LILACs on 28 February 2021. We also searched Clinicaltrials.gov and the World Health Organization's (WHO) International Clinical Trials Registry Platform, and reference lists of retrieved papers. </p> </section> <section id="CD002855-sec-0004"> <h3 class="title" id="CD002855-sec-0004">Selection criteria</h3> <p>We considered randomised controlled trials (RCTs) that compared different medical methods for abortion before the 12th week of gestation. The primary outcome is failure to achieve complete abortion. Secondary outcomes are mortality, surgical evacuation, ongoing pregnancy at follow‐up, time until passing of conceptus, blood transfusion, side effects and women's dissatisfaction with the method. </p> </section> <section id="CD002855-sec-0005"> <h3 class="title" id="CD002855-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected and evaluated studies for inclusion, and assessed the risk of bias. We processed data using Review Manager 5 software. We assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD002855-sec-0006"> <h3 class="title" id="CD002855-sec-0006">Main results</h3> <p>We included 99 studies in the review (58 from the original review and 41 new studies).</p> <p><b>1. Combined regimen mifepristone/prostaglandin</b> </p> <p>Mifepristone dose: high‐dose (600 mg) compared to low‐dose (200 mg) mifepristone probably has similar effectiveness in achieving complete abortion (RR 1.07, 95% CI 0.87 to 1.33; I<sup>2</sup> = 0%; 4 RCTs, 3494 women; moderate‐certainty evidence). </p> <p>Prostaglandin dose: 800 µg misoprostol probably reduces abortion failure compared to 400 µg (RR 0.63, 95% CI 0.51 to 0.78; I<sup>2</sup>= 0%; 3 RCTs, 4424 women; moderate‐certainty evidence). </p> <p>Prostaglandin timing: misoprostol administered on day one probably achieves more success on complete abortion than on day three (RR 1.94, 95% CI 1.05 to 3.58; 1489 women; 1 RCT; moderate‐certainty evidence). </p> <p>Administration strategy: there may be no difference in failure of complete abortion with self‐administration at home compared with hospital administration (RR 1.63, 95% CI 0.68 to 3.94; I<sup>2</sup> = 84%; 2263 women; 4 RCTs; low‐certainty evidence), but failure may be higher when administered by nurses in hospital compared to by doctors in hospital (RR 2.69, 95% CI 1.39 to 5.22; I<sup>2</sup> = 66%; 3 RCTs, 3056 women; low‐certainty evidence). </p> <p>Administration route: oral misoprostol probably leads to more failures than the vaginal route (RR 2.38, 95% CI 1.46 to 3.87; I<sup>2</sup> = 39%; 3 RCTs, 1704 women; moderate‐certainty evidence) and may be associated with more frequent side effects such as nausea (RR 1.14, 95% CI 1.03 to 1.26; I<sup>2</sup> = 0%; 2 RCTs, 1380 women; low‐certainty evidence) and diarrhoea (RR 1.80 95% CI 1.49 to 2.17; I<sup>2</sup> = 0%; 2 RCTs, 1379 women). Compared with the vaginal route, complete abortion failure is probably lower with sublingual (RR 0.68, 95% CI 0.22 to 2.11; I<sup>2</sup> = 59%; 2 RCTs, 3229 women; moderate‐certainty evidence) and may be lower with buccal administration (RR 0.71, 95% CI 0.34 to 1.46; I<sup>2</sup> = 0%; 2 RCTs, 479 women; low‐certainty evidence), but sublingual or buccal routes may lead to more side effects. Women may experience more vomiting with sublingual compared to buccal administration (RR 1.33, 95% CI 1.01 to 1.77; low‐certainty evidence). </p> <p><b>2. Mifepristone alone versus combined regimen</b> </p> <p>The efficacy of mifepristone alone in achieving complete abortion compared to combined mifepristone/prostaglandin up to 12 weeks is unclear (RR of failure 3.25, 95% CI 0.81 to 13.09; I<sup>2</sup> = 83%; 3 RCTs, 273 women; very low‐certainty evidence). </p> <p><b>3. Prostaglandin alone versus combined regimen</b> </p> <p>Nineteen studies compared prostaglandin alone to a combined regimen (prostaglandin combined with mifepristone, letrozole, estradiol valerate, tamoxifen, or methotrexate). Compared to any of the combination regimens, misoprostol alone may increase the risk for failure to achieve complete abortion (RR of failure 2.39, 95% CI 1.89 to 3.02; I<sup>2</sup> = 64%; 18 RCTs, 3471 women; low‐certainty evidence), and with more diarrhoea. </p> <p><b>4. Prostaglandin alone (route of administration)</b> </p> <p>Oral misoprostol alone may lead to more failures in complete abortion than the vaginal route (RR 3.68, 95% CI 1.56 to 8.71, 2 RCTs, 216 women; low‐certainty evidence). Failure to achieve complete abortion may be slightly reduced with sublingual compared with vaginal (RR 0.69, 95% CI 0.37 to 1.28; I<sup>2</sup> = 87%; 5 RCTs, 2705 women; low‐certainty evidence) and oral administration (RR 0.58, 95% CI 0.11 to 2.99; I<sup>2</sup> = 66%; 2 RCTs, 173 women). Failure to achieve complete abortion may be similar or slightly higher with sublingual administration compared to buccal administration (RR 1.11, 95% CI 0.71 to 1.74; 1 study, 401 women). </p> </section> <section id="CD002855-sec-0007"> <h3 class="title" id="CD002855-sec-0007">Authors' conclusions</h3> <p>Safe and effective medical abortion methods are available. Combined regimens (prostaglandin combined with mifepristone, letrozole, estradiol valerate, tamoxifen, or methotrexate) may be more effective than single agents (prostaglandin alone or mifepristone alone). In the combined regimen, the dose of mifepristone can probably be lowered to 200 mg without significantly decreasing effectiveness. Vaginal misoprostol is probably more effective than oral administration, and may have fewer side effects than sublingual or buccal. Some results are limited by the small numbers of participants on which they are based. Almost all studies were conducted in settings with good access to emergency services, which may limit the generalisability of these results. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002855-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002855-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002855-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002855-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002855-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002855-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002855-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002855-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD002855-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002855-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002855-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002855-abs-0002" lang="en"> <h3>Are medical methods for early termination of pregnancy effective and do they cause unwanted effects? </h3> <p><b>Key messages</b><br/>‐ Medical abortion is a safe and effective way to terminate pregnancy in the first three months. </p> <p>‐ Mifepristone combined with misoprostol is more effective than using these medications on their own. </p> <p>‐ Misoprostol is more effective when placed in the vagina than when swallowed, and is less uncomfortable than placing it under the tongue or in the cheek. </p> <p><b>What is medical abortion?</b> </p> <p>Medical abortion uses one or more medicines alone or in combination to end a pregnancy. The most common medicines are the hormones prostaglandin and mifepristone. Other medicines include methotrexate (a kind of chemotherapy), and letrozole, which slows the production of the hormone oestrogen. These medicines work by softening the cervix (neck of the womb) and causing the uterus (womb) to contract. They may be swallowed (taken orally), put under the tongue or in the cheek, or put in the vagina. They can be given by a nurse or a doctor in hospital, or taken by women at home. </p> <p>Medical abortion methods may cause unwanted effects such as heavy bleeding, pain, nausea, vomiting and diarrhoea, Failed abortion is an infrequent but important complication of medical abortion. Medical methods for early abortion are already widely available in some countries, and new medicines are being developed. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out which medicines were most successful in achieving complete abortion in the first three months of pregnancy, and if the dose or way they were given made a difference. We also wanted to know if there were any unwanted effects </p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated different medicines, doses and ways of giving the medicines to women having medical abortion in the first three months of pregnancy.<br/><br/><b>Study characteristics</b> </p> <p>We included 99 studies that investigated 24 different medicine combinations, doses, and ways of giving the medicine. </p> <p><b>Main results</b> </p> <p>Misoprostol put into the vagina is probably more effective to achieve abortion than taken orally, and may be associated with less stomach discomfort than if put under the tongue or between the tongue and cheek. Misoprostol alone and mifepristone alone may result in more failed abortions than misoprostol and mifepristone taken together. There may be little or no difference in the success rate of abortions based on whether the medicines are given at home or in hospital, the dosage of mifepristone, or single versus repeated doses of prostaglandin. However, abortions may be more successful if the medicines are given by a doctor in hospital rather than a nurse in hospital. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Overall, our confidence in the evidence is limited or very limited for several reasons. Most studies included enough participants and used adequate methods to select them and allocate them to a particular treatment. However, it was difficult to ensure that they and the doctors treating them didn't know what treatment they had received. Several studies did not publish their aims before they started, so it is hard to evaluate whether they measured and reported all their points of interest. Almost all the studies took place in high‐income countries, where women can return for a check‐up. We don't know if results would have been different in low‐income countries. </p> <p><b>How up to date is the evidence?</b><br/>This is a update of a review last published in 2011. The evidence is up to date to February 2021. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002855-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002855-sec-0105"></div> <h3 class="title" id="CD002855-sec-0106">Implications for practice</h3> <section id="CD002855-sec-0106"> <p>The available data from this review demonstrates that the combination mifepristone/misoprostol is probably the most effective abortion method in the first trimester. Effectiveness is probably not reduced by lowering the currently licensed dose of 600 mg of mifepristone to 200 mg. Vaginal misoprostol is probably more effective than oral administration, and may have fewer side effects than sublingual or buccal misoprostol. This review does not address introducing medical abortion where back‐up facilities are not available and women are less likely to attend for the follow‐up. </p> </section> <h3 class="title" id="CD002855-sec-0107">Implications for research</h3> <section id="CD002855-sec-0107"> <p>Letrozole in combination with a prostaglandin may be an alternative to the mifepristone/prostaglandin regimen in places where mifepristone is either unaffordable or unavailable. However, further research should be conducted to compare the letrozole/prostaglandin combination regimen with the standard mifepristone/prostaglandin regimen. </p> <p>Some important outcomes relating to efficacy and safety of medical abortion should be reported in greater detail, including conceptus expulsion time, bleeding volume, and number of women needing additional uterotonics in each intervention group. </p> <p>One of the most common and severe complication of medication abortion is blood loss requiring a blood transfusion, this important outcome should be reported in all future studies on medical abortion. </p> <p>Time and cost expenditure, and time to return to menstruation are not reported by previously published studies; these outcomes are important to women and should be further evaluated in future studies. </p> <p>There are scarce data on issues such as which method is preferable when addressing specific side effects, bleeding patterns, acceptability or the financial impact of the different methods. </p> <p>Good‐quality acceptability studies are important to investigate the components of medical abortion regimens that affect acceptability in different settings. </p> <p>There are still few studies on medical abortion in settings where back‐up facilities are not available and women are less likely to attend for follow‐up. For example, medical abortion in low‐income countries, where women may be less likely to follow up to evaluate efficacy and safety after they have received abortion medicine. </p> <p>The follow‐up duration for measuring outcomes of medical abortion was heterogeneous among the included studies. Further research is needed to determine the most clinically meaningful time point for measuring study outcomes, and also to understand the benefits, risks, and time and cost expenditures associated with required clinical follow‐up visits following medical abortion. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002855-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002855-sec-0008"></div> <div class="table" id="CD002855-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mifepristone (600 mg) plus prostaglandin versus mifepristone (200 mg) plus prostaglandin for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mifepristone (600 mg) combined with prostaglandin compared to mifepristone (200 mg) combined with prostaglandin for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> mifepristone (600 mg) combined with prostaglandin<br/><b>Comparison:</b> mifepristone (200 mg) combined with prostaglandin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with mifepristone (200 mg) combined with prostaglandin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with mifepristone (600 mg) combined with prostaglandin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.87 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3494<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000<br/>(75 to 114) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.95 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2432<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>459 per 1000<br/>(428 to 491) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency of intervention. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Misoprostol 800 µg plus mifepristone 200 mg versus misoprostol 400 µg plus mifepristone 200 mg for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Misoprostol (800 µg) compared to misoprostol (400 µg) for first trimester abortion as combined with mifepristone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> misoprostol 800 µg combined with mifepristone 200 mg<br/><b>Comparison:</b> misoprostol 400 µg combined with mifepristone 200 mg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with misoprostol 400 µg combined with mifepristone 200 mg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with misoprostol 800 µg combined with mifepristone 200 mg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.51 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4424<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/>(48 to 73) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.94 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4424<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>479 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000<br/>(450 to 503) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.60 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4420<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/>(49 to 76) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency of intervention. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Medical abortion self‐administered at home compared to administered in hospital for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Medical abortion self‐administered at home compared to administered in hospital for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> at home or hospital outpatient<br/><b>Intervention:</b> self‐administered at home<br/><b>Comparison:</b> administered in hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with hospital‐administered</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with self‐administered at home</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.63<br/>(0.68 to 3.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2263<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(34 to 199) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/>(0.74 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1532<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>258 per 1000<br/>(175 to 380) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.63<br/>(0.95 to 2.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2155<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(48 to 140) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/>(0.01 to 8.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>731<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 22) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded two levels due to risk of bias, as unclear randomisation method, no allocation concealment, no blinding.<br/><sup>d</sup>Downgraded one level due to imprecision, as the 95% confidence intervals is wide and overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Medical abortion administered by nurses compared to by doctors for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Medical abortion administrated by nurses compared to by doctors for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> administrated by nurses<br/><b>Comparison:</b> administrated by doctors </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with administrated by doctors</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with administrated by nurses</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.69<br/>(1.39 to 5.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3056<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(35 to 133) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.70<br/>(0.16 to 44.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1988<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(1 to 266) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1068<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded one level due to imprecision, as the 95% confidence interval is wide and overlaps no effect.<br/><sup>d</sup>Downgraded two levels due to risk of bias, as no blinding and attrition. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Oral misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Oral misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> oral mifepristone and oral misoprostol<br/><b>Comparison:</b> oral mifepristone and vaginal misoprostol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vaginal misoprostol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral misoprostol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.38<br/>(1.46 to 3.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1704<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000<br/>(63 to 168) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(1.03 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1380<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>482 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>549 per 1000<br/>(496 to 607) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sublingual misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Sublingual misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> oral mifepristone and sublingual misoprostol<br/><b>Comparison:</b> oral mifepristone and vaginal misoprostol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vaginal misoprostol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with sublingual misoprostol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/>(0.22 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3229<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/>(19 to 180) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.93 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3543<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>595 per 1000<br/>(499 to 713) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.67<br/>(0.80 to 3.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3303<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<br/>(52 to 230) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency of intervention. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mifepristone alone compared to mifepristone/prostaglandin for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mifepristone alone compared to mifepristone/prostaglandin for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> mifepristone alone<br/><b>Comparison:</b> mifepristone/prostaglandin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with mifepristone/prostaglandin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with mifepristone alone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.25<br/>(0.81 to 13.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>273<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>451 per 1000<br/>(113 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded one level due to imprecision, as the 95% confidence interval is wide and overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Prostaglandin alone compared to combined regimen for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Prostaglandin alone compared to combined regimen for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> prostaglandin alone<br/><b>Comparison:</b> combined regimen </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with combined regimen</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prostaglandin alone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.39<br/>(1.89 to 3.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3471<br/>(18 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>323 per 1000<br/>(255 to 408) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.74 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2722<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>412 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000<br/>(305 to 453) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.65<br/>(0.75 to 3.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1485<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>209 per 1000<br/>(95 to 461) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/>(0.03 to 3.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/>(1 to 63) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded one level due to imprecision and small sample size, as the 95% confidence interval is wide and overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Oral misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> oral misoprostol alone<br/><b>Comparison:</b> vaginal misoprostol alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vaginal misoprostol alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral misoprostol alone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.68<br/>(1.56 to 8.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>216<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000<br/>(83 to 462) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.21<br/>(0.92 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>216<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1000<br/>(261 to 456) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.25<br/>(0.65 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/>(156 to 574) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to imprecision and small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002855-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sublingual misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Sublingual misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> sublingual misoprostol alone<br/><b>Comparison:</b> vaginal misoprostol alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vaginal misoprostol alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with sublingual misoprostol alone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/>(0.37 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2705<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1000<br/>(74 to 254) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.61<br/>(0.78 to 3.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2505<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>226 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1000<br/>(176 to 753) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.14<br/>(0.07 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a, c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>464 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/>(32 to 134) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00 <br/>(0.24 to 102.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220 <br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝ <br/>Very low <sup>a, d</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 <br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded one level due to imprecision and small sample size.<br/><sup>d</sup> Downgraded two levels due to imprecision and small sample size, as the 95% confidence interval is wide and overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002855-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002855-sec-0009"></div> <section id="CD002855-sec-0010"> <h3 class="title" id="CD002855-sec-0010">Description of the condition</h3> <p>It is estimated that around 40 million abortions occur every year, either legal or illegal, resulting in an abortion rate of 35 per 1000 women (<a href="./references#CD002855-bbs2-0245" title="SedghG , BearakJ , SinghS , BankoleA , PopinchalkA , GanatraB , et al.Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. Lancet2016;388(10041):258-67.">Sedgh 2016</a>). Medical abortion has the potential to expand abortion services, where surgical services are limited, and to expand women's choice of abortion method and experience. </p> </section> <section id="CD002855-sec-0011"> <h3 class="title" id="CD002855-sec-0011">Description of the intervention</h3> <p>Medical abortion became an alternative method of pregnancy termination with the availability of prostaglandins in the early 1970s followed by the development of an antiprogesterone in the 1980s. Large, uncontrolled studies suggested that early medical abortion with mifepristone and a prostaglandin would be an effective method for pregnancy termination (<a href="./references#CD002855-bbs2-0248" title="UrquhartDR , TempletonAA , ShinewiF , ChapmanM , HawkinsK , McGarryJ .The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation: UK multicentre study - final results. Contraception1997;55:1-5.">Urquhart 1997</a>). </p> <p>Various drugs have been used for first trimester medical abortion. The most widely researched are prostaglandins alone, mifepristone alone, methotrexate alone, mifepristone with prostaglandins and methotrexate with prostaglandins. Prostaglandins soften the cervix, cause uterine contractions and are used orally (swallowed; put on sublingual mucosa or buccal mucosa) or vaginally (put on vaginal mucosa) for ripening the cervix before surgical or medical abortion. The most commonly used prostaglandins are misoprostol administered either orally or vaginally. </p> </section> <section id="CD002855-sec-0012"> <h3 class="title" id="CD002855-sec-0012">How the intervention might work</h3> <p>Misoprostol is a prostaglandin analogue registered for use in nonsteroidal anti‐inflammatory drug (NSAID)‐induced gastric ulcer prevention and treatment. It has a strong uterotonic effect and is used alone to induce pregnancy terminations, illegally in some parts of the world (<a href="./references#CD002855-bbs2-0220" title="BlanchardK , WinikoffB , EllertsonC .Misoprostol used alone for the termination of early pregnancy. Contraception1999;59:209-17.">Blanchard 1999</a>; <a href="./references#CD002855-bbs2-0226" title="CostaSH .Commercial availability of misoprostol and induced abortion in Brazil. International Journal of Gynaecology and Obstetrics1998;63 Suppl 1:S:131-9.">Costa 1998</a>), as well as legally, in areas where mifepristone is not available. The reported complete abortion rate for misoprostol alone varies between 61% for single use and 93% for repeat doses (<a href="./references#CD002855-bbs2-0221" title="BugalhoA , FaundesA , JamisseL , UsfaM , MariaE , BiqueC .Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. Contraception1996;53:243-6.">Bugalho 1996</a>; <a href="./references#CD002855-bbs2-0224" title="CarbonellJL , VarelaL , VelazcoA , FernandezC .The use of misoprostol for termination of early pregnancy. Contraception1997;55:165-8.">Carbonell 1997a</a>). Gemeprost used alone appears to be less effective in inducing complete abortion than when used in combination with mifepristone (<a href="./references#CD002855-bbs2-0174" title="NormanJE , ThongKJ , RodgerMW , BairdDT .Medical abortion in women of &lt;56 days amenorrhoea: a comparison between gemeprost (a PGE1 analogue) alone and mifepristone and gemeprost. British Journal of Obstetrics and Gynaecology1992;99:601-6. ">Norman 1992</a>). </p> <p>Mifepristone, an antiprogestogen, blocks the receptors for progesterone and glucocorticosteroid and increases the sensitivity of the uterus to prostaglandins (<a href="./references#CD002855-bbs2-0222" title="BygdemanM , SwahnML .Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception1985;32:45-51.">Bygdeman 1985</a>). This blockage results in the breakdown of maternal capillaries in the decidua, the synthesis of prostaglandins by the epithelium of decidual glands and inhibition of prostaglandin dehydrogenase (<a href="./references#CD002855-bbs2-0249" title="WHO Scientific Group.Medical methods for termination of pregnancy. Report of a WHO Scientific Group. WHO Technical Report Series. WHO edition. Vol. 871. Geneva: WHO, 1997.">WHO 1997</a>). </p> <p>Mifepristone has been licensed in France and China since 1988, in the UK since 1991 and, in the USA and India since 2000 and 2002, respectively. Mifepristone given alone has been shown to result in abortion only in 60% to 80% of cases, depending on the gestational age and the dose given (<a href="./references#CD002855-bbs2-0249" title="WHO Scientific Group.Medical methods for termination of pregnancy. Report of a WHO Scientific Group. WHO Technical Report Series. WHO edition. Vol. 871. Geneva: WHO, 1997.">WHO 1997</a>). However, in combination with a prostaglandin at up to 63 days of amenorrhoea, it leads to complete abortion in about 95% of pregnancies or more. The effect of mifepristone develops over a time period of 24 to 48 hours; therefore, prostaglandins have usually been administered after 36 to 48 hours. Currently, different regimens are in use. The recommended regimen by the manufacturer is mifepristone 600 mg followed by misoprostol (between 400 µg to 800 µg) or gemeprost (0.5 mg to 1 mg vaginally) and is registered for abortion in pregnancies up to 49 days in France and up to 63 days of amenorrhoea in the UK. However, a reduced dose of mifepristone combined with a prostaglandin has similar effectiveness and has the advantage of being much less expensive (<a href="./references#CD002855-bbs2-0249" title="WHO Scientific Group.Medical methods for termination of pregnancy. Report of a WHO Scientific Group. WHO Technical Report Series. WHO edition. Vol. 871. Geneva: WHO, 1997.">WHO 1997</a>). </p> <p>Methotrexate has been used successfully for the treatment of unruptured tubal pregnancy. It is a folic acid antagonist that inhibits purine and pyrimidine synthesis and is cytotoxic to the trophoblast. The use of methotrexate with misoprostol for first trimester abortion was first introduced in 1993 (<a href="./references#CD002855-bbs2-0228" title="CreininMD , DarneyPD .Methotrexate and misoprostol for early abortion. Contraception1993;48:339-48.">Creinin 1993</a>; <a href="./references#CD002855-bbs2-0232" title="GrimesDA .Medical abortion in early pregnancy: a review of the evidence. Obstetrics and Gynecology1997;89:790-6.">Grimes 1997</a>). This combination was more effective when misoprostol was administered seven days after methotrexate compared to three days, leading to a complete abortion rate of 98% (<a href="./references#CD002855-bbs2-0020" title="CreininMD , VittinghoffE , GalbraithS , KlaisleC .A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. American Journal of Obstetrics and Gynecology1995;173:1578-84. ">Creinin 1995</a>). </p> <p>Letrozole is one of the aromatase inhibitors, which is used to block the synthesis of oestrogen, and stimulate ovulation. It is suggested that prescription of aromatase inhibitors prior to misoprostol or mifepristone for inducing medical abortion, might increase efficiency of the treatment regimen and decrease the need for surgical interventions (<a href="./references#CD002855-bbs2-0251" title="YeungTW , LeeVC , NgEH , HoPC .A pilot study on the use of a 7-day course of letrozole followed by misoprostol for the termination of early pregnancy up to 63 days. Contraception2012;86:763-9.">Yeung 2012</a>). </p> </section> <section id="CD002855-sec-0013"> <h3 class="title" id="CD002855-sec-0013">Why it is important to do this review</h3> <p>Side‐effects of medical methods are heavy bleeding, pain, nausea, vomiting and diarrhoea, varying in severity according to the protocols and gestational age (<a href="./references#CD002855-bbs2-0217" title="BaijuN , AcharyaG , D'AntonioF , BergRC .Effectiveness, safety and acceptability of self-assessment of the outcome of first-trimester medical abortion: a systematic review and meta-analysis. BJOG2019;126(13):1536-44.">Baiju 2019</a>). In two studies included in the Cochrane Review of the topic, compared to surgical procedures, medical methods are associated with a longer duration of bleeding (<a href="./references#CD002855-bbs2-0243" title="SayL , KulierR , GulmezogluAM , CampanaA .Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD003037. [CENTRAL: CD003037] [DOI: 10.1002/14651858.CD003037.pub2]">Say 2010</a>). </p> <p>Failed abortion is an infrequent but important complication of medical abortion. Both methotrexate and misoprostol may lead to fetal anomalies if the pregnancy persists (<a href="./references#CD002855-bbs2-0232" title="GrimesDA .Medical abortion in early pregnancy: a review of the evidence. Obstetrics and Gynecology1997;89:790-6.">Grimes 1997</a>). However, other reports state that none of the malformations reported could be conclusively related to medications used for medical abortion (<a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a>). </p> <p>Some women prefer medical to surgical abortion. Reasons some women opted for a medical abortion included 'more natural', 'being easier', 'more private', and 'can be done earlier in pregnancy' (<a href="./references#CD002855-bbs2-0229" title="CreininMD , BurkeAE .Methotrexate and misoprostol for early abortion: a multicenter trial. Acceptability. Contraception1996;54:19-22.">Creinin 1996</a>). Characteristics such as the method being newer, less invasive and the possibility of verifying the expulsion were reported by others (<a href="./references#CD002855-bbs2-0216" title="BachelotA , CludyL , SpiraA .Conditions for choosing between drug-induced and surgical abortions. Contraception1992;45:547-59.">Bachelot 1992</a>). </p> <p>Medical methods for first trimester abortion are already widely available in some countries and increasingly available throughout the world. New medication has been identified for use in medical abortion, it is therefore important to identify the best available agents and regimen for use. This review is an update of a previous review, which was first published in 2004, and updated twice, in 2004 and 2011. Comparison of medical methods with surgical evacuation in the first trimester is the subject of another Cochrane Review, <a href="./references#CD002855-bbs2-0243" title="SayL , KulierR , GulmezogluAM , CampanaA .Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD003037. [CENTRAL: CD003037] [DOI: 10.1002/14651858.CD003037.pub2]">Say 2010</a>. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002855-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002855-sec-0014"></div> <p>To compare the effectiveness and side effects of different medical methods for first trimester abortion. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002855-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002855-sec-0015"></div> <section id="CD002855-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002855-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) that compared different medical methods (e.g. single drug or combined, ways of application, or different dose regimens for medical abortion. </p> </section> <section id="CD002855-sec-0018"> <h4 class="title">Types of participants</h4> <p>Women, pregnant in the first trimester, undergoing medical abortion.</p> </section> <section id="CD002855-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Different medical methods used for first trimester abortion, compared with each other.</p> </section> <section id="CD002855-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD002855-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>The main outcome measure was failure to achieve complete abortion two weeks after medical abortion. </p> <p>Sonography was performed to verify abortion completion. If the sonographer reported that the uterus was empty, with no products of conception identified, complete success and efficacy of the drug were recorded. </p> </section> <section id="CD002855-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>We also assessed other unwanted outcomes, such as side effects:</p> <p> <ul id="CD002855-list-0001"> <li> <p>surgical evacuation (as emergency procedure, non‐emergency procedure, or undefined);</p> </li> <li> <p>ongoing pregnancy at follow‐up, time until passing of conceptus (greater than three to six hours); </p> </li> <li> <p>blood transfusion;</p> </li> <li> <p>blood loss (measured or clinically relevant drop in haemoglobin);</p> </li> <li> <p>days of bleeding;</p> </li> <li> <p>pain resulting from the procedure (reported by the women or measured by use of analgesics, especially for abdominal pain); </p> </li> <li> <p>additional uterotonics used (reported as repeated medical abortion in some studies);</p> </li> <li> <p>women's dissatisfaction with the procedure;</p> </li> <li> <p>Nausea;</p> </li> <li> <p>Vomiting;</p> </li> <li> <p>Diarrhoea.</p> </li> </ul> </p> <p>Although mortality is considered an important outcome, we did not anticipate analysing abortion‐related mortality within the context of these studies. To date, no studies have reported mortality. </p> </section> </section> </section> <section id="CD002855-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane Fertility Regulation Information Specialist conducted a search for all published, unpublished, and ongoing studies, without restrictions on language or publication status. The search strategies for each database were modelled on the updated search strategy designed for MEDLINE ALL (all update search strategies are available in <a href="./appendices#CD002855-sec-0111">Appendix 1</a>, previous search strategies are available in <a href="./appendices#CD002855-sec-0112">Appendix 2</a>). We contacted authors of included studies for data clarification and further information. We considered adverse effects described in included studies only. Searches were date limited from 2010 to February 2021 to extend from and include literature published since the last review. POPLINE database ceased publication in the interim and thus was not searched for this update. Searches were conducted in 2003 and 2011 for the original reviews, with update searches in February 2021. </p> <section id="CD002855-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ul id="CD002855-list-0002"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via EBM Reviews (Ovid, January 2010 to February 2021); </p> </li> <li> <p>MEDLINE ALL (Ovid) (January 2010 to February 2021);</p> </li> <li> <p>Embase.com (January 2010 to February 2021);</p> </li> <li> <p>Global Health (Ovid) (January 2010 to February 2021);</p> </li> <li> <p>LILACs <a href="http://lilacs.bvsalud.org/en/" target="_blank">lilacs.bvsalud.org/en/</a> (January 2010 to February 2021). </p> </li> </ul> </p> <p>We searched the following trials registries:</p> <p> <ul id="CD002855-list-0003"> <li> <p>ClinicalTrials.gov <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a> (January 2010 to February 2021); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform <a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a> (January 2010 to February 2021). </p> </li> </ul> </p> </section> <section id="CD002855-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists from articles identified by the search, as well as key review articles, to identify additional articles. </p> </section> </section> <section id="CD002855-sec-0026"> <h3 class="title" id="CD002855-sec-0026">Data collection and analysis</h3> <p>See: <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>; <a href="./references#CD002855-sec-0124" title="">Characteristics of excluded studies</a>; Additional tables </p> <section id="CD002855-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ZJ, ZK) independently selected studies for inclusion in the review using <a href="./references#CD002855-bbs2-0227" title="Veritas Health InnovationCovidence.Version accessed 2021. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>, after employing the search strategy described previously. The review authors evaluated studies under consideration for appropriateness for inclusion and methodological quality without consideration of their results. We included only RCTs. </p> <p>After the initial screen of titles and abstracts retrieved by the search conducted by ZJ and ZK, we retrieved the full texts of the potentially eligible studies for further classification. Two review authors (ZJ, ZK) independently examined the full text of the studies claimed to be randomised. Only the studies with random allocation were included in this updated review. We resolved disagreements by discussion or by consultation with a third review author (SD). We documented the selection process with a PRISMA flow chart (<a href="./references#CD002855-bbs2-0240" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71. [DOI: 10.1136/bmj.n71]">Page 2021</a>; <a href="#CD002855-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD002855-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram of updated process" data-id="CD002855-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of updated process</p> </div> </div> </div> </section> <section id="CD002855-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (ZJ, ZK), independently extracted data using <a href="./references#CD002855-bbs2-0227" title="Veritas Health InnovationCovidence.Version accessed 2021. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>. If there were any discrepancies between review authors in either the inclusion or exclusion of studies, or in data extraction, we resolved them by consensus. We attempted to obtain additional information from study authors if required (ZJ, LX). We examined whether the primary study carried out an intention‐to‐treat analysis. </p> <p>Two review authors (ZJ, ZK) independently extracted the study characteristics and outcome data of the included studies using a data extraction form designed according to Cochrane guidelines (<a href="./references#CD002855-bbs2-0238" title="LiT , HigginsJP , DeeksJJ , editor(s).Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Li 2021</a>; <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>). Discrepancies were described and resolved by discussion (ZJ, ZK, SD). </p> <p>Failure to achieve complete abortion is defined as an abortion that is not completed by the described intended method within two weeks. Other outcomes are failure of expulsion after four to six hours, expulsion time, side effects (nausea, vomiting, diarrhoea, abdominal pain), and mean duration of days of bleeding, bleeding volume, and blood transfusion (see <a href="#CD002855-sec-0020">Types of outcome measures</a>). We further divided studies into early (49 days or fewer of amenorrhoea) and late (more than 49 days) gestational age at the time of abortion for subgroup analysis. Complications are defined as any serious complication described by the study authors and that was not a failure or side effect. </p> </section> <section id="CD002855-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (ZJ, ZK) independently assessed the risk of bias for the update included studies using Cochrane tools and criteria (<a href="./references#CD002855-bbs2-0234" title="HigginsJP , AltmanDG , Sterne JA editor(s).Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/PDF/v5.2/chapter-08.">Higgins 2017</a>). These were the six domains of: selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting); and other bias (such as funding). We assigned each study a judgement of low risk of bias, high risk of bias, or unclear risk of bias. We stated and resolved disagreements by consensus (ZJ, ZK, SD). We described all judgements fully and presented our conclusions in the risk of bias table (<a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>). We described the risk of bias data in detail in the Results and facilitated the interpretation of the reliability of the results by quoting the original text or listing the reasons for judgements in the risk of bias table (see: <a href="#CD002855-sec-0049">Risk of bias in included studies</a> and <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>). We took care to search for within‐study selective reporting, which is studies failing to report obvious outcomes or reporting them in insufficient detail. We searched for published protocols of studies online and compared the outcomes specified in the protocol versus those reported in the final published study (LX). </p> </section> <section id="CD002855-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we used the numbers of events in the control and experimental groups of each study to calculate Mantel‐Haenszel risk ratios (RRs). For continuous data, if all studies reported exactly the same outcomes, we planned to calculate mean difference (MD) between treatment groups. If they reported similar outcomes on different scales, we planned to calculate the standardised mean difference (SMD). We reported confidence intervals (95% CI) for all outcomes. We conducted intention‐to‐treat (ITT) analysis to measure the treatment effect. We converted continuous data reported as medians and quartiles in studies to means and standard deviations (SD). </p> </section> <section id="CD002855-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was each woman randomised. Three update studies had multiple treatment groups; we included only one study with four arms in the meta‐analysis (<a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>). We synthesised the four arms into two arms based on the identical application route or dosage of misoprostol. We could not pool the other two studies, but have narratively synthesised them (<a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a>; <a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a>). </p> </section> <section id="CD002855-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We described for each included study, and for each outcome, the completeness of data including attrition and exclusions from the analysis. We stated whether studies reported attrition and exclusions and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where studies reported, or study authors could supply sufficient information, we planned to re‐include missing data in the analyses that we undertook. We analysed the data on an ITT basis for the studies with participant depletion. We imputed individual values for attrition of dichotomous data, assuming events existing in the control group, but absent in the experimental group, such as the outcome of failure to achieve complete abortion. </p> </section> <section id="CD002855-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated clinical heterogeneity by looking at the variability in participant factors (such as baseline characteristics and diagnostic criteria), interventions (such as therapeutic strategies, co‐intervention, and time of treatment), and the outcomes studied (such as definition, format and time points of measurement). We assessed methodological heterogeneity from differences in the design factors of studies (such as randomisation methods). </p> <p>The clinical heterogeneity documented in <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a> was high among these studies, especially for the different interventions, gestational week and follow‐up duration. We performed subgroup analysis based on different gestational week for resolving clinical heterogeneity. </p> <p>Clinical and methodological diversity can contribute to statistical heterogeneity. We used two methods to evaluate statistical heterogeneity: the Chi<sup>2</sup> test (P value) and I<sup>2</sup> statistic (<a href="./references#CD002855-bbs2-0233" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG .Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). A low P value (&lt; 0.10) qualitatively indicated heterogeneity of intervention effects. The I<sup>2</sup> statistic quantitatively estimated the heterogeneity across studies: an I<sup>2</sup> statistic greater than 50% was taken to indicate substantial heterogeneity (<a href="./references#CD002855-bbs2-0230" title="DeeksJJ , HigginsJP , Altman DG editor(s).Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>). </p> </section> <section id="CD002855-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, review authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by staying alert for duplication of data. We evaluated selective reporting by comparing the protocols of RCTs with the published full‐texts if the protocols were available. </p> <p>We assessed potential publication bias using a funnel plot for the outcome of failure to achieve complete abortion, if there were 10 or more included studies (<a href="./references#CD002855-fig-0074" title="">Analysis 15.1</a>). Possible sources of asymmetry of funnel plots include publication bias and other biases, so the visual inspection of the funnel plot may be misleading, and we will not place excessive emphasis on it. </p> </section> <section id="CD002855-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We processed data using Review Manager 5 software (<a href="./references#CD002855-bbs2-0242" title="The Cochrane CollaborationReview Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). The studies in this field use various combinations of agents, doses, intervals between the antiprogesterone and prostaglandin, and route of administration for prostaglandin. Since all of these variables may affect the outcomes, we did not consider it appropriate to combine similar studies into meta‐analysis in many cases. However, it was possible to identify an experimental intervention and a constant (fixed) intervention, which enabled us to group the studies as follows, then use the random‐effects model for significant clinical heterogeneity. </p> <section id="CD002855-sec-0036"> <h5 class="title">Combined regimen mifepristone/prostaglandin</h5> <p> <ul id="CD002855-list-0004"> <li> <p>Comparison 1: different doses of mifepristone</p> </li> <li> <p>Comparison 2: different doses of prostaglandin</p> </li> <li> <p>Comparison 3: type of prostaglandin (gemeprost versus misoprostol; PGF2alpha versus misoprostol) </p> </li> <li> <p>Comparison 4: timing of prostaglandin</p> </li> <li> <p>Comparison 5: administration strategy of prostaglandin</p> </li> <li> <p>Comparison 6: route of administration of misoprostol ‐ oral versus vaginal</p> </li> <li> <p>Comparison 7: route of administration of misoprostol ‐ buccal versus vaginal</p> </li> <li> <p>Comparison 8: route of administration of misoprostol ‐ buccal versus oral</p> </li> <li> <p>Comparison 9: route of administration of misoprostol ‐ sublingual versus vaginal</p> </li> <li> <p>Comparison 10: route of administration of misoprostol ‐ sublingual versus oral</p> </li> <li> <p>Comparison 11: route of administration of misoprostol ‐ sublingual versus buccal</p> </li> <li> <p>Comparison 12: single versus split dose of prostaglandin</p> </li> <li> <p>Comparison 13: single versus continuous misoprostol</p> </li> <li> <p>Comparison 14: mifepristone alone versus combined regimen mifepristone/prostaglandin</p> </li> <li> <p>Comparison 15: prostaglandin alone versus a combined regimen (all)</p> </li> </ul> </p> </section> <section id="CD002855-sec-0037"> <h5 class="title">Single regimen</h5> <p> <ul id="CD002855-list-0005"> <li> <p>Comparison 16: prostaglandin alone ‐ route of administration</p> </li> <li> <p>Comparison 17: mifepristone alone ‐ high versus low dose</p> </li> </ul> </p> </section> <section id="CD002855-sec-0038"> <h5 class="title">Combined regimen methotrexate/prostaglandin</h5> <p> <ul id="CD002855-list-0006"> <li> <p>Comparison 18: timing of prostaglandin</p> </li> <li> <p>Comparison 19: route of methotrexate ‐ intramuscular versus oral</p> </li> <li> <p>Comparison 20: dose of methotrexate</p> </li> <li> <p>Comparison 21: route of prostaglandin</p> </li> </ul> </p> </section> <section id="CD002855-sec-0039"> <h5 class="title">Tamoxifen versus methotrexate (combined with prostaglandin)</h5> <p> <ul id="CD002855-list-0007"> <li> <p>Comparison 22: low‐dose tamoxifen (40 mg)</p> </li> <li> <p>Comparison 23: high‐dose tamoxifen (160 mg)</p> </li> </ul> </p> </section> <section id="CD002855-sec-0040"> <h5 class="title">Combined regimen mifepristone/prostaglandin versus mifepristone/prostaglandin plus tamoxifen </h5> <p> <ul id="CD002855-list-0008"> <li> <p>Comparison 24: combined mifepristone/prostaglandin versus mifepristone/prostaglandin plus tamoxifen </p> </li> </ul> </p> </section> </section> <section id="CD002855-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible we performed subgroup analyses for early and late first trimester abortions as the performance of some methods may differ with gestational age. </p> <p> <ul id="CD002855-list-0009"> <li> <p>Abortion up to 49 days</p> </li> <li> <p>Abortion over 49 days of amenorrhoea, such as in the comparison group of 1, 2, 4, 8, 10, 11, 13, 15 and 16 </p> </li> </ul> </p> </section> <section id="CD002855-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses (if we identified at least three studies) for the outcome of failure to achieve complete abortion to determine whether conclusions were robust to different decisions made regarding eligibility and analysis (<a href="./references#CD002855-fig-0074" title="">Analysis 15.1</a>). These analyses included consideration of whether review conclusions would have differed if we had restricted eligibility to studies at low risk of bias (studies with low risk of bias in the domains of random sequence generation and allocation concealment) or if we had restricted analyses to studies without imputed data. </p> </section> <section id="CD002855-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of the evidence relating to the main outcomes (failure to achieve complete abortion, nausea, women's dissatisfaction and blood transfusion) for 10 comparisons relating to administration dose, strategy, route and regimen as below. </p> <p> <ul id="CD002855-list-0010"> <li> <p>Mifepristone (600 mg) combined with prostaglandin versus mifepristone (200 mg) combined with prostaglandin </p> </li> <li> <p>Misoprostol 800 µg combined with mifepristone 200 mg versus misoprostol 400 µg combined with mifepristone 200 mg </p> </li> <li> <p>Medical abortion self‐administered at home versus hospital‐administered</p> </li> <li> <p>Medical abortion administered by nurses versus administered by doctors</p> </li> <li> <p>Mifepristone/prostaglandin: misoprostol oral versus vaginal</p> </li> <li> <p>Mifepristone/prostaglandin: misoprostol sublingual versus vaginal</p> </li> <li> <p>Mifepristone alone versus mifepristone/prostaglandin</p> </li> <li> <p>Prostaglandin alone versus combined regimen</p> </li> <li> <p>Prostaglandin alone: misoprostol oral versus vaginal</p> </li> <li> <p>Prostaglandin alone: misoprostol sublingual versus vaginal</p> </li> </ul> </p> <p>We used <a href="./references#CD002855-bbs2-0231" title="McMaster University (developed by Evidence Prime)GRADEpro GDT.Version accessed 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> to import data from Review Manager 5 (<a href="./references#CD002855-bbs2-0242" title="The Cochrane CollaborationReview Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>), in order to create summary of findings tables. We produced a summary of the intervention effect and a measure of certainty for the main outcomes using the GRADE approach. The GRADE approach uses five considerations (risk of bias, inconsistency, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence for the outcomes. The evidence can be downgraded from 'high certainty' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. Two review authors (ZJ, SD), working independently, made judgements about evidence certainty (high, moderate, low or very low), with disagreements resolved by discussion (ZJ, ZK, SD). We justified and documented our judgements, and incorporated them into reporting of results for the outcomes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002855-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002855-sec-0044"></div> <section id="CD002855-sec-0045"> <h3 class="title">Description of studies</h3> <p>The search for the previous latest version of the review was conducted in 2011 and there were 58 included studies. The updated search, conducted in February 2021, identified 1870 records. </p> <section id="CD002855-sec-0046"> <h4 class="title">Results of the search</h4> <p>During this updated search, we screened 1473 records after excluding 397 duplicates. Of these 1473 records, we excluded 1327 records for the following reasons: non‐RCT, surgical abortion, second trimester abortion or duplications after screening abstracts. We tried to retrieve 136 full texts for further evaluation; we excluded 79 for different reasons (<a href="./references#CD002855-sec-0124" title="">Characteristics of excluded studies</a>). We could not assess the full texts for 10 records; we contacted study authors for more information (<a href="./references#CD002855-sec-0125" title="">Characteristics of studies awaiting classification</a>). Eleven ongoing studies are waiting for completion and publication (<a href="./references#CD002855-sec-0126" title="">Characteristics of ongoing studies</a>). We added and updated 41 new studies (including 46 articles), and included 99 studies in total in this updated review (<a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>). Of the 41 included studies, five studies presented data in two different publications respectively, including 10 published articles (<a href="./references#CD002855-bbs2-0039" title="CleeveA , ByamugishaJ , Gemzell-DanielssonK , Mbona TumwesigyeN , AtuhairweS , FaxelidE , et al.Women's acceptability of misoprostol treatment for incomplete abortion by midwives and physicians - secondary outcome analysis from a randomized controlled equivalence trial at district level in Uganda. PloS One2016;11(2):e0149172. [DOI: https://dx.doi.org/10.1371/journal.pone.0149172]Klingberg-AllvinM , CleeveA , AtuhairweS , TumwesigyeNM , FaxelidE , ByamugishaJ , et al.Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet2015;385(9985):2392-8. [DOI: https://dx.doi.org/10.1016/S0140-6736(14)61935-8]">Klingberg Allvin 2015</a>; <a href="./references#CD002855-bbs2-0035" title="IyengarK , Klingberg-AllvinM , IyengarSD , PaulM , EssenB , Gemzell-DanielssonK .Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica2016;95(2):173-81. [DOI: https://dx.doi.org/10.1111/aogs.12815]IyengarK , PaulM , IyengarSD , Klingberg-AllvinM , EssenB , BringJ , et al.Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet2015;3(9):e537-45. [DOI: https://dx.doi.org/10.1016/S2214-109X(15)00150-3]">Iyengar 2015</a>; <a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>; <a href="./references#CD002855-bbs2-0086" title="TamangA , ShahIH , ShresthaP , WarrinerIK , WangD , ThapaK , et al.Comparative satisfaction of receiving medical abortion service from nurses and auxiliary nurse-midwives or doctors in Nepal: results of a randomized trial. Reproductive Health2017;14(1):176. [DOI: https://dx.doi.org/10.1186/s12978-017-0438-7]WarrinerIK , WangD , HuongNTM , ThapaK , TamangA , ShahI , et al.Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet2011;377(9772):1155-61. [DOI: https://dx.doi.org/10.1016/S0140-6736(10)62229-5]">Warriner 2011</a>; <a href="./references#CD002855-bbs2-0081" title="HonkanenH , PiaggioG , Von HertzenH , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women’s perceptions. BJOG2004;111:715-25. Von HertzenH , HonkanenH , PiaggioG , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG2003;110:808-18. ">von Hertzen 2003</a>). The PRISMA study flow of the updated review was illustrated in <a href="#CD002855-fig-0001">Figure 1</a> (<a href="./references#CD002855-bbs2-0240" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71. [DOI: 10.1136/bmj.n71]">Page 2021</a>). </p> </section> <section id="CD002855-sec-0047"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>. </p> <p>Of the 41 newly added studies, four were multiple‐arm RCTs (<a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a>; <a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a>; <a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a>; <a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>); the others were two‐arm RCTs. The participants include women with missed abortion (an abortion in which the fetus dies but is retained within the uterus, without bleeding or abdominal pain), incomplete abortion (a miscarriage in which some fetal or placental tissue remains in the uterus, with bleeding or abdominal pain) and normal first trimester pregnancy. The follow‐up duration of the included studies ranged from one day to 30 days. We added different strategies of administering medical abortions in this updated review, with seven included studies (<a href="./references#CD002855-fig-0074" title="">Analysis 15.1</a>). Administration was by a nurse or a doctor, at home or in hospital. Several studies divided women by gestational age at the time of abortion into subgroups: early (49 days or fewer of amenorrhoea) and late (more than 49 days of amenorrhoea) (<a href="./references#CD002855-bbs2-0010" title="BlumJ , RaghavanS , DabashR , Ngoc NtN, ChelliH , HajriS , et al.Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. International Journal of Gynaecology and Obstetrics2012;118(2):166-71. [DOI: https://dx.doi.org/10.1016/j.ijgo.2012.03.039]">Blum 2012</a>; <a href="./references#CD002855-bbs2-0014" title="ChaiJ , WongCY , HoPC .A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception2013;87(4):480-5. [DOI: https://dx.doi.org/10.1016/j.contraception.2012.09.022]">Chai 2013</a>; <a href="./references#CD002855-bbs2-0017" title="ChongE , TsereteliT , NguyenNN , WinikoffB .A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception2012;86(3):251-6. [DOI: https://dx.doi.org/10.1016/j.contraception.2011.12.012]">Chong 2012</a>; <a href="./references#CD002855-bbs2-0042" title="LeeVC , NgEH , YeungWS , HoPC .Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial. Obstetrics and Gynecology2011;117(2 Pt 1):317-23. [DOI: https://dx.doi.org/10.1097/AOG.0b013e3182073fbf]">Lee 2011</a>; <a href="./references#CD002855-bbs2-0051" title="NgocNT , BlumJ , RaghavanS , NgaNT , DabashR , DiopA , et al.Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception2011;83(5):410-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.09.002]">Ngoc 2011</a>; <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a>; <a href="./references#CD002855-bbs2-0066" title="SheldonWR , DurocherJ , DzubaIG , SayetteH , MartinR , VelascoMC , et al.Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception2019;99(5):272-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2019.02.002]">Sheldon 2019</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>). One study explored the efficacy of traditional Chinese medicine combined with mifepristone and misoprostol (<a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a>). Letrozole has recently been used to treat missed abortion, so we added studies that compared misoprostol and misoprostol combined with letrozole to the present review. However, tamoxifen and methotrexate have been used less frequently in recent years, so few studies referred to these abortion methods. </p> <p>Our main outcome was failure to achieve complete abortion with the method intended. Three studies reported time until passing of conceptus as mean and SD (<a href="./references#CD002855-bbs2-0038" title="JavadiEH , MohammadiM , BarikaniA .Induction of abortion in the first trimester by misoprostol or misoprostol with letrozole. Biotechnology and Health Sciences2015;2(3):e29562. ">Javadi 2015</a>; <a href="./references#CD002855-bbs2-0068" title="SinhaP , SunejaA , GuleriaK , AggarwalR , VaidNB .Comparison of mifepristone followed by misoprostol with misoprostol alone for treatment of early pregnancy failure: a randomized double-blind placebo-controlled trial. Journal of Obstetrics and Gynaecology of India2018;68(1):39-44. [DOI: https://dx.doi.org/10.1007/s13224-017-0992-5]">Sinha 2018</a>; <a href="./references#CD002855-bbs2-0077" title="TorkyHA , MarieH , ElDesoukyES , GebreelS , RaslanO , MoussaAA , et al.Letrozole vs. placebo pretreatment in the medical management of first trimester missed miscarriage: a randomized controlled trial. Geburtshilfe und Frauenheilkunde2018;78(1):63-9. [DOI: https://dx.doi.org/10.1055/s-0043-122499]">Torky 2018</a>). Few studies reported blood loss measured in haemoglobin (<a href="./references#CD002855-bbs2-0002" title="AbdelshafyA , AwwadH , Abo-GamraA , AlanwarA , ElkotbAM , ShahinM , et al.Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2019;24(2):134-9. [DOI: https://dx.doi.org/10.1080/13625187.2019.1569224]">Abdelshafy 2019</a>; <a href="./references#CD002855-bbs2-0014" title="ChaiJ , WongCY , HoPC .A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception2013;87(4):480-5. [DOI: https://dx.doi.org/10.1016/j.contraception.2012.09.022]">Chai 2013</a>; <a href="./references#CD002855-bbs2-0050" title="NgBK , AnnamalaiR , LimPS , Aqmar SurayaS , Nur AzurahAG , Muhammad Abdul JamilMY .Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of Gynecology and Obstetrics2015;291(1):105-13. [DOI: https://dx.doi.org/10.1007/s00404-014-3388-0]">Ng 2015</a>; <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a>), and blood transfusion. Some studies chose the outcome bleeding more than expected (<a href="./references#CD002855-bbs2-0035" title="IyengarK , Klingberg-AllvinM , IyengarSD , PaulM , EssenB , Gemzell-DanielssonK .Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica2016;95(2):173-81. [DOI: https://dx.doi.org/10.1111/aogs.12815]IyengarK , PaulM , IyengarSD , Klingberg-AllvinM , EssenB , BringJ , et al.Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet2015;3(9):e537-45. [DOI: https://dx.doi.org/10.1016/S2214-109X(15)00150-3]">Iyengar 2015</a>; <a href="./references#CD002855-bbs2-0039" title="CleeveA , ByamugishaJ , Gemzell-DanielssonK , Mbona TumwesigyeN , AtuhairweS , FaxelidE , et al.Women's acceptability of misoprostol treatment for incomplete abortion by midwives and physicians - secondary outcome analysis from a randomized controlled equivalence trial at district level in Uganda. PloS One2016;11(2):e0149172. [DOI: https://dx.doi.org/10.1371/journal.pone.0149172]Klingberg-AllvinM , CleeveA , AtuhairweS , TumwesigyeNM , FaxelidE , ByamugishaJ , et al.Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet2015;385(9985):2392-8. [DOI: https://dx.doi.org/10.1016/S0140-6736(14)61935-8]">Klingberg Allvin 2015</a>; <a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>; <a href="./references#CD002855-bbs2-0051" title="NgocNT , BlumJ , RaghavanS , NgaNT , DabashR , DiopA , et al.Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception2011;83(5):410-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.09.002]">Ngoc 2011</a>; <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a>; <a href="./references#CD002855-bbs2-0064" title="SchreiberCA , CreininMD , AtrioJ , SonalkarS , RatcliffeSJ , BarnhartKT .Mifepristone pretreatment for the medical management of early pregnancy loss. New England Journal of Medicine2013;378(23):2161-70. ">Schreiber 2018</a>; <a href="./references#CD002855-bbs2-0070" title="SonsanohA , ChullapramT .Comparison of sublingual and vaginal misoprostol for termination of early pregnancy failure: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2014;22(3):128. ">Sonsanoh 2014</a>; <a href="./references#CD002855-bbs2-0075" title="TanhaFD , FeiziM , ShariatM .Sublingual versus vaginal misoprostol for the management of missed abortion. Journal of Obstetrics and Gynaecology Research2010;36(3):525-32. [DOI: 10.1111/j.1447-0756.2010.01229.x]">Tanha 2010</a>; <a href="./references#CD002855-bbs2-0077" title="TorkyHA , MarieH , ElDesoukyES , GebreelS , RaslanO , MoussaAA , et al.Letrozole vs. placebo pretreatment in the medical management of first trimester missed miscarriage: a randomized controlled trial. Geburtshilfe und Frauenheilkunde2018;78(1):63-9. [DOI: https://dx.doi.org/10.1055/s-0043-122499]">Torky 2018</a>; <a href="./references#CD002855-bbs2-0086" title="TamangA , ShahIH , ShresthaP , WarrinerIK , WangD , ThapaK , et al.Comparative satisfaction of receiving medical abortion service from nurses and auxiliary nurse-midwives or doctors in Nepal: results of a randomized trial. Reproductive Health2017;14(1):176. [DOI: https://dx.doi.org/10.1186/s12978-017-0438-7]WarrinerIK , WangD , HuongNTM , ThapaK , TamangA , ShahI , et al.Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet2011;377(9772):1155-61. [DOI: https://dx.doi.org/10.1016/S0140-6736(10)62229-5]">Warriner 2011</a>). Hospitalisation and unscheduled visits were the primary outcomes in studies performing medical abortion at home (<a href="./references#CD002855-bbs2-0035" title="IyengarK , Klingberg-AllvinM , IyengarSD , PaulM , EssenB , Gemzell-DanielssonK .Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica2016;95(2):173-81. [DOI: https://dx.doi.org/10.1111/aogs.12815]IyengarK , PaulM , IyengarSD , Klingberg-AllvinM , EssenB , BringJ , et al.Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet2015;3(9):e537-45. [DOI: https://dx.doi.org/10.1016/S2214-109X(15)00150-3]">Iyengar 2015</a>; <a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>; <a href="./references#CD002855-bbs2-0067" title="ShresthaA , SedhaiLB .A randomized trial of hospital vs home self administration of vaginal misoprostol for medical abortion. Kathmandu University Medical Journal2014;12(47):185-9. ">Shrestha 2014</a>). Acceptability and completion were further reported in studies administrating medical abortion by nurse (<a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>). Time spent in hospital, cost, and menstruation were evaluated (<a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>). Pelvic infection was reported by only one study (<a href="./references#CD002855-bbs2-0064" title="SchreiberCA , CreininMD , AtrioJ , SonalkarS , RatcliffeSJ , BarnhartKT .Mifepristone pretreatment for the medical management of early pregnancy loss. New England Journal of Medicine2013;378(23):2161-70. ">Schreiber 2018</a>). Five studies defined additional uterotonics used as repeated medical abortion (<a href="./references#CD002855-bbs2-0035" title="IyengarK , Klingberg-AllvinM , IyengarSD , PaulM , EssenB , Gemzell-DanielssonK .Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica2016;95(2):173-81. [DOI: https://dx.doi.org/10.1111/aogs.12815]IyengarK , PaulM , IyengarSD , Klingberg-AllvinM , EssenB , BringJ , et al.Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet2015;3(9):e537-45. [DOI: https://dx.doi.org/10.1016/S2214-109X(15)00150-3]">Iyengar 2015</a>; <a href="./references#CD002855-bbs2-0051" title="NgocNT , BlumJ , RaghavanS , NgaNT , DabashR , DiopA , et al.Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception2011;83(5):410-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.09.002]">Ngoc 2011</a>; <a href="./references#CD002855-bbs2-0066" title="SheldonWR , DurocherJ , DzubaIG , SayetteH , MartinR , VelascoMC , et al.Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception2019;99(5):272-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2019.02.002]">Sheldon 2019</a>; <a href="./references#CD002855-bbs2-0068" title="SinhaP , SunejaA , GuleriaK , AggarwalR , VaidNB .Comparison of mifepristone followed by misoprostol with misoprostol alone for treatment of early pregnancy failure: a randomized double-blind placebo-controlled trial. Journal of Obstetrics and Gynaecology of India2018;68(1):39-44. [DOI: https://dx.doi.org/10.1007/s13224-017-0992-5]">Sinha 2018</a>; <a href="./references#CD002855-bbs2-0076" title="TeimooriB , EsmaeilpoorM , AshkezariAK , FarzanehF .Comparison of induction abortion in the first trimester using misoprostol alone and misoprostol with estrogen priming. International Journal of Women’s Health and Reproduction Sciences2019;7(3):404. ">Teimoori 2019</a>). As well as nausea, vomiting, diarrhoea and abdominal pain, several studies also reported other side effects, such as fever, chills, dizziness and headache (<a href="./references#CD002855-bbs2-0035" title="IyengarK , Klingberg-AllvinM , IyengarSD , PaulM , EssenB , Gemzell-DanielssonK .Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica2016;95(2):173-81. [DOI: https://dx.doi.org/10.1111/aogs.12815]IyengarK , PaulM , IyengarSD , Klingberg-AllvinM , EssenB , BringJ , et al.Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet2015;3(9):e537-45. [DOI: https://dx.doi.org/10.1016/S2214-109X(15)00150-3]">Iyengar 2015</a>; <a href="./references#CD002855-bbs2-0039" title="CleeveA , ByamugishaJ , Gemzell-DanielssonK , Mbona TumwesigyeN , AtuhairweS , FaxelidE , et al.Women's acceptability of misoprostol treatment for incomplete abortion by midwives and physicians - secondary outcome analysis from a randomized controlled equivalence trial at district level in Uganda. PloS One2016;11(2):e0149172. [DOI: https://dx.doi.org/10.1371/journal.pone.0149172]Klingberg-AllvinM , CleeveA , AtuhairweS , TumwesigyeNM , FaxelidE , ByamugishaJ , et al.Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet2015;385(9985):2392-8. [DOI: https://dx.doi.org/10.1016/S0140-6736(14)61935-8]">Klingberg Allvin 2015</a>; <a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>; <a href="./references#CD002855-bbs2-0051" title="NgocNT , BlumJ , RaghavanS , NgaNT , DabashR , DiopA , et al.Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception2011;83(5):410-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.09.002]">Ngoc 2011</a>; <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a>; <a href="./references#CD002855-bbs2-0066" title="SheldonWR , DurocherJ , DzubaIG , SayetteH , MartinR , VelascoMC , et al.Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception2019;99(5):272-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2019.02.002]">Sheldon 2019</a>; <a href="./references#CD002855-bbs2-0067" title="ShresthaA , SedhaiLB .A randomized trial of hospital vs home self administration of vaginal misoprostol for medical abortion. Kathmandu University Medical Journal2014;12(47):185-9. ">Shrestha 2014</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>; <a href="./references#CD002855-bbs2-0070" title="SonsanohA , ChullapramT .Comparison of sublingual and vaginal misoprostol for termination of early pregnancy failure: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2014;22(3):128. ">Sonsanoh 2014</a>; <a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a>; <a href="./references#CD002855-bbs2-0075" title="TanhaFD , FeiziM , ShariatM .Sublingual versus vaginal misoprostol for the management of missed abortion. Journal of Obstetrics and Gynaecology Research2010;36(3):525-32. [DOI: 10.1111/j.1447-0756.2010.01229.x]">Tanha 2010</a>; <a href="./references#CD002855-bbs2-0077" title="TorkyHA , MarieH , ElDesoukyES , GebreelS , RaslanO , MoussaAA , et al.Letrozole vs. placebo pretreatment in the medical management of first trimester missed miscarriage: a randomized controlled trial. Geburtshilfe und Frauenheilkunde2018;78(1):63-9. [DOI: https://dx.doi.org/10.1055/s-0043-122499]">Torky 2018</a>; <a href="./references#CD002855-bbs2-0080" title="VermaML , SinghU , SinghN , SankhwarPL , QureshiS .Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human Fertility2017;20(1):43-7. ">Verma 2017</a>; <a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>). </p> <p>Of the 58 previously included studies, one study presented data in two different publications (<a href="./references#CD002855-bbs2-0081" title="HonkanenH , PiaggioG , Von HertzenH , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women’s perceptions. BJOG2004;111:715-25. Von HertzenH , HonkanenH , PiaggioG , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG2003;110:808-18. ">von Hertzen 2003</a>). One study used two different comparisons (<a href="./references#CD002855-bbs2-0093" title="WiebeER .Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception1999;59:265-70. ">Wiebe 1999a</a>, <a href="./references#CD002855-bbs2-0094" title="WiebeER .Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. American Journal of Obstetrics &amp; Gynecology1999;181:149-52. ">Wiebe 1999b</a>). Five studies used different regimens, doses or timing of the medicines that could not be combined with any of the other regimens in the comparisons and were therefore listed separately in <a href="#CD002855-tbl-0011">Table 1</a> (<a href="./references#CD002855-bbs2-0045" title="LiaoA , HanXJ , WuSY , XiaoDZ , XiongCL , WuXR .Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;116:211-6. ">Liao 2004</a>; <a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a>; <a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a>; <a href="./references#CD002855-bbs2-0088" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility1991;56:32-40. ">WHO 1991</a>; <a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a>). Instead of failure to achieve complete abortion, 14 studies used either other definitions (i.e. surgical intervention) or administered additional prostaglandins (<a href="./references#CD002855-bbs2-0012" title="CarbonellJL , VelazcoA , VarelaL , CabezasE , FernandezC , SanchezC .Misoprostol 3, 4, or 5 days after methotrexate for early abortion. Contraception1997;56:169-74. ">Carbonell 1997b</a>; <a href="./references#CD002855-bbs2-0019" title="CreininDM , VittinghoffE .Methotrexate and misoprostol vs misoprostol alone for early abortion. JAMA1994;272(15):1190-5. ">Creinin 1994</a>; <a href="./references#CD002855-bbs2-0020" title="CreininMD , VittinghoffE , GalbraithS , KlaisleC .A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. American Journal of Obstetrics and Gynecology1995;173:1578-84. ">Creinin 1995</a>; <a href="./references#CD002855-bbs2-0021" title="CreininMD .Oral methotrexate and vaginal misoprostol for early abortion. Contraception1996;54:15-8. ">Creinin 1996a</a>; <a href="./references#CD002855-bbs2-0022" title="CreininMD , KrohnMA .Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. American Journal of Obstetrics and Gynecology1997;177:1444-9. ">Creinin 1997</a>; <a href="./references#CD002855-bbs2-0023" title="CreininMD , PymarHC , SchwartzJL .Mifepristone 100 mg in abortion regimens. Obstetrics and Gynecology2001;98(3):434-9. ">Creinin 2001a</a>; <a href="./references#CD002855-bbs2-0024" title="CreininMD , SchwartzJL , PymarHC , FinkW .Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. British Journal of Obstetrics and Gynaecology2001;108:469-73. ">Creinin 2001b</a>; <a href="./references#CD002855-bbs2-0034" title="HamodaH , AshokPW , FlettGM , TempletonA .A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG2005;112:1102–8. ">Hamoda 2005</a>; <a href="./references#CD002855-bbs2-0036" title="JainJK , MeckstrothKR , ParkM , Mishell DR Jr.A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception1999;60(6):353-6. ">Jain 1999</a>; <a href="./references#CD002855-bbs2-0040" title="KoopersmithTB , MishellDR .The use of misoprostol for termination of early pregnancy. Contraception1996;53:237-42. ">Koopersmith 1996</a>; <a href="./references#CD002855-bbs2-0053" title="OzerenM , BilekliC , AydemirV , BozkayaH .Methotrexate and misoprostol used alone or in combination for early abortion. Contraception1999;59:389-94. ">Ozeren 1999</a>; <a href="./references#CD002855-bbs2-0062" title="SchaffEA , FieldingSL , WesthoffC , EllertsonC , EisingerSH , StadaliusLS , et al.Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion. JAMA2000;284(15):1948-53. ">Schaff 2000</a>; <a href="./references#CD002855-bbs2-0093" title="WiebeER .Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception1999;59:265-70. ">Wiebe 1999a</a>; <a href="./references#CD002855-bbs2-0094" title="WiebeER .Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. American Journal of Obstetrics &amp; Gynecology1999;181:149-52. ">Wiebe 1999b</a>). </p> <div class="table" id="CD002855-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other studies included in the review</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 1‐3: antibiotic and oestrogen. After gestational sac passed out: oxytocin, 20 U, IM </p> <p>Day 3: mifepristone 150 mg, oral</p> <p>Day 4: misoprostol 600 µg, vaginal</p> <p>Group 1: Shenghua decoction from day 1 to 2 weeks after gestational sac passed out</p> <p>Group 2: Shenghua decoction from day 4 to 2 weeks after gestational sac passed out</p> <p>Group 3: without Shenghua decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding duration</p> <p>Time until passing of conceptus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 1: oral mifepristone from 150‐50 mg</p> <p>Day 2: 200 µg of oral misoprostol</p> <p>Group 1: 6 pills of mifepristone (150 mg)</p> <p>Group 2: 5 pills of mifepristone plus 1 pill of placebo (125 mg)</p> <p>Group 3: 4 pills of mifepristone plus 2 pills of placebo (100 mg)</p> <p>Group 4: 3 pills of mifepristone plus 3 pills of placebo (75 mg)</p> <p>Group 5: 2 pills of mifepristone plus 4 pills of placebo (50 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 24/500</p> <p>Group 2: 27/500</p> <p>Group 3: 25/500</p> <p>Group 4: 22/500</p> <p>Group 5: 28/500</p> <p>Ongoing pregnancy</p> <p>Group 1: 18/500</p> <p>Group 2: 20/500</p> <p>Group 3: 18/500</p> <p>Group 4: 19/500</p> <p>Group 5: 25/500</p> <p>Nausea</p> <p>Group 1: 211/500</p> <p>Group 2: 203/500</p> <p>Group 3: 197/500</p> <p>Group 4: 109/500</p> <p>Group 5: 84/500</p> <p>Vomiting</p> <p>Group 1: 64/500</p> <p>Group 2: 62/500</p> <p>Group 3: 55/500</p> <p>Group 4: 43/500</p> <p>Group 5: 32/500</p> <p>Diarrhoea</p> <p>Group 1: 50/500</p> <p>Group 2: 50/500</p> <p>Group 3: 37/500</p> <p>Group 4: 29/500</p> <p>Group 5: 24/500</p> <p>Abdominal pain</p> <p>Group 1: 394/500</p> <p>Group 2: 380/500</p> <p>Group 3: 354/500</p> <p>Group 4: 299/500</p> <p>Group 5: 119/500</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0045" title="LiaoA , HanXJ , WuSY , XiaoDZ , XiongCL , WuXR .Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;116:211-6. ">Liao 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: mifepristone given: 50 mg, then 12 h later 25 mg, then 12 h later 50 mg, and finally, 12 h later, 25 mg mifepristone. 24 h after, 600 µg misoprostol oral (total: 150 mg) </p> <p>Group 2: mifepristone given 30 mg, then 15 mg every 12 h for 3 doses. 24 h after last dose, 600 µg misoprostol given oral (total: 75 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 11/240<br/>Group 2: 9/240 </p> <p>Ongoing pregnancy</p> <p>Group 1: 2/240<br/>Group 2: 1/240 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1:</p> <p>Day 1: mifepristone 50 mg/oral/12‐hourly, 2 doses, day 2‐7: mifepristone 25 mg oral/day</p> <p>Day 3: misoprostol 600 µg/oral, day 4‐6: misoprostol 200 µg/day</p> <p>Group 2:</p> <p>Day 1: mifepristone 50 mg, followed by 25 mg/12‐hourly/4 times</p> <p>Day 3: misoprostol 600 µg, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 18/1118</p> <p>Group 2: 59/494</p> <p>Ongoing pregnancy</p> <p>Group 1: 2/1118</p> <p>Group 2: 6/494</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: mifepristone 25 mg/twice daily for 3 days (total 150 mg) and sulprostone 0.25 mg IM on morning of 3rd day </p> <p>Group 2: mifepristone 25 mg /twice daily for 4 days (total 200 mg) and sulprostone 0.25 mg IM on morning of fourth day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion<br/>Group 1: 15/125<br/>Group 2: 13/126 </p> <p>Ongoing pregnancy</p> <p>Group 1: 3/125<br/>Group 2: 3/126 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0088" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility1991;56:32-40. ">WHO 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: mifepristone 25 mg/12‐hourly, 5 doses (total 125 mg) and gemeprost 1 mg vaginally 60 h after the start of the treatment </p> <p>Group 2: mifepristone 600 mg single dose and gemeprost 1 mg vaginally 60 h after the start of the treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 12/181</p> <p>Group 2: 15/187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: methotrexate 50 mg/m<sup>2</sup> followed by &gt;/72 h by 400 µg misoprostol vaginal </p> <p>Group 2: misoprostol 400 µg sublingual and 400 µg misoprostol vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 62/149<br/>Group 2: 57/149 </p> <p>Nausea</p> <p>Group 1: 53/49<br/>Group 2: 54/149 </p> <p>Vomiting</p> <p>Group 1: 17/149<br/>Group 2: 21/149 </p> <p>Diarrhoea</p> <p>Group 1: 16/149<br/>Group 2: 41/149 </p> <p>Surgical abortion</p> <p>Group 1: 9/149<br/>Group 2: 18/149 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>IM:</b> intramuscular </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD002855-sec-0048"> <h4 class="title">Excluded studies</h4> <p>In total, we excluded 93 studies from the review, for different reasons (<a href="./references#CD002855-sec-0124" title="">Characteristics of excluded studies</a>). Of the 79 newly excluded studies, 22 were duplicate abstracts, 25 were ineligible study designs, 12 were ineligible interventions, seven were incomplete studies, five were ineligible patient population, four were quasi‐RCTs, two were ineligible outcomes, and two were non‐English full texts without translation. Of the 14 previously excluded studies, seven were ineligible study designs, four had ineligible interventions, one an ineligible patient population, one had ineligible outcomes, and one was a quasi‐RCT. </p> </section> </section> <section id="CD002855-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>For a summary of each risk of bias item across all included studies, see <a href="#CD002855-fig-0002">Figure 2</a> and <a href="#CD002855-fig-0003">Figure 3</a>. Further information including the reasons for judgements may be found in the risk of bias sections of the <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD002855-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002855-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD002855-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Review authors' judgements about each risk of bias item presented as percentages across all studies" data-id="CD002855-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review authors' judgements about each risk of bias item presented as percentages across all studies </p> </div> </div> </div> <section id="CD002855-sec-0050"> <h4 class="title">Allocation</h4> <p>The random sequence generation methods were adequate in 81 studies (see <a href="#CD002855-fig-0003">Figure 3</a>). Most used computer or random number tables, but 18 were unclear because of the absence of detailed randomisation methods (<a href="./references#CD002855-bbs2-0005" title="BairdDT , SukcharoenN , ThongKJ .Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Human Reproduction (Oxford, England)1995;10(6):1521-7. ">Baird 1995</a>; <a href="./references#CD002855-bbs2-0008" title="BirgersonL , OdlindV .The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception1988;38(4):391-400. ">Birgerson 1988</a>; <a href="./references#CD002855-bbs2-0011" title="CameronIT , MichieAF , BairdDT .Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (gemeprost). Contraception1986;34(5):459-68. ">Cameron 1986</a>; <a href="./references#CD002855-bbs2-0038" title="JavadiEH , MohammadiM , BarikaniA .Induction of abortion in the first trimester by misoprostol or misoprostol with letrozole. Biotechnology and Health Sciences2015;2(3):e29562. ">Javadi 2015</a>; <a href="./references#CD002855-bbs2-0040" title="KoopersmithTB , MishellDR .The use of misoprostol for termination of early pregnancy. Contraception1996;53:237-42. ">Koopersmith 1996</a>; <a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0047" title="McKinleyC , ThongKJ , BairdDT .The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction (Oxford, England)1993;8(9):1502-5. ">McKinley 1993</a>; <a href="./references#CD002855-bbs2-0058" title="RodgerMW , LoganAF , BairdDT .Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception1989;39(5):497-502. ">Rodger 1989</a>; <a href="./references#CD002855-bbs2-0059" title="SandstromO , BrooksL , SchantzA , GrinstedJ , GrinstedL , JacobsenJD , et al.Interruption of early pregnancy with mifepristone in combination with gemeprost. Acta Obstetricia et Gynecologica Scandinavica1999;78:806-9. ">Sandstrom 1999</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>; <a href="./references#CD002855-bbs2-0072" title="SwahnML , UgocsaiG , BygdemanM , KovacsL , BelseyEM , Van LookPF .Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy. Human Reproduction (Oxford, England)1989;4(1):21-8. ">Swahn 1989</a>; <a href="./references#CD002855-bbs2-0076" title="TeimooriB , EsmaeilpoorM , AshkezariAK , FarzanehF .Comparison of induction abortion in the first trimester using misoprostol alone and misoprostol with estrogen priming. International Journal of Women’s Health and Reproduction Sciences2019;7(3):404. ">Teimoori 2019</a>; <a href="./references#CD002855-bbs2-0078" title="Vahid RoudsariF , AyatiS , SaghafyN , ShakeriM .Misoprostol alone or in combination with methotrexate for termination of pregnancy at first trimester. Iranian Journal of Pharmaceutical Research2010;9(1):89-94. ">Vahid Roudsari 2010</a>; <a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a>; <a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a>; <a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a>; <a href="./references#CD002855-bbs2-0098" title="WuYM , LiY , FanHM , ZhuXJ , ZhengS , WangS , et al.Clinical study of mifepristone in combination with tamoxifen and 15-methyl-PGF2alpha methylester for termination of early pregnancy. Sheng Zhi Yi Xue Za Zhi1993;4:224-7. ">Wu 1993</a>; <a href="./references#CD002855-bbs2-0099" title="ZhengSR .RU486 (mifepristone): clinical trials in China. Acta Obstetricia et Gynecologica Scandinavica. Supplement1989;149:19-23. ">Zheng 1989</a>; see <a href="#CD002855-fig-0002">Figure 2</a>). </p> <p>The risk of selection bias in allocation concealment was high in 13 studies without concealment (<a href="./references#CD002855-bbs2-0001" title="AbbasalizadehF , SahhafF , Sadeghi-ShabestariP , Mirza-Aghazadeh-AttariM , Naghavi-BehzadM .Comparison between effect of letrozole plus misoprostol and misoprostol alone in terminating non-viable first trimester pregnancies: a single blind randomized trial. Journal of Family and Reproductive Health2018;12(1):27-33. ">Abbasalizadeh 2018</a>; <a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>; <a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a>; <a href="./references#CD002855-bbs2-0027" title="DahiyaK , MannS , NandaS .Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion. Archives of Gynecology and Obstetrics2011;284(1):59-63. [DOI: https://dx.doi.org/10.1007/s00404-010-1590-2]">Dahiya 2011</a>; <a href="./references#CD002855-bbs2-0031" title="GargG , TakkarN , SehgalA .Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions. Journal of Obstetrics and Gynaecology of India2015;65(2):111-6. [DOI: https://dx.doi.org/10.1007/s13224-014-0605-5]">Garg 2015</a>; <a href="./references#CD002855-bbs2-0038" title="JavadiEH , MohammadiM , BarikaniA .Induction of abortion in the first trimester by misoprostol or misoprostol with letrozole. Biotechnology and Health Sciences2015;2(3):e29562. ">Javadi 2015</a>; <a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0046" title="MarwahS , GuptaS , BatraNP , BhasinV , SarnaV , KaurN .A comparative study to evaluate the efficacy of vaginal vs oral prostaglandin E1 analogue (misoprostol) in management of first trimester missed abortion. Journal of Clinical and Diagnostic Research2016;10(5):QC14-8. [DOI: https://dx.doi.org/10.7860/JCDR/2016/18178.7891]">Marwah 2016</a>; <a href="./references#CD002855-bbs2-0050" title="NgBK , AnnamalaiR , LimPS , Aqmar SurayaS , Nur AzurahAG , Muhammad Abdul JamilMY .Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of Gynecology and Obstetrics2015;291(1):105-13. [DOI: https://dx.doi.org/10.1007/s00404-014-3388-0]">Ng 2015</a>; <a href="./references#CD002855-bbs2-0067" title="ShresthaA , SedhaiLB .A randomized trial of hospital vs home self administration of vaginal misoprostol for medical abortion. Kathmandu University Medical Journal2014;12(47):185-9. ">Shrestha 2014</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>; <a href="./references#CD002855-bbs2-0076" title="TeimooriB , EsmaeilpoorM , AshkezariAK , FarzanehF .Comparison of induction abortion in the first trimester using misoprostol alone and misoprostol with estrogen priming. International Journal of Women’s Health and Reproduction Sciences2019;7(3):404. ">Teimoori 2019</a>; <a href="./references#CD002855-bbs2-0079" title="VermaML , SinghU , SinghN , ShankhwarP , SrivastavaD .Efficacy of misoprostol administration 24 hours after mifepristone for termination of early pregnancy. Indian Journal of Medical Sciences2010;65(12):511-7. ">Verma 2011</a>), unclear in 23 studies without enough information about concealment (<a href="./references#CD002855-bbs2-0003" title="AllamehZ , GoharianM , EslamianM .Share effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. International Journal of Gynaecology and Obstetrics2020;151(2):214-8. ">Allameh 2020</a>; <a href="./references#CD002855-bbs2-0005" title="BairdDT , SukcharoenN , ThongKJ .Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Human Reproduction (Oxford, England)1995;10(6):1521-7. ">Baird 1995</a>; <a href="./references#CD002855-bbs2-0006" title="BartleyJ , BrownA , EltonR , BairdDT .Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Human Reproduction (Oxford, England)2001;16(10):2098-102. ">Bartley 2001</a>; <a href="./references#CD002855-bbs2-0008" title="BirgersonL , OdlindV .The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception1988;38(4):391-400. ">Birgerson 1988</a>; <a href="./references#CD002855-bbs2-0011" title="CameronIT , MichieAF , BairdDT .Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (gemeprost). Contraception1986;34(5):459-68. ">Cameron 1986</a>; <a href="./references#CD002855-bbs2-0040" title="KoopersmithTB , MishellDR .The use of misoprostol for termination of early pregnancy. Contraception1996;53:237-42. ">Koopersmith 1996</a>; <a href="./references#CD002855-bbs2-0047" title="McKinleyC , ThongKJ , BairdDT .The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction (Oxford, England)1993;8(9):1502-5. ">McKinley 1993</a>; <a href="./references#CD002855-bbs2-0051" title="NgocNT , BlumJ , RaghavanS , NgaNT , DabashR , DiopA , et al.Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception2011;83(5):410-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.09.002]">Ngoc 2011</a>; <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a>; <a href="./references#CD002855-bbs2-0058" title="RodgerMW , LoganAF , BairdDT .Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception1989;39(5):497-502. ">Rodger 1989</a>; <a href="./references#CD002855-bbs2-0059" title="SandstromO , BrooksL , SchantzA , GrinstedJ , GrinstedL , JacobsenJD , et al.Interruption of early pregnancy with mifepristone in combination with gemeprost. Acta Obstetricia et Gynecologica Scandinavica1999;78:806-9. ">Sandstrom 1999</a>; <a href="./references#CD002855-bbs2-0060" title="SangGW , WengLJ , ShaoQX , DuMK , WuXZ , LuYL , et al.Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05 - a multicentre randomized clinical trial in China. Contraception1994;50:501-10. ">Sang 1994</a>; <a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a>; <a href="./references#CD002855-bbs2-0072" title="SwahnML , UgocsaiG , BygdemanM , KovacsL , BelseyEM , Van LookPF .Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy. Human Reproduction (Oxford, England)1989;4(1):21-8. ">Swahn 1989</a>; <a href="./references#CD002855-bbs2-0073" title="TangOS , LeeSW , HoPC .A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. Human Reproduction (Oxford, England)2002;17(11):2865-8. ">Tang 2002</a>; <a href="./references#CD002855-bbs2-0074" title="TangOS , ChanCC , NgEH , Lee SW and HoPC .A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Human Reproduction (Oxford, England)2003;18:2315-8. ">Tang 2003</a>; <a href="./references#CD002855-bbs2-0078" title="Vahid RoudsariF , AyatiS , SaghafyN , ShakeriM .Misoprostol alone or in combination with methotrexate for termination of pregnancy at first trimester. Iranian Journal of Pharmaceutical Research2010;9(1):89-94. ">Vahid Roudsari 2010</a>; <a href="./references#CD002855-bbs2-0080" title="VermaML , SinghU , SinghN , SankhwarPL , QureshiS .Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human Fertility2017;20(1):43-7. ">Verma 2017</a>; <a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a>; <a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a>; <a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a>; <a href="./references#CD002855-bbs2-0098" title="WuYM , LiY , FanHM , ZhuXJ , ZhengS , WangS , et al.Clinical study of mifepristone in combination with tamoxifen and 15-methyl-PGF2alpha methylester for termination of early pregnancy. Sheng Zhi Yi Xue Za Zhi1993;4:224-7. ">Wu 1993</a>; <a href="./references#CD002855-bbs2-0099" title="ZhengSR .RU486 (mifepristone): clinical trials in China. Acta Obstetricia et Gynecologica Scandinavica. Supplement1989;149:19-23. ">Zheng 1989</a>; see <a href="#CD002855-fig-0002">Figure 2</a>), and low in the other 63 studies with adequate allocation concealment. Some participants would receive additional misoprostol if the gestational sac was present at the first follow‐up visit. It is not clear how these participants were distributed by treatment group (<a href="./references#CD002855-bbs2-0062" title="SchaffEA , FieldingSL , WesthoffC , EllertsonC , EisingerSH , StadaliusLS , et al.Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion. JAMA2000;284(15):1948-53. ">Schaff 2000</a>). </p> </section> <section id="CD002855-sec-0051"> <h4 class="title">Blinding</h4> <p>Blinding of participants and outcome assessment was difficult for most studies. About 30% of included studies achieved adequate blinding by using placebo (<a href="./references#CD002855-bbs2-0001" title="AbbasalizadehF , SahhafF , Sadeghi-ShabestariP , Mirza-Aghazadeh-AttariM , Naghavi-BehzadM .Comparison between effect of letrozole plus misoprostol and misoprostol alone in terminating non-viable first trimester pregnancies: a single blind randomized trial. Journal of Family and Reproductive Health2018;12(1):27-33. ">Abbasalizadeh 2018</a>; <a href="./references#CD002855-bbs2-0002" title="AbdelshafyA , AwwadH , Abo-GamraA , AlanwarA , ElkotbAM , ShahinM , et al.Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2019;24(2):134-9. [DOI: https://dx.doi.org/10.1080/13625187.2019.1569224]">Abdelshafy 2019</a>; <a href="./references#CD002855-bbs2-0003" title="AllamehZ , GoharianM , EslamianM .Share effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. International Journal of Gynaecology and Obstetrics2020;151(2):214-8. ">Allameh 2020</a>; <a href="./references#CD002855-bbs2-0006" title="BartleyJ , BrownA , EltonR , BairdDT .Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Human Reproduction (Oxford, England)2001;16(10):2098-102. ">Bartley 2001</a>; <a href="./references#CD002855-bbs2-0007" title="Behroozi-LakT , Derakhshan-AydenlooS , BroomandF .Evaluation of effect of letrozole prior to misoprostol in comparison with misoprostol alone in success rate of induced abortion. Journal of Gynecology Obstetrics and Human Reproduction2018;47(3):113-7. [DOI: https://dx.doi.org/10.1016/j.jogoh.2017.11.002]">Behroozi Lak 2018</a>; <a href="./references#CD002855-bbs2-0010" title="BlumJ , RaghavanS , DabashR , Ngoc NtN, ChelliH , HajriS , et al.Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. International Journal of Gynaecology and Obstetrics2012;118(2):166-71. [DOI: https://dx.doi.org/10.1016/j.ijgo.2012.03.039]">Blum 2012</a>; <a href="./references#CD002855-bbs2-0014" title="ChaiJ , WongCY , HoPC .A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception2013;87(4):480-5. [DOI: https://dx.doi.org/10.1016/j.contraception.2012.09.022]">Chai 2013</a>; <a href="./references#CD002855-bbs2-0016" title="ChengLN , ZhouYF , SongJY , LiH , ChenJK .A randomized clinical trial in comparison of termination of early pregnancy by 16, 16-dimethyl-trans PGE1 ester alone or in combination with testosterone propionate. Sheng zhi yu bi yun (Reproduction and Contraception)1994;1:29-33. ">Cheng 1994</a>; <a href="./references#CD002855-bbs2-0017" title="ChongE , TsereteliT , NguyenNN , WinikoffB .A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception2012;86(3):251-6. [DOI: https://dx.doi.org/10.1016/j.contraception.2011.12.012]">Chong 2012</a>; <a href="./references#CD002855-bbs2-0018" title="CoyajiK , KrishnaU , AmbardekarS , BrackenH , RaoteV , MandlekarA , et al.Are two doses of misoprostol after mifepristone for early abortion better than one?BJOG2007;114:271–8. ">Coyaji 2007</a>; <a href="./references#CD002855-bbs2-0081" title="HonkanenH , PiaggioG , Von HertzenH , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women’s perceptions. BJOG2004;111:715-25. Von HertzenH , HonkanenH , PiaggioG , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG2003;110:808-18. ">von Hertzen 2003</a>; <a href="./references#CD002855-bbs2-0036" title="JainJK , MeckstrothKR , ParkM , Mishell DR Jr.A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception1999;60(6):353-6. ">Jain 1999</a>; <a href="./references#CD002855-bbs2-0037" title="JainJK , DuttonC , HarwoodB , MeckstrothKR , MishellDR .A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Human Reproduction (Oxford, England)2002;17(6):1477-82. ">Jain 2002</a>; <a href="./references#CD002855-bbs2-0038" title="JavadiEH , MohammadiM , BarikaniA .Induction of abortion in the first trimester by misoprostol or misoprostol with letrozole. Biotechnology and Health Sciences2015;2(3):e29562. ">Javadi 2015</a>; <a href="./references#CD002855-bbs2-0042" title="LeeVC , NgEH , YeungWS , HoPC .Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial. Obstetrics and Gynecology2011;117(2 Pt 1):317-23. [DOI: https://dx.doi.org/10.1097/AOG.0b013e3182073fbf]">Lee 2011</a>; <a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a>; <a href="./references#CD002855-bbs2-0045" title="LiaoA , HanXJ , WuSY , XiaoDZ , XiongCL , WuXR .Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;116:211-6. ">Liao 2004</a>; <a href="./references#CD002855-bbs2-0047" title="McKinleyC , ThongKJ , BairdDT .The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction (Oxford, England)1993;8(9):1502-5. ">McKinley 1993</a>; <a href="./references#CD002855-bbs2-0051" title="NgocNT , BlumJ , RaghavanS , NgaNT , DabashR , DiopA , et al.Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception2011;83(5):410-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.09.002]">Ngoc 2011</a>; <a href="./references#CD002855-bbs2-0058" title="RodgerMW , LoganAF , BairdDT .Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception1989;39(5):497-502. ">Rodger 1989</a>; <a href="./references#CD002855-bbs2-0064" title="SchreiberCA , CreininMD , AtrioJ , SonalkarS , RatcliffeSJ , BarnhartKT .Mifepristone pretreatment for the medical management of early pregnancy loss. New England Journal of Medicine2013;378(23):2161-70. ">Schreiber 2018</a>; <a href="./references#CD002855-bbs2-0066" title="SheldonWR , DurocherJ , DzubaIG , SayetteH , MartinR , VelascoMC , et al.Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception2019;99(5):272-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2019.02.002]">Sheldon 2019</a>; <a href="./references#CD002855-bbs2-0068" title="SinhaP , SunejaA , GuleriaK , AggarwalR , VaidNB .Comparison of mifepristone followed by misoprostol with misoprostol alone for treatment of early pregnancy failure: a randomized double-blind placebo-controlled trial. Journal of Obstetrics and Gynaecology of India2018;68(1):39-44. [DOI: https://dx.doi.org/10.1007/s13224-017-0992-5]">Sinha 2018</a>; <a href="./references#CD002855-bbs2-0072" title="SwahnML , UgocsaiG , BygdemanM , KovacsL , BelseyEM , Van LookPF .Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy. Human Reproduction (Oxford, England)1989;4(1):21-8. ">Swahn 1989</a>; <a href="./references#CD002855-bbs2-0074" title="TangOS , ChanCC , NgEH , Lee SW and HoPC .A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Human Reproduction (Oxford, England)2003;18:2315-8. ">Tang 2003</a>; <a href="./references#CD002855-bbs2-0077" title="TorkyHA , MarieH , ElDesoukyES , GebreelS , RaslanO , MoussaAA , et al.Letrozole vs. placebo pretreatment in the medical management of first trimester missed miscarriage: a randomized controlled trial. Geburtshilfe und Frauenheilkunde2018;78(1):63-9. [DOI: https://dx.doi.org/10.1055/s-0043-122499]">Torky 2018</a>; <a href="./references#CD002855-bbs2-0081" title="HonkanenH , PiaggioG , Von HertzenH , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women’s perceptions. BJOG2004;111:715-25. Von HertzenH , HonkanenH , PiaggioG , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG2003;110:808-18. ">von Hertzen 2003</a>; <a href="./references#CD002855-bbs2-0083" title="vonHertzenH , PiaggioG , WojdylaD , MarionsL , My HuongNT , TangOS , et al, for the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG2009;116:381–9. ">von Hertzen 2009</a>; <a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>; <a href="./references#CD002855-bbs2-0089" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Termination of pregnancy with reduced doses of mifepristone. BMJ1993;307:532-7. ">WHO 1993</a>; <a href="./references#CD002855-bbs2-0090" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG2000;107:524-30. ">WHO 2000</a>; <a href="./references#CD002855-bbs2-0091" title="World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation.Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost. Acta Obstetrica et Gynecologica Scandinavica2001;80:447-51. ">WHO 2001a</a>; <a href="./references#CD002855-bbs2-0092" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG2001;108:738-42. ">WHO 2001b</a>; <a href="#CD002855-fig-0003">Figure 3</a>). Some studies did not report details about blinding methods and we evaluated them as unclear risk of bias (<a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>; <a href="./references#CD002855-bbs2-0005" title="BairdDT , SukcharoenN , ThongKJ .Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Human Reproduction (Oxford, England)1995;10(6):1521-7. ">Baird 1995</a>; <a href="./references#CD002855-bbs2-0008" title="BirgersonL , OdlindV .The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception1988;38(4):391-400. ">Birgerson 1988</a>; <a href="./references#CD002855-bbs2-0011" title="CameronIT , MichieAF , BairdDT .Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (gemeprost). Contraception1986;34(5):459-68. ">Cameron 1986</a>; <a href="./references#CD002855-bbs2-0028" title="El-RefaeyH , TempletonA .Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure. British Journal of Obstetrics and Gynaecology1994;101:792-6. ">El‐Refaey 1994</a>; <a href="./references#CD002855-bbs2-0029" title="El-RefaeyH , RajasekarD , AbdallaM , CalderL , TempletonA .Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. New England Journal of Medicine1995;332:983-7. ">El‐Refaey 1995</a>; <a href="./references#CD002855-bbs2-0040" title="KoopersmithTB , MishellDR .The use of misoprostol for termination of early pregnancy. Contraception1996;53:237-42. ">Koopersmith 1996</a>; <a href="./references#CD002855-bbs2-0053" title="OzerenM , BilekliC , AydemirV , BozkayaH .Methotrexate and misoprostol used alone or in combination for early abortion. Contraception1999;59:389-94. ">Ozeren 1999</a>; <a href="./references#CD002855-bbs2-0056" title="RaghavanS , ComendantR , DigolI , UngureanuS , FriptuV , BrackenH , et al.Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol. Contraception2009;79:84-90. ">Raghavan 2009</a>; <a href="./references#CD002855-bbs2-0059" title="SandstromO , BrooksL , SchantzA , GrinstedJ , GrinstedL , JacobsenJD , et al.Interruption of early pregnancy with mifepristone in combination with gemeprost. Acta Obstetricia et Gynecologica Scandinavica1999;78:806-9. ">Sandstrom 1999</a>; <a href="./references#CD002855-bbs2-0060" title="SangGW , WengLJ , ShaoQX , DuMK , WuXZ , LuYL , et al.Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05 - a multicentre randomized clinical trial in China. Contraception1994;50:501-10. ">Sang 1994</a>; <a href="./references#CD002855-bbs2-0061" title="SangGW , HeCH , ShaoQX , ZhuangLQ , WengLJ , WuBX , et al.A large scale introductory trial on termination of early pregnancy by mifepristone in combination with different prostaglandins. Chinese Journal for Clinical Pharmacology1999;15(5):323-9. ">Sang 1999</a>; <a href="./references#CD002855-bbs2-0073" title="TangOS , LeeSW , HoPC .A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. Human Reproduction (Oxford, England)2002;17(11):2865-8. ">Tang 2002</a>; <a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a>; <a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a>; <a href="./references#CD002855-bbs2-0088" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility1991;56:32-40. ">WHO 1991</a>; <a href="./references#CD002855-bbs2-0093" title="WiebeER .Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception1999;59:265-70. ">Wiebe 1999a</a>; <a href="./references#CD002855-bbs2-0094" title="WiebeER .Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. American Journal of Obstetrics &amp; Gynecology1999;181:149-52. ">Wiebe 1999b</a>; <a href="./references#CD002855-bbs2-0095" title="WiebeER , TroutonK .Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion. Contraception2004;70:463-6. ">Wiebe 2004</a>; <a href="./references#CD002855-bbs2-0098" title="WuYM , LiY , FanHM , ZhuXJ , ZhengS , WangS , et al.Clinical study of mifepristone in combination with tamoxifen and 15-methyl-PGF2alpha methylester for termination of early pregnancy. Sheng Zhi Yi Xue Za Zhi1993;4:224-7. ">Wu 1993</a>; <a href="./references#CD002855-bbs2-0099" title="ZhengSR .RU486 (mifepristone): clinical trials in China. Acta Obstetricia et Gynecologica Scandinavica. Supplement1989;149:19-23. ">Zheng 1989</a>; <a href="#CD002855-fig-0002">Figure 2</a>). If the studies were open label, then we evaluated them as high risk of bias (<a href="./references#CD002855-bbs2-0009" title="BlanchardK , Tara ShochetT , CoyajicK , NgocN , WinikoffB .Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception2005;72:91-7. ">Blanchard 2005</a>; <a href="./references#CD002855-bbs2-0012" title="CarbonellJL , VelazcoA , VarelaL , CabezasE , FernandezC , SanchezC .Misoprostol 3, 4, or 5 days after methotrexate for early abortion. Contraception1997;56:169-74. ">Carbonell 1997b</a>; <a href="./references#CD002855-bbs2-0013" title="CarbonellJL , VarelaL , VelazcoA , CabezasE , FernandezC , SanchezC .Oral methotrexate and vaginal misoprostol for early abortion. Contraception1998;57:83-8. ">Carbonell 1998</a>; <a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a>; <a href="./references#CD002855-bbs2-0019" title="CreininDM , VittinghoffE .Methotrexate and misoprostol vs misoprostol alone for early abortion. JAMA1994;272(15):1190-5. ">Creinin 1994</a>; <a href="./references#CD002855-bbs2-0020" title="CreininMD , VittinghoffE , GalbraithS , KlaisleC .A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. American Journal of Obstetrics and Gynecology1995;173:1578-84. ">Creinin 1995</a>; <a href="./references#CD002855-bbs2-0021" title="CreininMD .Oral methotrexate and vaginal misoprostol for early abortion. Contraception1996;54:15-8. ">Creinin 1996a</a>; <a href="./references#CD002855-bbs2-0022" title="CreininMD , KrohnMA .Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. American Journal of Obstetrics and Gynecology1997;177:1444-9. ">Creinin 1997</a>; <a href="./references#CD002855-bbs2-0023" title="CreininMD , PymarHC , SchwartzJL .Mifepristone 100 mg in abortion regimens. Obstetrics and Gynecology2001;98(3):434-9. ">Creinin 2001a</a>; <a href="./references#CD002855-bbs2-0024" title="CreininMD , SchwartzJL , PymarHC , FinkW .Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. British Journal of Obstetrics and Gynaecology2001;108:469-73. ">Creinin 2001b</a>; <a href="./references#CD002855-bbs2-0025" title="CreininMD , FoxMC , TealS , ChenA , SchaffEA , MeynLA .A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstetrics and Gynecology2004;103:851-9. ">Creinin 2004</a>; <a href="./references#CD002855-bbs2-0026" title="CreininMD , SchreiberCA , BednarekP , LintuH , WagnerMS , MeynLA .Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion. Obstetrics and Gynecology2007;109:885-94. ">Creinin 2007</a>; <a href="./references#CD002855-bbs2-0027" title="DahiyaK , MannS , NandaS .Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion. Archives of Gynecology and Obstetrics2011;284(1):59-63. [DOI: https://dx.doi.org/10.1007/s00404-010-1590-2]">Dahiya 2011</a>; <a href="./references#CD002855-bbs2-0030" title="FekihM , FathallahK , Ben RegayaL , BouguizaneS , ChaiebA , BibiM , et al.Sublingual misoprostol for first trimester termination of pregnancy. International Journal of Gynaecology and Obstetrics2010;109(1):67-70. [DOI: https://dx.doi.org/10.1016/j.ijgo.2009.11.008]">Fekih 2010</a>; <a href="./references#CD002855-bbs2-0031" title="GargG , TakkarN , SehgalA .Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions. Journal of Obstetrics and Gynaecology of India2015;65(2):111-6. [DOI: https://dx.doi.org/10.1007/s13224-014-0605-5]">Garg 2015</a>; <a href="./references#CD002855-bbs2-0032" title="GoelA , MittalS , TanejaBK , SingalN , AttriS .Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2011;283(6):1409-13. [DOI: https://dx.doi.org/10.1007/s00404-011-1881-2]">Goel 2011</a>; <a href="./references#CD002855-bbs2-0033" title="GuestJ , ChienPF , ThomsonMA , KosseimML .Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG2007;114:207-15. ">Guest 2007</a>; <a href="./references#CD002855-bbs2-0034" title="HamodaH , AshokPW , FlettGM , TempletonA .A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG2005;112:1102–8. ">Hamoda 2005</a>; <a href="./references#CD002855-bbs2-0035" title="IyengarK , Klingberg-AllvinM , IyengarSD , PaulM , EssenB , Gemzell-DanielssonK .Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica2016;95(2):173-81. [DOI: https://dx.doi.org/10.1111/aogs.12815]IyengarK , PaulM , IyengarSD , Klingberg-AllvinM , EssenB , BringJ , et al.Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet2015;3(9):e537-45. [DOI: https://dx.doi.org/10.1016/S2214-109X(15)00150-3]">Iyengar 2015</a>; <a href="./references#CD002855-bbs2-0039" title="CleeveA , ByamugishaJ , Gemzell-DanielssonK , Mbona TumwesigyeN , AtuhairweS , FaxelidE , et al.Women's acceptability of misoprostol treatment for incomplete abortion by midwives and physicians - secondary outcome analysis from a randomized controlled equivalence trial at district level in Uganda. PloS One2016;11(2):e0149172. [DOI: https://dx.doi.org/10.1371/journal.pone.0149172]Klingberg-AllvinM , CleeveA , AtuhairweS , TumwesigyeNM , FaxelidE , ByamugishaJ , et al.Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet2015;385(9985):2392-8. [DOI: https://dx.doi.org/10.1016/S0140-6736(14)61935-8]">Klingberg Allvin 2015</a>; <a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>; <a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0046" title="MarwahS , GuptaS , BatraNP , BhasinV , SarnaV , KaurN .A comparative study to evaluate the efficacy of vaginal vs oral prostaglandin E1 analogue (misoprostol) in management of first trimester missed abortion. Journal of Clinical and Diagnostic Research2016;10(5):QC14-8. [DOI: https://dx.doi.org/10.7860/JCDR/2016/18178.7891]">Marwah 2016</a>; <a href="./references#CD002855-bbs2-0048" title="MiddletonT , SchaffE , FieldingSL , ScahillM , ShannonC , WestheimerE , et al.Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception2005;72:328-32. ">Middleton 2005</a>; <a href="./references#CD002855-bbs2-0049" title="MizrachiY , DekaloA , GluckO , MirembergH , DafnaL , FeldsteinO , et al.Single versus repeat doses of misoprostol for treatment of early pregnancy loss-a randomized clinical trial. Human Reproduction (Oxford, England)2017;32(6):1202-7. [DOI: https://dx.doi.org/10.1093/humrep/dex074]">Mizrachi 2017</a>; <a href="./references#CD002855-bbs2-0050" title="NgBK , AnnamalaiR , LimPS , Aqmar SurayaS , Nur AzurahAG , Muhammad Abdul JamilMY .Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of Gynecology and Obstetrics2015;291(1):105-13. [DOI: https://dx.doi.org/10.1007/s00404-014-3388-0]">Ng 2015</a>; <a href="./references#CD002855-bbs2-0052" title="OlavarrietaCD , GanatraB , SorhaindoA , KarverTS , SeucA , VillalobosA , et al.Nurse versus physician-provision of early medical abortion in Mexico: a randomized controlled non-inferiority trial. Bulletin of the World Health Organization2015;93(4):249-58. [DOI: https://dx.doi.org/10.2471/BLT.14.143990]">Olavarrieta 2015</a>; <a href="./references#CD002855-bbs2-0054" title="ParitakulP , PhupongV .Comparative study between oral and sublingual 600 micro g misoprostol for the treatment of incomplete abortion. Journal of Obstetrics and Gynaecology Research2010;36(5):978-83. [DOI: https://dx.doi.org/10.1111/j.1447-0756.2010.01264.x]">Paritakul 2010</a>; <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a>; <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a>; <a href="./references#CD002855-bbs2-0062" title="SchaffEA , FieldingSL , WesthoffC , EllertsonC , EisingerSH , StadaliusLS , et al.Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion. JAMA2000;284(15):1948-53. ">Schaff 2000</a>; <a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a>; <a href="./references#CD002855-bbs2-0065" title="ShannonC , WiebeE , JacotF , GuilbertE , DunnS , SheldonW , et al.Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG2006;113:621–8. ">Shannon 2006</a>; <a href="./references#CD002855-bbs2-0067" title="ShresthaA , SedhaiLB .A randomized trial of hospital vs home self administration of vaginal misoprostol for medical abortion. Kathmandu University Medical Journal2014;12(47):185-9. ">Shrestha 2014</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>; <a href="./references#CD002855-bbs2-0070" title="SonsanohA , ChullapramT .Comparison of sublingual and vaginal misoprostol for termination of early pregnancy failure: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2014;22(3):128. ">Sonsanoh 2014</a>; <a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a>; <a href="./references#CD002855-bbs2-0075" title="TanhaFD , FeiziM , ShariatM .Sublingual versus vaginal misoprostol for the management of missed abortion. Journal of Obstetrics and Gynaecology Research2010;36(3):525-32. [DOI: 10.1111/j.1447-0756.2010.01229.x]">Tanha 2010</a>; <a href="./references#CD002855-bbs2-0076" title="TeimooriB , EsmaeilpoorM , AshkezariAK , FarzanehF .Comparison of induction abortion in the first trimester using misoprostol alone and misoprostol with estrogen priming. International Journal of Women’s Health and Reproduction Sciences2019;7(3):404. ">Teimoori 2019</a>; <a href="./references#CD002855-bbs2-0078" title="Vahid RoudsariF , AyatiS , SaghafyN , ShakeriM .Misoprostol alone or in combination with methotrexate for termination of pregnancy at first trimester. Iranian Journal of Pharmaceutical Research2010;9(1):89-94. ">Vahid Roudsari 2010</a>; <a href="./references#CD002855-bbs2-0079" title="VermaML , SinghU , SinghN , ShankhwarP , SrivastavaD .Efficacy of misoprostol administration 24 hours after mifepristone for termination of early pregnancy. Indian Journal of Medical Sciences2010;65(12):511-7. ">Verma 2011</a>; <a href="./references#CD002855-bbs2-0080" title="VermaML , SinghU , SinghN , SankhwarPL , QureshiS .Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human Fertility2017;20(1):43-7. ">Verma 2017</a>; <a href="./references#CD002855-bbs2-0086" title="TamangA , ShahIH , ShresthaP , WarrinerIK , WangD , ThapaK , et al.Comparative satisfaction of receiving medical abortion service from nurses and auxiliary nurse-midwives or doctors in Nepal: results of a randomized trial. Reproductive Health2017;14(1):176. [DOI: https://dx.doi.org/10.1186/s12978-017-0438-7]WarrinerIK , WangD , HuongNTM , ThapaK , TamangA , ShahI , et al.Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet2011;377(9772):1155-61. [DOI: https://dx.doi.org/10.1016/S0140-6736(10)62229-5]">Warriner 2011</a>; <a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a>; <a href="./references#CD002855-bbs2-0097" title="WinikoffB , DzubaIG , CreininMD , CrowdenWA , GoldbergAB , GonzalesJ , et al.Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstetrics and Gynecology2008;112(6):1303-10. ">Winikoff 2008</a>; <a href="#CD002855-fig-0002">Figure 2</a>). </p> </section> <section id="CD002855-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition bias was high in four studies with unbalanced and large percentage of attrition but without ITT analysis (<a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>; <a href="./references#CD002855-bbs2-0011" title="CameronIT , MichieAF , BairdDT .Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (gemeprost). Contraception1986;34(5):459-68. ">Cameron 1986</a>; <a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>), unclear in 36 studies with unbalanced and small percentage of attrition but without ITT analysis (<a href="./references#CD002855-bbs2-0002" title="AbdelshafyA , AwwadH , Abo-GamraA , AlanwarA , ElkotbAM , ShahinM , et al.Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2019;24(2):134-9. [DOI: https://dx.doi.org/10.1080/13625187.2019.1569224]">Abdelshafy 2019</a>; <a href="./references#CD002855-bbs2-0003" title="AllamehZ , GoharianM , EslamianM .Share effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. International Journal of Gynaecology and Obstetrics2020;151(2):214-8. ">Allameh 2020</a>; <a href="./references#CD002855-bbs2-0005" title="BairdDT , SukcharoenN , ThongKJ .Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Human Reproduction (Oxford, England)1995;10(6):1521-7. ">Baird 1995</a>; <a href="./references#CD002855-bbs2-0010" title="BlumJ , RaghavanS , DabashR , Ngoc NtN, ChelliH , HajriS , et al.Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. International Journal of Gynaecology and Obstetrics2012;118(2):166-71. [DOI: https://dx.doi.org/10.1016/j.ijgo.2012.03.039]">Blum 2012</a>; <a href="./references#CD002855-bbs2-0012" title="CarbonellJL , VelazcoA , VarelaL , CabezasE , FernandezC , SanchezC .Misoprostol 3, 4, or 5 days after methotrexate for early abortion. Contraception1997;56:169-74. ">Carbonell 1997b</a>; <a href="./references#CD002855-bbs2-0013" title="CarbonellJL , VarelaL , VelazcoA , CabezasE , FernandezC , SanchezC .Oral methotrexate and vaginal misoprostol for early abortion. Contraception1998;57:83-8. ">Carbonell 1998</a>; <a href="./references#CD002855-bbs2-0027" title="DahiyaK , MannS , NandaS .Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion. Archives of Gynecology and Obstetrics2011;284(1):59-63. [DOI: https://dx.doi.org/10.1007/s00404-010-1590-2]">Dahiya 2011</a>; <a href="./references#CD002855-bbs2-0028" title="El-RefaeyH , TempletonA .Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure. British Journal of Obstetrics and Gynaecology1994;101:792-6. ">El‐Refaey 1994</a>; <a href="./references#CD002855-bbs2-0029" title="El-RefaeyH , RajasekarD , AbdallaM , CalderL , TempletonA .Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. New England Journal of Medicine1995;332:983-7. ">El‐Refaey 1995</a>; <a href="./references#CD002855-bbs2-0033" title="GuestJ , ChienPF , ThomsonMA , KosseimML .Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG2007;114:207-15. ">Guest 2007</a>; <a href="./references#CD002855-bbs2-0034" title="HamodaH , AshokPW , FlettGM , TempletonA .A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG2005;112:1102–8. ">Hamoda 2005</a>; <a href="./references#CD002855-bbs2-0037" title="JainJK , DuttonC , HarwoodB , MeckstrothKR , MishellDR .A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Human Reproduction (Oxford, England)2002;17(6):1477-82. ">Jain 2002</a>; <a href="./references#CD002855-bbs2-0039" title="CleeveA , ByamugishaJ , Gemzell-DanielssonK , Mbona TumwesigyeN , AtuhairweS , FaxelidE , et al.Women's acceptability of misoprostol treatment for incomplete abortion by midwives and physicians - secondary outcome analysis from a randomized controlled equivalence trial at district level in Uganda. PloS One2016;11(2):e0149172. [DOI: https://dx.doi.org/10.1371/journal.pone.0149172]Klingberg-AllvinM , CleeveA , AtuhairweS , TumwesigyeNM , FaxelidE , ByamugishaJ , et al.Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet2015;385(9985):2392-8. [DOI: https://dx.doi.org/10.1016/S0140-6736(14)61935-8]">Klingberg Allvin 2015</a>; <a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0050" title="NgBK , AnnamalaiR , LimPS , Aqmar SurayaS , Nur AzurahAG , Muhammad Abdul JamilMY .Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of Gynecology and Obstetrics2015;291(1):105-13. [DOI: https://dx.doi.org/10.1007/s00404-014-3388-0]">Ng 2015</a>; <a href="./references#CD002855-bbs2-0051" title="NgocNT , BlumJ , RaghavanS , NgaNT , DabashR , DiopA , et al.Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception2011;83(5):410-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.09.002]">Ngoc 2011</a>; <a href="./references#CD002855-bbs2-0054" title="ParitakulP , PhupongV .Comparative study between oral and sublingual 600 micro g misoprostol for the treatment of incomplete abortion. Journal of Obstetrics and Gynaecology Research2010;36(5):978-83. [DOI: https://dx.doi.org/10.1111/j.1447-0756.2010.01264.x]">Paritakul 2010</a>; <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a>; <a href="./references#CD002855-bbs2-0056" title="RaghavanS , ComendantR , DigolI , UngureanuS , FriptuV , BrackenH , et al.Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol. Contraception2009;79:84-90. ">Raghavan 2009</a>; <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a>; <a href="./references#CD002855-bbs2-0062" title="SchaffEA , FieldingSL , WesthoffC , EllertsonC , EisingerSH , StadaliusLS , et al.Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion. JAMA2000;284(15):1948-53. ">Schaff 2000</a>; <a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a>; <a href="./references#CD002855-bbs2-0066" title="SheldonWR , DurocherJ , DzubaIG , SayetteH , MartinR , VelascoMC , et al.Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception2019;99(5):272-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2019.02.002]">Sheldon 2019</a>; <a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a>; <a href="./references#CD002855-bbs2-0072" title="SwahnML , UgocsaiG , BygdemanM , KovacsL , BelseyEM , Van LookPF .Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy. Human Reproduction (Oxford, England)1989;4(1):21-8. ">Swahn 1989</a>; <a href="./references#CD002855-bbs2-0073" title="TangOS , LeeSW , HoPC .A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. Human Reproduction (Oxford, England)2002;17(11):2865-8. ">Tang 2002</a>; <a href="./references#CD002855-bbs2-0079" title="VermaML , SinghU , SinghN , ShankhwarP , SrivastavaD .Efficacy of misoprostol administration 24 hours after mifepristone for termination of early pregnancy. Indian Journal of Medical Sciences2010;65(12):511-7. ">Verma 2011</a>; <a href="./references#CD002855-bbs2-0080" title="VermaML , SinghU , SinghN , SankhwarPL , QureshiS .Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human Fertility2017;20(1):43-7. ">Verma 2017</a>; <a href="./references#CD002855-bbs2-0082" title="vonHertzenH , PiaggioG , HuongN , ArustamyanK , CabezasE , GomezM , et al, on behalf of the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet2007;369:1938-46. ">von Hertzen 2007</a>; <a href="./references#CD002855-bbs2-0083" title="vonHertzenH , PiaggioG , WojdylaD , MarionsL , My HuongNT , TangOS , et al, for the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG2009;116:381–9. ">von Hertzen 2009</a>; <a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a>; <a href="./references#CD002855-bbs2-0086" title="TamangA , ShahIH , ShresthaP , WarrinerIK , WangD , ThapaK , et al.Comparative satisfaction of receiving medical abortion service from nurses and auxiliary nurse-midwives or doctors in Nepal: results of a randomized trial. Reproductive Health2017;14(1):176. [DOI: https://dx.doi.org/10.1186/s12978-017-0438-7]WarrinerIK , WangD , HuongNTM , ThapaK , TamangA , ShahI , et al.Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet2011;377(9772):1155-61. [DOI: https://dx.doi.org/10.1016/S0140-6736(10)62229-5]">Warriner 2011</a>; <a href="./references#CD002855-bbs2-0088" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility1991;56:32-40. ">WHO 1991</a>; <a href="./references#CD002855-bbs2-0093" title="WiebeER .Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception1999;59:265-70. ">Wiebe 1999a</a>; <a href="./references#CD002855-bbs2-0094" title="WiebeER .Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. American Journal of Obstetrics &amp; Gynecology1999;181:149-52. ">Wiebe 1999b</a>; <a href="./references#CD002855-bbs2-0098" title="WuYM , LiY , FanHM , ZhuXJ , ZhengS , WangS , et al.Clinical study of mifepristone in combination with tamoxifen and 15-methyl-PGF2alpha methylester for termination of early pregnancy. Sheng Zhi Yi Xue Za Zhi1993;4:224-7. ">Wu 1993</a>; see <a href="#CD002855-fig-0002">Figure 2</a>), and low in the other 59 studies with balanced attrition or with ITT analysis performed by study authors or with no attrition. </p> </section> <section id="CD002855-sec-0053"> <h4 class="title">Selective reporting</h4> <p>One study did not report side effects as stated in their published protocol, and we judged the risk of bias for reporting as high (<a href="./references#CD002855-bbs2-0076" title="TeimooriB , EsmaeilpoorM , AshkezariAK , FarzanehF .Comparison of induction abortion in the first trimester using misoprostol alone and misoprostol with estrogen priming. International Journal of Women’s Health and Reproduction Sciences2019;7(3):404. ">Teimoori 2019</a>). We judged risk of bias as unclear in 23 studies without enough information from protocols (<a href="./references#CD002855-bbs2-0003" title="AllamehZ , GoharianM , EslamianM .Share effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. International Journal of Gynaecology and Obstetrics2020;151(2):214-8. ">Allameh 2020</a>; <a href="./references#CD002855-bbs2-0007" title="Behroozi-LakT , Derakhshan-AydenlooS , BroomandF .Evaluation of effect of letrozole prior to misoprostol in comparison with misoprostol alone in success rate of induced abortion. Journal of Gynecology Obstetrics and Human Reproduction2018;47(3):113-7. [DOI: https://dx.doi.org/10.1016/j.jogoh.2017.11.002]">Behroozi Lak 2018</a>; <a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a>; <a href="./references#CD002855-bbs2-0027" title="DahiyaK , MannS , NandaS .Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion. Archives of Gynecology and Obstetrics2011;284(1):59-63. [DOI: https://dx.doi.org/10.1007/s00404-010-1590-2]">Dahiya 2011</a>; <a href="./references#CD002855-bbs2-0031" title="GargG , TakkarN , SehgalA .Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions. Journal of Obstetrics and Gynaecology of India2015;65(2):111-6. [DOI: https://dx.doi.org/10.1007/s13224-014-0605-5]">Garg 2015</a>; <a href="./references#CD002855-bbs2-0032" title="GoelA , MittalS , TanejaBK , SingalN , AttriS .Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2011;283(6):1409-13. [DOI: https://dx.doi.org/10.1007/s00404-011-1881-2]">Goel 2011</a>; <a href="./references#CD002855-bbs2-0038" title="JavadiEH , MohammadiM , BarikaniA .Induction of abortion in the first trimester by misoprostol or misoprostol with letrozole. Biotechnology and Health Sciences2015;2(3):e29562. ">Javadi 2015</a>; <a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a>; <a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0046" title="MarwahS , GuptaS , BatraNP , BhasinV , SarnaV , KaurN .A comparative study to evaluate the efficacy of vaginal vs oral prostaglandin E1 analogue (misoprostol) in management of first trimester missed abortion. Journal of Clinical and Diagnostic Research2016;10(5):QC14-8. [DOI: https://dx.doi.org/10.7860/JCDR/2016/18178.7891]">Marwah 2016</a>; <a href="./references#CD002855-bbs2-0050" title="NgBK , AnnamalaiR , LimPS , Aqmar SurayaS , Nur AzurahAG , Muhammad Abdul JamilMY .Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of Gynecology and Obstetrics2015;291(1):105-13. [DOI: https://dx.doi.org/10.1007/s00404-014-3388-0]">Ng 2015</a>; <a href="./references#CD002855-bbs2-0052" title="OlavarrietaCD , GanatraB , SorhaindoA , KarverTS , SeucA , VillalobosA , et al.Nurse versus physician-provision of early medical abortion in Mexico: a randomized controlled non-inferiority trial. Bulletin of the World Health Organization2015;93(4):249-58. [DOI: https://dx.doi.org/10.2471/BLT.14.143990]">Olavarrieta 2015</a>; <a href="./references#CD002855-bbs2-0054" title="ParitakulP , PhupongV .Comparative study between oral and sublingual 600 micro g misoprostol for the treatment of incomplete abortion. Journal of Obstetrics and Gynaecology Research2010;36(5):978-83. [DOI: https://dx.doi.org/10.1111/j.1447-0756.2010.01264.x]">Paritakul 2010</a>; <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a>; <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a>; <a href="./references#CD002855-bbs2-0067" title="ShresthaA , SedhaiLB .A randomized trial of hospital vs home self administration of vaginal misoprostol for medical abortion. Kathmandu University Medical Journal2014;12(47):185-9. ">Shrestha 2014</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>; <a href="./references#CD002855-bbs2-0070" title="SonsanohA , ChullapramT .Comparison of sublingual and vaginal misoprostol for termination of early pregnancy failure: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2014;22(3):128. ">Sonsanoh 2014</a>; <a href="./references#CD002855-bbs2-0075" title="TanhaFD , FeiziM , ShariatM .Sublingual versus vaginal misoprostol for the management of missed abortion. Journal of Obstetrics and Gynaecology Research2010;36(3):525-32. [DOI: 10.1111/j.1447-0756.2010.01229.x]">Tanha 2010</a>; <a href="./references#CD002855-bbs2-0078" title="Vahid RoudsariF , AyatiS , SaghafyN , ShakeriM .Misoprostol alone or in combination with methotrexate for termination of pregnancy at first trimester. Iranian Journal of Pharmaceutical Research2010;9(1):89-94. ">Vahid Roudsari 2010</a>; <a href="./references#CD002855-bbs2-0080" title="VermaML , SinghU , SinghN , SankhwarPL , QureshiS .Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human Fertility2017;20(1):43-7. ">Verma 2017</a>; <a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a>; <a href="./references#CD002855-bbs2-0086" title="TamangA , ShahIH , ShresthaP , WarrinerIK , WangD , ThapaK , et al.Comparative satisfaction of receiving medical abortion service from nurses and auxiliary nurse-midwives or doctors in Nepal: results of a randomized trial. Reproductive Health2017;14(1):176. [DOI: https://dx.doi.org/10.1186/s12978-017-0438-7]WarrinerIK , WangD , HuongNTM , ThapaK , TamangA , ShahI , et al.Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet2011;377(9772):1155-61. [DOI: https://dx.doi.org/10.1016/S0140-6736(10)62229-5]">Warriner 2011</a>; <a href="#CD002855-fig-0002">Figure 2</a>), and low in the other 75 studies with efficacy and side effects outcomes as per their protocols. </p> </section> <section id="CD002855-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>Risk of bias for other potential sources of bias was unclear in 22 studies (<a href="./references#CD002855-bbs2-0001" title="AbbasalizadehF , SahhafF , Sadeghi-ShabestariP , Mirza-Aghazadeh-AttariM , Naghavi-BehzadM .Comparison between effect of letrozole plus misoprostol and misoprostol alone in terminating non-viable first trimester pregnancies: a single blind randomized trial. Journal of Family and Reproductive Health2018;12(1):27-33. ">Abbasalizadeh 2018</a>; <a href="./references#CD002855-bbs2-0003" title="AllamehZ , GoharianM , EslamianM .Share effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. International Journal of Gynaecology and Obstetrics2020;151(2):214-8. ">Allameh 2020</a>; <a href="./references#CD002855-bbs2-0008" title="BirgersonL , OdlindV .The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception1988;38(4):391-400. ">Birgerson 1988</a>; <a href="./references#CD002855-bbs2-0010" title="BlumJ , RaghavanS , DabashR , Ngoc NtN, ChelliH , HajriS , et al.Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. International Journal of Gynaecology and Obstetrics2012;118(2):166-71. [DOI: https://dx.doi.org/10.1016/j.ijgo.2012.03.039]">Blum 2012</a>; <a href="./references#CD002855-bbs2-0011" title="CameronIT , MichieAF , BairdDT .Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (gemeprost). Contraception1986;34(5):459-68. ">Cameron 1986</a>; <a href="./references#CD002855-bbs2-0026" title="CreininMD , SchreiberCA , BednarekP , LintuH , WagnerMS , MeynLA .Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion. Obstetrics and Gynecology2007;109:885-94. ">Creinin 2007</a>; <a href="./references#CD002855-bbs2-0045" title="LiaoA , HanXJ , WuSY , XiaoDZ , XiongCL , WuXR .Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;116:211-6. ">Liao 2004</a>; <a href="./references#CD002855-bbs2-0051" title="NgocNT , BlumJ , RaghavanS , NgaNT , DabashR , DiopA , et al.Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception2011;83(5):410-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.09.002]">Ngoc 2011</a>; <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a>; <a href="./references#CD002855-bbs2-0056" title="RaghavanS , ComendantR , DigolI , UngureanuS , FriptuV , BrackenH , et al.Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol. Contraception2009;79:84-90. ">Raghavan 2009</a>; <a href="./references#CD002855-bbs2-0058" title="RodgerMW , LoganAF , BairdDT .Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception1989;39(5):497-502. ">Rodger 1989</a>; <a href="./references#CD002855-bbs2-0059" title="SandstromO , BrooksL , SchantzA , GrinstedJ , GrinstedL , JacobsenJD , et al.Interruption of early pregnancy with mifepristone in combination with gemeprost. Acta Obstetricia et Gynecologica Scandinavica1999;78:806-9. ">Sandstrom 1999</a>; <a href="./references#CD002855-bbs2-0061" title="SangGW , HeCH , ShaoQX , ZhuangLQ , WengLJ , WuBX , et al.A large scale introductory trial on termination of early pregnancy by mifepristone in combination with different prostaglandins. Chinese Journal for Clinical Pharmacology1999;15(5):323-9. ">Sang 1999</a>; <a href="./references#CD002855-bbs2-0062" title="SchaffEA , FieldingSL , WesthoffC , EllertsonC , EisingerSH , StadaliusLS , et al.Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion. JAMA2000;284(15):1948-53. ">Schaff 2000</a>; <a href="./references#CD002855-bbs2-0065" title="ShannonC , WiebeE , JacotF , GuilbertE , DunnS , SheldonW , et al.Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG2006;113:621–8. ">Shannon 2006</a>; <a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a>; <a href="./references#CD002855-bbs2-0072" title="SwahnML , UgocsaiG , BygdemanM , KovacsL , BelseyEM , Van LookPF .Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy. Human Reproduction (Oxford, England)1989;4(1):21-8. ">Swahn 1989</a>; <a href="./references#CD002855-bbs2-0080" title="VermaML , SinghU , SinghN , SankhwarPL , QureshiS .Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human Fertility2017;20(1):43-7. ">Verma 2017</a>; <a href="./references#CD002855-bbs2-0083" title="vonHertzenH , PiaggioG , WojdylaD , MarionsL , My HuongNT , TangOS , et al, for the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG2009;116:381–9. ">von Hertzen 2009</a>; <a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a>; <a href="./references#CD002855-bbs2-0092" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG2001;108:738-42. ">WHO 2001b</a>; <a href="./references#CD002855-bbs2-0099" title="ZhengSR .RU486 (mifepristone): clinical trials in China. Acta Obstetricia et Gynecologica Scandinavica. Supplement1989;149:19-23. ">Zheng 1989</a>), for pharmaceutical company support; funding from an anonymous donor; unexpectedly high number of ongoing pregnancies; cessation of study; and participants with eight to 20 weeks' gestation were included, and not stratified by gestational weeks. The other 77 studies without these factors, we judged as low risk (see <a href="#CD002855-fig-0002">Figure 2</a>; <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>). </p> </section> </section> <section id="CD002855-sec-0055"> <h3 class="title" id="CD002855-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD002855-tbl-0001"><b>Summary of findings 1</b> Mifepristone (600 mg) plus prostaglandin versus mifepristone (200 mg) plus prostaglandin for first trimester abortion</a>; <a href="./full#CD002855-tbl-0002"><b>Summary of findings 2</b> Misoprostol 800 µg plus mifepristone 200 mg versus misoprostol 400 µg plus mifepristone 200 mg for first trimester abortion</a>; <a href="./full#CD002855-tbl-0003"><b>Summary of findings 3</b> Medical abortion self‐administered at home compared to administered in hospital for first trimester abortion</a>; <a href="./full#CD002855-tbl-0004"><b>Summary of findings 4</b> Medical abortion administered by nurses compared to by doctors for first trimester abortion</a>; <a href="./full#CD002855-tbl-0005"><b>Summary of findings 5</b> Oral misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</a>; <a href="./full#CD002855-tbl-0006"><b>Summary of findings 6</b> Sublingual misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</a>; <a href="./full#CD002855-tbl-0007"><b>Summary of findings 7</b> Mifepristone alone compared to mifepristone/prostaglandin for first trimester abortion</a>; <a href="./full#CD002855-tbl-0008"><b>Summary of findings 8</b> Prostaglandin alone compared to combined regimen for first trimester abortion</a>; <a href="./full#CD002855-tbl-0009"><b>Summary of findings 9</b> Oral misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</a>; <a href="./full#CD002855-tbl-0010"><b>Summary of findings 10</b> Sublingual misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</a> </p> <p>Due to the many interventions, we grouped included studies into comparisons, as listed below. The main outcome for which we performed meta‐analyses was failure to achieve complete abortion with the method intended. Data on side effects could be combined for some comparisons. Subgroup analysis was performed based on different gestational ages where possible (less than or equal to 49 days, and greater than 49 days). One study used two different comparisons, and was therefore listed as two different studies (<a href="./references#CD002855-bbs2-0093" title="WiebeER .Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception1999;59:265-70. ">Wiebe 1999a</a>; <a href="./references#CD002855-bbs2-0094" title="WiebeER .Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. American Journal of Obstetrics &amp; Gynecology1999;181:149-52. ">Wiebe 1999b</a>). Three, four and five arms were included in four studies respectively (<a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a>; <a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a>; <a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a>; <a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>). Seven studies in total used different regimens/doses/timing of the drugs that could not be combined with any of the other regimens in the comparisons and were therefore listed separately in additional <a href="#CD002855-tbl-0011">Table 1</a> (<a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a>; <a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a>; <a href="./references#CD002855-bbs2-0045" title="LiaoA , HanXJ , WuSY , XiaoDZ , XiongCL , WuXR .Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;116:211-6. ">Liao 2004</a>; <a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a>; <a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a>; <a href="./references#CD002855-bbs2-0088" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility1991;56:32-40. ">WHO 1991</a>; <a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a>). </p> <section id="CD002855-sec-0056"> <h4 class="title"><i>1. Combined regimen mifepristone/prostaglandin</i> </h4> <section id="CD002855-sec-0057"> <h5 class="title">Comparison 1: different doses of mifepristone</h5> <p>We included 10 studies in this comparison; six were included in the meta‐analysis of different comparison groups. The comparisons were 600 mg versus 200 mg, 200 mg versus 100 mg, and 200 mg versus 50 mg of mifepristone (<a href="./references#CD002855-bbs2-0047" title="McKinleyC , ThongKJ , BairdDT .The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction (Oxford, England)1993;8(9):1502-5. ">McKinley 1993</a>; <a href="./references#CD002855-bbs2-0083" title="vonHertzenH , PiaggioG , WojdylaD , MarionsL , My HuongNT , TangOS , et al, for the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG2009;116:381–9. ">von Hertzen 2009</a>; <a href="./references#CD002855-bbs2-0089" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Termination of pregnancy with reduced doses of mifepristone. BMJ1993;307:532-7. ">WHO 1993</a>; <a href="./references#CD002855-bbs2-0090" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG2000;107:524-30. ">WHO 2000</a>; <a href="./references#CD002855-bbs2-0091" title="World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation.Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost. Acta Obstetrica et Gynecologica Scandinavica2001;80:447-51. ">WHO 2001a</a>; <a href="./references#CD002855-bbs2-0092" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG2001;108:738-42. ">WHO 2001b</a>). We present details about split doses of mifepristone (i.e. administered as several doses or one dose; <a href="./references#CD002855-bbs2-0045" title="LiaoA , HanXJ , WuSY , XiaoDZ , XiongCL , WuXR .Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;116:211-6. ">Liao 2004</a>; <a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a>; <a href="./references#CD002855-bbs2-0088" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility1991;56:32-40. ">WHO 1991</a>), and five different doses of mifepristone (150 mg, 125 mg, 100 mg, 75 mg, 50 mg; <a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a>) in <a href="#CD002855-tbl-0011">Table 1</a>. </p> <section id="CD002855-sec-0058"> <h6 class="title">Mifepristone 600 mg versus 200 mg</h6> <p>Six studies reported this comparison (<a href="./references#CD002855-bbs2-0047" title="McKinleyC , ThongKJ , BairdDT .The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction (Oxford, England)1993;8(9):1502-5. ">McKinley 1993</a>; <a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a>; <a href="./references#CD002855-bbs2-0088" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility1991;56:32-40. ">WHO 1991</a>; <a href="./references#CD002855-bbs2-0089" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Termination of pregnancy with reduced doses of mifepristone. BMJ1993;307:532-7. ">WHO 1993</a>; <a href="./references#CD002855-bbs2-0090" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG2000;107:524-30. ">WHO 2000</a>; <a href="./references#CD002855-bbs2-0091" title="World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation.Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost. Acta Obstetrica et Gynecologica Scandinavica2001;80:447-51. ">WHO 2001a</a>), of which we included data from four studies with 3494 participants in the meta‐analysis (<a href="./references#CD002855-bbs2-0047" title="McKinleyC , ThongKJ , BairdDT .The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction (Oxford, England)1993;8(9):1502-5. ">McKinley 1993</a>; <a href="./references#CD002855-bbs2-0089" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Termination of pregnancy with reduced doses of mifepristone. BMJ1993;307:532-7. ">WHO 1993</a>; <a href="./references#CD002855-bbs2-0090" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG2000;107:524-30. ">WHO 2000</a>; <a href="./references#CD002855-bbs2-0091" title="World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation.Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost. Acta Obstetrica et Gynecologica Scandinavica2001;80:447-51. ">WHO 2001a</a>). <a href="./references#CD002855-bbs2-0047" title="McKinleyC , ThongKJ , BairdDT .The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction (Oxford, England)1993;8(9):1502-5. ">McKinley 1993</a> used misoprostol 600 µg orally, <a href="./references#CD002855-bbs2-0089" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Termination of pregnancy with reduced doses of mifepristone. BMJ1993;307:532-7. ">WHO 1993</a> and <a href="./references#CD002855-bbs2-0091" title="World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation.Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost. Acta Obstetrica et Gynecologica Scandinavica2001;80:447-51. ">WHO 2001a</a> used gemeprost 1 mg vaginally, <a href="./references#CD002855-bbs2-0090" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG2000;107:524-30. ">WHO 2000</a> used misoprostol 400 µg orally. Compared to 200 mg of mifepristone, 600 mg of mifepristone probably has a similar effect on failure to achieve complete abortion (RR 1.07, 95% CI 0.87 to 1.33; I<sup>2</sup> = 0%; 4 RCTs, 3494 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0005" title="">Analysis 1.1</a>; <a href="./full#CD002855-tbl-0001">summary of findings Table 1</a>). The pooled analysis of the two studies that used the same dose and type of prostaglandin (gemeprost 1 mg) after 600 mg or 200 mg of mifepristone, also showed that 600 mg of mifepristone might have a similar effect on complete abortion as 200 mg (RR 1.02, 95% CI 0.72 to 1.45; 2 RCTs; 1685 women; <a href="./references#CD002855-fig-0005" title="">Analysis 1.1</a>). Nausea was similar between the two groups (RR 1.02, 95% CI 0.95 to 1.09; I<sup>2</sup> = 83%; 2 RCTs, 2432 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0006" title="">Analysis 1.2</a>; <a href="./full#CD002855-tbl-0001">summary of findings Table 1</a>). Time until passing of conceptus longer than three to six hours was similar for the two groups in the two studies that reported it (1116 women; <a href="./references#CD002855-fig-0007" title="">Analysis 1.3</a>). The five studies that reported ongoing pregnancy at follow‐up (<a href="./references#CD002855-bbs2-0047" title="McKinleyC , ThongKJ , BairdDT .The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction (Oxford, England)1993;8(9):1502-5. ">McKinley 1993</a>; <a href="./references#CD002855-bbs2-0083" title="vonHertzenH , PiaggioG , WojdylaD , MarionsL , My HuongNT , TangOS , et al, for the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG2009;116:381–9. ">von Hertzen 2009</a>; <a href="./references#CD002855-bbs2-0089" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Termination of pregnancy with reduced doses of mifepristone. BMJ1993;307:532-7. ">WHO 1993</a>; <a href="./references#CD002855-bbs2-0090" title="WHO Task Force on Post-Ovulatory Methods of Fertility Regulation.Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG2000;107:524-30. ">WHO 2000</a>; <a href="./references#CD002855-bbs2-0092" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG2001;108:738-42. ">WHO 2001b</a>), showed similar efficacy between the two groups (<a href="./references#CD002855-fig-0008" title="">Analysis 1.4</a>). The dosage or route of misoprostol were different among these four included RCTs, so pooled analysis was not performed. </p> </section> <section id="CD002855-sec-0059"> <h6 class="title">Mifepristone 200 mg versus 100 mg</h6> <p>One study was included in this comparison (<a href="./references#CD002855-bbs2-0083" title="vonHertzenH , PiaggioG , WojdylaD , MarionsL , My HuongNT , TangOS , et al, for the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG2009;116:381–9. ">von Hertzen 2009</a>). This was a four‐arm study, comparing 200 mg versus 100 mg of mifepristone followed by 800 µg misoprostol vaginally after 24 or 48 hours. Compared to 100 mg of mifepristone, 200 mg of mifepristone probably made little difference in failure to achieve complete abortion (RR 0.89 95%; CI 0.61 to 1.29; 1182 women; <a href="./references#CD002855-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD002855-sec-0060"> <h6 class="title">Mifepristone 200 mg versus 50 mg</h6> <p><a href="./references#CD002855-bbs2-0092" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG2001;108:738-42. ">WHO 2001b</a> used 200 mg or 50 mg followed by 0.5 mg or 1 mg of gemeprost vaginally. The group receiving mifepristone 50 mg and gemeprost 0.5 mg was discontinued after 249 women were enrolled because the complete abortion rate was below the pre‐determined cut‐off. </p> </section> <section id="CD002855-sec-0061"> <h6 class="title">Mifepristone 150 mg, 125 mg, 100 mg, 75 mg versus 50 mg</h6> <p><a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a> was a five‐arm study that compared five different dosage of mifepristone followed by 200 µg misoprostol orally after 24 hours. Failure to achieve abortion was similar between the groups (one study, 2500 women; <a href="#CD002855-tbl-0011">Table 1</a>). However, the side effects of nausea, vomiting, diarrhoea and abdominal pain might be higher when the dosage of mifepristone was 100 mg or higher (<a href="#CD002855-tbl-0011">Table 1</a>). </p> </section> </section> <section id="CD002855-sec-0062"> <h5 class="title">Comparison 2: different doses of prostaglandin</h5> <p>We included eight studies in the review for this comparison; we were able to include data from seven of them in the meta‐analysis of different comparison groups as below (<a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>; <a href="./references#CD002855-bbs2-0017" title="ChongE , TsereteliT , NguyenNN , WinikoffB .A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception2012;86(3):251-6. [DOI: https://dx.doi.org/10.1016/j.contraception.2011.12.012]">Chong 2012</a>; <a href="./references#CD002855-bbs2-0018" title="CoyajiK , KrishnaU , AmbardekarS , BrackenH , RaoteV , MandlekarA , et al.Are two doses of misoprostol after mifepristone for early abortion better than one?BJOG2007;114:271–8. ">Coyaji 2007</a>; <a href="./references#CD002855-bbs2-0058" title="RodgerMW , LoganAF , BairdDT .Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception1989;39(5):497-502. ">Rodger 1989</a>; <a href="./references#CD002855-bbs2-0065" title="ShannonC , WiebeE , JacotF , GuilbertE , DunnS , SheldonW , et al.Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG2006;113:621–8. ">Shannon 2006</a>; <a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>; <a href="./references#CD002855-bbs2-0092" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG2001;108:738-42. ">WHO 2001b</a>). </p> <section id="CD002855-sec-0063"> <h6 class="title">Combined dosage comparison: gemeprost 1 mg versus 0.5 mg with different dosage of mifepristone </h6> <p>Two studies compared gemeprost 1 mg versus gemeprost 0.5 mg in 1034 women (<a href="./references#CD002855-bbs2-0058" title="RodgerMW , LoganAF , BairdDT .Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception1989;39(5):497-502. ">Rodger 1989</a>; <a href="./references#CD002855-bbs2-0092" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG2001;108:738-42. ">WHO 2001b</a>). The largest study in this comparison used a factorial design (mifepristone 50/200 mg and gemeprost 1/0.5 mg; <a href="./references#CD002855-bbs2-0092" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. BJOG2001;108:738-42. ">WHO 2001b</a>). Looking at the group with mifepristone 200 mg only, the failure to achieve complete abortion between the two doses of gemeprost was similar. The arm with the smallest dose (mifepristone 50 mg and gemeprost 0.5 mg) was stopped prematurely after 249 women were enrolled, as the effectiveness was below the predetermined cut‐off point. <a href="./references#CD002855-bbs2-0058" title="RodgerMW , LoganAF , BairdDT .Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception1989;39(5):497-502. ">Rodger 1989</a> included 120 women in the study using mifepristone of 600 mg, the first 60 women were not randomised; therefore, only data for the second 60 women were reported in this review (<a href="./references#CD002855-bbs2-0058" title="RodgerMW , LoganAF , BairdDT .Induction of early abortion with mifepristone (RU 486) and two different doses of prostaglandin pessary (gemeprost). Contraception1989;39(5):497-502. ">Rodger 1989</a>). </p> </section> <section id="CD002855-sec-0064"> <h6 class="title">Misoprostol 800 µg versus 400 µg</h6> <p>Five studies compared different doses of misoprostol after 200 mg of mifepristone. <a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a> used four groups, comparing misoprostol 800 µg administered sublingually, 400 µg administered sublingually, 800 µg administered vaginally, and 400 µg administered vaginally. We pooled the outcome data of 800 µg sublingually and 800 µg vaginally; 400 µg sublingually and 400 µg vaginally, respectively, for exploring the efficacy of different doses with similar routes. The route of misoprostol between groups was similar in three (<a href="./references#CD002855-bbs2-0017" title="ChongE , TsereteliT , NguyenNN , WinikoffB .A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception2012;86(3):251-6. [DOI: https://dx.doi.org/10.1016/j.contraception.2011.12.012]">Chong 2012</a>; <a href="./references#CD002855-bbs2-0018" title="CoyajiK , KrishnaU , AmbardekarS , BrackenH , RaoteV , MandlekarA , et al.Are two doses of misoprostol after mifepristone for early abortion better than one?BJOG2007;114:271–8. ">Coyaji 2007</a>; <a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>), but different in two studies (<a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>; <a href="./references#CD002855-bbs2-0065" title="ShannonC , WiebeE , JacotF , GuilbertE , DunnS , SheldonW , et al.Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG2006;113:621–8. ">Shannon 2006</a>). <a href="./references#CD002855-bbs2-0018" title="CoyajiK , KrishnaU , AmbardekarS , BrackenH , RaoteV , MandlekarA , et al.Are two doses of misoprostol after mifepristone for early abortion better than one?BJOG2007;114:271–8. ">Coyaji 2007</a> compared misoprostol 400 µg to 800 µg (given orally; 800 µg was administered as a repeat dose of 400 µg after three hours). <a href="./references#CD002855-bbs2-0017" title="ChongE , TsereteliT , NguyenNN , WinikoffB .A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception2012;86(3):251-6. [DOI: https://dx.doi.org/10.1016/j.contraception.2011.12.012]">Chong 2012</a> compared misoprostol 400 µg to 800 µg (given buccally; 400 µg was administered using two pills of misoprostol and two pills of placebo). <a href="./references#CD002855-bbs2-0065" title="ShannonC , WiebeE , JacotF , GuilbertE , DunnS , SheldonW , et al.Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG2006;113:621–8. ">Shannon 2006</a> used three groups, comparing misoprostol 400 µg, 600 µg and 800 µg. We included data from the 400 µg and 800 µg groups in the subgroup of misoprostol 400 µg orally versus 800 µg vaginally with <a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>. </p> <p>In total, 800 µg misoprostol probably showed a lower failure to achieve complete abortion than 400 µg (RR 0.63, 95% CI 0.51 to 0.78; I<sup>2</sup>= 0%; 3 RCTs, 4424 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0009" title="">Analysis 2.1</a>; <a href="./full#CD002855-tbl-0002">summary of findings Table 2</a>) when the misoprostol was prescribed using a similar route between groups. Results from the largest study (<a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>), using misoprostol sublingually or vaginally, carried most weight (RR 0.61, 95% CI 0.48 to 0.77; 3005 women; <a href="./references#CD002855-fig-0009" title="">Analysis 2.1</a>). However, the failure to achieve complete abortion was probably similar between groups when using misoprostol orally or buccally, no matter whether gestation was less than 49 days or not. The difference between 800 µg vaginally and 400 µg orally may also be similar. </p> <p>Misoprostol 800 µg probably resulted in fewer ongoing pregnancies (RR 0.41, 95% CI 0.26 to 0.65; I<sup>2</sup> = 5%; 4 RCTs, 5060 women; <a href="./references#CD002855-fig-0011" title="">Analysis 2.3</a>), lower dissatisfaction with the procedure (RR 0.75, 95% CI 0.60 to 0.93; I<sup>2</sup>= 0; 3 RCTs, 4420 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0016" title="">Analysis 2.8</a>; <a href="./full#CD002855-tbl-0002">summary of findings Table 2</a>), but similar nausea (RR 0.99, 95% CI 0.94 to 1.05; I<sup>2</sup> = 0%; 3 RCTs, 4424 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0012" title="">Analysis 2.4</a>; <a href="./full#CD002855-tbl-0002">summary of findings Table 2</a>) and more severe diarrhoea (RR 1.70, 95% CI 1.43 to 2.03; I<sup>2</sup> = 0%; 2 RCTs, 3302 women; <a href="./references#CD002855-fig-0014" title="">Analysis 2.6</a>) when compared to the 400 µg group. Surgical evacuation (<a href="./references#CD002855-fig-0010" title="">Analysis 2.2</a>), vomiting (<a href="./references#CD002855-fig-0013" title="">Analysis 2.5</a>), and abdominal pain (<a href="./references#CD002855-fig-0015" title="">Analysis 2.7</a>), were similar between the groups. </p> </section> </section> <section id="CD002855-sec-0065"> <h5 class="title">Comparison 3: type of prostaglandin</h5> <section id="CD002855-sec-0066"> <h6 class="title">Gemeprost versus misoprostol</h6> <p>We included two studies that used different doses of misoprostol and different routes of administration (<a href="./references#CD002855-bbs2-0005" title="BairdDT , SukcharoenN , ThongKJ .Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Human Reproduction (Oxford, England)1995;10(6):1521-7. ">Baird 1995</a>; <a href="./references#CD002855-bbs2-0006" title="BartleyJ , BrownA , EltonR , BairdDT .Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Human Reproduction (Oxford, England)2001;16(10):2098-102. ">Bartley 2001</a>). Therefore, we did not combine the results in a meta‐analysis. However, according to data from a single study (<a href="./references#CD002855-bbs2-0006" title="BartleyJ , BrownA , EltonR , BairdDT .Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Human Reproduction (Oxford, England)2001;16(10):2098-102. ">Bartley 2001</a>), misoprostol used at a higher dose (800 µg) and administered vaginally, might be more effective than gemeprost 0.5 mg (failure to achieve complete abortion: RR 2.86, 95% CI 1.14 to 7.18; 910 women; <a href="./references#CD002855-fig-0017" title="">Analysis 3.1</a>). Misoprostol might result more vomiting (RR 1.49, 95% CI 1.06 to 2.10; 910 women; <a href="./references#CD002855-fig-0018" title="">Analysis 3.2</a>) and diarrhoea (RR 2.66, 95% CI 1.35 to 5.26; 910 women; <a href="./references#CD002855-fig-0018" title="">Analysis 3.2</a>) compared to gemeprost, but might have a similar effect on ongoing pregnancy (<a href="./references#CD002855-fig-0019" title="">Analysis 3.3</a>) and time until passing of conceptus longer than three to six hours (<a href="./references#CD002855-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002855-sec-0067"> <h6 class="title">PGF2α versus misoprostol</h6> <p>Misoprostol (600 µg, orally) probably leads to a similar effect on complete abortion compared to PGF2α (failure to achieve complete abortion: RR 0.84, 95% CI 0.44 to 1.58; I<sup>2</sup> = 47%; 2 RCTs, 17,974 women; <a href="./references#CD002855-fig-0017" title="">Analysis 3.1</a> (<a href="./references#CD002855-bbs2-0060" title="SangGW , WengLJ , ShaoQX , DuMK , WuXZ , LuYL , et al.Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05 - a multicentre randomized clinical trial in China. Contraception1994;50:501-10. ">Sang 1994</a>; <a href="./references#CD002855-bbs2-0061" title="SangGW , HeCH , ShaoQX , ZhuangLQ , WengLJ , WuBX , et al.A large scale introductory trial on termination of early pregnancy by mifepristone in combination with different prostaglandins. Chinese Journal for Clinical Pharmacology1999;15(5):323-9. ">Sang 1999</a>)). </p> </section> </section> <section id="CD002855-sec-0068"> <h5 class="title">Comparison 4: timing of prostaglandin</h5> <p>We included nine studies for this comparison. Three studies used different dose regimens as well as time intervals (<a href="./references#CD002855-bbs2-0024" title="CreininMD , SchwartzJL , PymarHC , FinkW .Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. British Journal of Obstetrics and Gynaecology2001;108:469-73. ">Creinin 2001b</a>; <a href="./references#CD002855-bbs2-0033" title="GuestJ , ChienPF , ThomsonMA , KosseimML .Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG2007;114:207-15. ">Guest 2007</a>; <a href="./references#CD002855-bbs2-0062" title="SchaffEA , FieldingSL , WesthoffC , EllertsonC , EisingerSH , StadaliusLS , et al.Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion. JAMA2000;284(15):1948-53. ">Schaff 2000</a>); therefore, we have presented the results for each study separately. </p> <section id="CD002855-sec-0069"> <h6 class="title">Day 3 versus day 1</h6> <p>Misoprostol administered on day one was probably more effective than on day three following mifepristone (failure to achieve complete abortion: RR 1.94, 95% CI 1.05 to 3.58; 1489 women; <a href="./references#CD002855-fig-0021" title="">Analysis 4.1</a>) in the one study that reported this comparison (<a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a>). The follow‐up for women was on day eight after mifepristone. Misoprostol administered on day three might slightly increase need for surgical evacuation (RR 1.49, 95% CI 0.78 to 2.83; 1489 women; <a href="./references#CD002855-fig-0023" title="">Analysis 4.3</a>), increase ongoing pregnancy (RR 1.56, 95% CI 0.51 to 4.73; 1489 women; <a href="./references#CD002855-fig-0024" title="">Analysis 4.4</a>) or increase women' dissatisfaction with the method (RR 0.99, 95% CI 0.80 to 1.23; 2 RCTs, 1429 women; <a href="./references#CD002855-fig-0025" title="">Analysis 4.5</a>). </p> </section> <section id="CD002855-sec-0070"> <h6 class="title">Day 3 versus day 2</h6> <p>Misoprostol administration on day three might lead to slightly higher failure to achieve complete abortion compared with day two (RR 1.69, 95% CI 0.95 to 3.01; 1521 women; <a href="./references#CD002855-fig-0021" title="">Analysis 4.1</a>) based on evidence from one study (<a href="./references#CD002855-bbs2-0062" title="SchaffEA , FieldingSL , WesthoffC , EllertsonC , EisingerSH , StadaliusLS , et al.Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion. JAMA2000;284(15):1948-53. ">Schaff 2000</a>). </p> </section> <section id="CD002855-sec-0071"> <h6 class="title">Day 2 versus day 1</h6> <p>Misoprostol administration on day two might lead to similar efficacy on failure to achieve complete abortion compared with day one when combining results for gestational ages up to 63 days based on four studies (RR 0.99, 95% CI 0.61 to 1.61; I<sup>2</sup> = 48%; 4 RCTs, 3887 women; <a href="./references#CD002855-fig-0021" title="">Analysis 4.1</a>). However, in the subgroup analysis based on gestational weeks, failure might be higher on day two compared to day one in women at more than 49 days' gestation (RR 1.57, 95% CI 1.09 to 2.27; I<sup>2</sup> = 0%; 2 RCTs, 1207 women; <a href="./references#CD002855-fig-0021" title="">Analysis 4.1</a>), but lower in women at 49 days or fewer of gestation (RR 0.90, 95% CI 0.58 to 1.38; I<sup>2</sup> = 0%; 2 RCTs, 1116 women; <a href="./references#CD002855-fig-0021" title="">Analysis 4.1</a>). </p> </section> <section id="CD002855-sec-0072"> <h6 class="title">Day 2 versus day 0</h6> <p>Three studies compared misoprostol on day two versus day zero for failure to achieve a complete abortion (<a href="./references#CD002855-bbs2-0024" title="CreininMD , SchwartzJL , PymarHC , FinkW .Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. British Journal of Obstetrics and Gynaecology2001;108:469-73. ">Creinin 2001b</a>; <a href="./references#CD002855-bbs2-0033" title="GuestJ , ChienPF , ThomsonMA , KosseimML .Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG2007;114:207-15. ">Guest 2007</a>; <a href="./references#CD002855-bbs2-0080" title="VermaML , SinghU , SinghN , SankhwarPL , QureshiS .Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human Fertility2017;20(1):43-7. ">Verma 2017</a>). <a href="./references#CD002855-bbs2-0024" title="CreininMD , SchwartzJL , PymarHC , FinkW .Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. British Journal of Obstetrics and Gynaecology2001;108:469-73. ">Creinin 2001b</a> compared mifepristone 600 mg followed by misoprostol 400 µg; <a href="./references#CD002855-bbs2-0033" title="GuestJ , ChienPF , ThomsonMA , KosseimML .Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG2007;114:207-15. ">Guest 2007</a> compared mifepristone 200 mg followed by misoprostol 800 µg, and <a href="./references#CD002855-bbs2-0080" title="VermaML , SinghU , SinghN , SankhwarPL , QureshiS .Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy. Human Fertility2017;20(1):43-7. ">Verma 2017</a> compared mifepristone 200 mg followed by misoprostol 400 µg. Misoprostol administered at 36 to 48 hours might lead to lower failure to achieve complete abortion (RR 0.53, 95% CI 0.25 to 1.09; I<sup>2</sup> = 26%; 711 women; <a href="./references#CD002855-fig-0021" title="">Analysis 4.1</a>) and less need for surgical evacuation (RR 0.40, 95% CI 0.19 to 0.86; I<sup>2</sup> = 0%; 2 RCTs, 511 women; <a href="./references#CD002855-fig-0023" title="">Analysis 4.3</a>), when compared to six hours after mifepristone. </p> <p>Women using misoprostol on day two might experience less nausea than those using mifepristone and misoprostol concurrently (RR 0.75, 95% CI 0.58 to 0.98; I<sup>2</sup> = 0%; 3 RCTs, 644 women; <a href="./references#CD002855-fig-0022" title="">Analysis 4.2</a>). There was no difference in the occurrence of side effects (vomiting, diarrhoea, abdominal pain, ongoing pregnancy, and women's dissatisfaction with the procedure) among the different time interval groups of misoprostol. </p> </section> <section id="CD002855-sec-0073"> <h6 class="title">Day 1 versus day 0</h6> <p>Three studies used the same route, but different dosages of misoprostol (<a href="./references#CD002855-bbs2-0025" title="CreininMD , FoxMC , TealS , ChenA , SchaffEA , MeynLA .A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstetrics and Gynecology2004;103:851-9. ">Creinin 2004</a>; <a href="./references#CD002855-bbs2-0026" title="CreininMD , SchreiberCA , BednarekP , LintuH , WagnerMS , MeynLA .Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion. Obstetrics and Gynecology2007;109:885-94. ">Creinin 2007</a>; <a href="./references#CD002855-bbs2-0032" title="GoelA , MittalS , TanejaBK , SingalN , AttriS .Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2011;283(6):1409-13. [DOI: https://dx.doi.org/10.1007/s00404-011-1881-2]">Goel 2011</a>). Mifepristone 200 mg followed by misoprostol 800 µg vaginally or 400 µg vaginally (<a href="./references#CD002855-bbs2-0032" title="GoelA , MittalS , TanejaBK , SingalN , AttriS .Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2011;283(6):1409-13. [DOI: https://dx.doi.org/10.1007/s00404-011-1881-2]">Goel 2011</a>), administered on day one might be more effective than administration six hours or less after mifepristone (failure to achieve complete abortion: RR 0.65, 95% CI 0.46 to 0.91; I<sup>2</sup> = 0%; 3 RCTs, 2236 women; <a href="./references#CD002855-fig-0021" title="">Analysis 4.1</a>), no matter whether the gestational week was more than 49 days or not. </p> <p>Passing time of conceptus, bleeding time and additional usage of uterotonics were reported by only one study (<a href="./references#CD002855-bbs2-0032" title="GoelA , MittalS , TanejaBK , SingalN , AttriS .Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2011;283(6):1409-13. [DOI: https://dx.doi.org/10.1007/s00404-011-1881-2]">Goel 2011</a>). There was no difference between day one versus day zero (<a href="./references#CD002855-fig-0026" title="">Analysis 4.6</a>; <a href="./references#CD002855-fig-0027" title="">Analysis 4.7</a>; <a href="./references#CD002855-fig-0028" title="">Analysis 4.8</a>). </p> </section> </section> <section id="CD002855-sec-0074"> <h5 class="title">Comparison 5: administration strategy of prostaglandin</h5> <p>We included seven studies with a total of 5319 women in the review and meta‐analysis. Four studies compared home‐ (self‐administered) and hospital‐administered medical abortion (<a href="./references#CD002855-bbs2-0035" title="IyengarK , Klingberg-AllvinM , IyengarSD , PaulM , EssenB , Gemzell-DanielssonK .Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica2016;95(2):173-81. [DOI: https://dx.doi.org/10.1111/aogs.12815]IyengarK , PaulM , IyengarSD , Klingberg-AllvinM , EssenB , BringJ , et al.Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet2015;3(9):e537-45. [DOI: https://dx.doi.org/10.1016/S2214-109X(15)00150-3]">Iyengar 2015</a>; <a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0067" title="ShresthaA , SedhaiLB .A randomized trial of hospital vs home self administration of vaginal misoprostol for medical abortion. Kathmandu University Medical Journal2014;12(47):185-9. ">Shrestha 2014</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>). Three studies compared misoprostol provided by a nurse in the hospital versus a doctor in the hospital (<a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>; <a href="./references#CD002855-bbs2-0052" title="OlavarrietaCD , GanatraB , SorhaindoA , KarverTS , SeucA , VillalobosA , et al.Nurse versus physician-provision of early medical abortion in Mexico: a randomized controlled non-inferiority trial. Bulletin of the World Health Organization2015;93(4):249-58. [DOI: https://dx.doi.org/10.2471/BLT.14.143990]">Olavarrieta 2015</a>; <a href="./references#CD002855-bbs2-0086" title="TamangA , ShahIH , ShresthaP , WarrinerIK , WangD , ThapaK , et al.Comparative satisfaction of receiving medical abortion service from nurses and auxiliary nurse-midwives or doctors in Nepal: results of a randomized trial. Reproductive Health2017;14(1):176. [DOI: https://dx.doi.org/10.1186/s12978-017-0438-7]WarrinerIK , WangD , HuongNTM , ThapaK , TamangA , ShahI , et al.Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet2011;377(9772):1155-61. [DOI: https://dx.doi.org/10.1016/S0140-6736(10)62229-5]">Warriner 2011</a>). </p> <p>The administration groups used different doses and routes of misoprostol. <a href="./references#CD002855-bbs2-0035" title="IyengarK , Klingberg-AllvinM , IyengarSD , PaulM , EssenB , Gemzell-DanielssonK .Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica2016;95(2):173-81. [DOI: https://dx.doi.org/10.1111/aogs.12815]IyengarK , PaulM , IyengarSD , Klingberg-AllvinM , EssenB , BringJ , et al.Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet2015;3(9):e537-45. [DOI: https://dx.doi.org/10.1016/S2214-109X(15)00150-3]">Iyengar 2015</a> used 800 µg misoprostol (oral, vaginal or sublingual) administered by women themselves two days after 200 mg oral mifepristone. The abortion outcomes were assessed by women at home (followed up by phone) or by nurses and or doctors in hospitals. <a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a> used 75 mg oral mifepristone, followed by 400 µg oral misoprostol 24 hours later by home administration or hospital administration. <a href="./references#CD002855-bbs2-0067" title="ShresthaA , SedhaiLB .A randomized trial of hospital vs home self administration of vaginal misoprostol for medical abortion. Kathmandu University Medical Journal2014;12(47):185-9. ">Shrestha 2014</a> compared home administered versus hospital‐administered vaginal misoprostol (800 µg) 24 hours after 200 mg oral mifepristone. <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a> applied 100 mg oral mifepristone in hospital, followed by 200 µg of sublingual misoprostol 24 hours later at home versus in hospital. </p> <p>Home administration might result in a similar effect on complete abortion compared to hospital administration when combining results for gestational ages up to 63 days, based on four studies (RR 1.63, 95% CI 0.68 to 3.94; I<sup>2</sup> = 84%; 4 RCTs, 2263 women; low‐certainty evidence; <a href="./references#CD002855-fig-0029" title="">Analysis 5.1</a>; <a href="./full#CD002855-tbl-0003">summary of findings Table 3</a>). However, hospital administration showed lower failure in abortion for women at less than 49 days' gestation (<a href="./references#CD002855-bbs2-0044" title="LiCL , SongLP , TangSY , ZhouLJ , HeH , MoXT , et al.Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reproductive Sciences2017;24(5):731-7. [DOI: https://dx.doi.org/10.1177/1933719116669055]">Li 2017</a>; <a href="./references#CD002855-bbs2-0069" title="SongLP , TangSY , LiCL , ZhouLJ , MoXT .Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol. Journal of Obstetrics and Gynaecology Research2018;44(9):1705-11. [DOI: https://dx.doi.org/10.1111/jog.13716]">Song 2018</a>). </p> <p>Oral administration of 200 mg mifepristone followed by 800 µg misoprostol (vaginally or buccally) one to two days later was provided by nurses or doctors (<a href="./references#CD002855-bbs2-0041" title="KallnerHK , GompertsR , SalomonssonE , JohanssonM , MarionsL , DanielssonKG .The efficacy, safety, and acceptability of medical abortion provided by nurse-midwives or physicians-a randomized controlled equivalence trial. European Journal of Contraception and Reproductive Health Care2014;19:S84-5. [DOI: 10.3109/13625187.2014.894779.10]Kopp KallnerH , GompertsR , SalomonssonE , JohanssonM , MarionsL , Gemzell-DanielssonK .The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG2015;122(4):510-7. [DOI: https://dx.doi.org/10.1111/1471-0528.12982]">Kopp Kallner 2015</a>; <a href="./references#CD002855-bbs2-0052" title="OlavarrietaCD , GanatraB , SorhaindoA , KarverTS , SeucA , VillalobosA , et al.Nurse versus physician-provision of early medical abortion in Mexico: a randomized controlled non-inferiority trial. Bulletin of the World Health Organization2015;93(4):249-58. [DOI: https://dx.doi.org/10.2471/BLT.14.143990]">Olavarrieta 2015</a>; <a href="./references#CD002855-bbs2-0086" title="TamangA , ShahIH , ShresthaP , WarrinerIK , WangD , ThapaK , et al.Comparative satisfaction of receiving medical abortion service from nurses and auxiliary nurse-midwives or doctors in Nepal: results of a randomized trial. Reproductive Health2017;14(1):176. [DOI: https://dx.doi.org/10.1186/s12978-017-0438-7]WarrinerIK , WangD , HuongNTM , ThapaK , TamangA , ShahI , et al.Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet2011;377(9772):1155-61. [DOI: https://dx.doi.org/10.1016/S0140-6736(10)62229-5]">Warriner 2011</a>). Misoprostol provided by doctors might lead to lower failure in complete abortion than that provided by nurses (RR 2.69, 95% CI 1.39 to 5.22; I<sup>2</sup> = 66%; 3 RCTs, 3056 women; low‐certainty evidence; <a href="./references#CD002855-fig-0029" title="">Analysis 5.1</a>; <a href="./full#CD002855-tbl-0004">summary of findings Table 4</a>). However, among women at less than 10 weeks' gestational age, failure to achieve complete abortion might be similar when the medication was administered by nurses or doctors (RR 1.33, 95% CI 0.50 to 3.55, 884 women; <a href="./references#CD002855-fig-0029" title="">Analysis 5.1</a>; <a href="./references#CD002855-bbs2-0052" title="OlavarrietaCD , GanatraB , SorhaindoA , KarverTS , SeucA , VillalobosA , et al.Nurse versus physician-provision of early medical abortion in Mexico: a randomized controlled non-inferiority trial. Bulletin of the World Health Organization2015;93(4):249-58. [DOI: https://dx.doi.org/10.2471/BLT.14.143990]">Olavarrieta 2015</a>). </p> <p>Mifepristone and misoprostol administered at home (self‐administered) versus administered in the hospital were similar in terms of requiring subsequent surgical evacuation (RR 1.71, 95% CI 0.37 to 7.87; I<sup>2</sup> = 91%; 2 RCTs, 1331 women; <a href="./references#CD002855-fig-0030" title="">Analysis 5.2</a>). However, administration by doctors, compared with nurses showed lower incomplete abortion requiring surgical evacuation (RR 3.36, 95% CI 1.67 to 6.78; 2 RCTs, 2172 women; <a href="./references#CD002855-fig-0030" title="">Analysis 5.2</a>). </p> <p>It is uncertain whether misoprostol administered by a nurse or at home has a similar effect on ongoing pregnancy or not, when compared to misoprostol administered by doctors or in hospital respectively. The clinical heterogeneity among populations is too significant to draw any conclusion. The side effects (nausea, vomiting, diarrhoea, abdominal pain, women's dissatisfaction with the procedure, bleeding days and blood transfusion) might be similar between the different administration groups of misoprostol. </p> </section> <section id="CD002855-sec-0075"> <h5 class="title">Comparison 6: route of administration of misoprostol ‐ oral versus vaginal</h5> <p>We included seven studies in the review for this comparison (<a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>; <a href="./references#CD002855-bbs2-0023" title="CreininMD , PymarHC , SchwartzJL .Mifepristone 100 mg in abortion regimens. Obstetrics and Gynecology2001;98(3):434-9. ">Creinin 2001a</a>; <a href="./references#CD002855-bbs2-0029" title="El-RefaeyH , RajasekarD , AbdallaM , CalderL , TempletonA .Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. New England Journal of Medicine1995;332:983-7. ">El‐Refaey 1995</a>; <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a>; <a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a>; <a href="./references#CD002855-bbs2-0065" title="ShannonC , WiebeE , JacotF , GuilbertE , DunnS , SheldonW , et al.Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG2006;113:621–8. ">Shannon 2006</a>; <a href="./references#CD002855-bbs2-0073" title="TangOS , LeeSW , HoPC .A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. Human Reproduction (Oxford, England)2002;17(11):2865-8. ">Tang 2002</a>), and we included three RCTs with a total of 1704 women in the meta‐analysis (<a href="./references#CD002855-bbs2-0029" title="El-RefaeyH , RajasekarD , AbdallaM , CalderL , TempletonA .Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. New England Journal of Medicine1995;332:983-7. ">El‐Refaey 1995</a>; <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a>; <a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a>). <a href="./references#CD002855-bbs2-0029" title="El-RefaeyH , RajasekarD , AbdallaM , CalderL , TempletonA .Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. New England Journal of Medicine1995;332:983-7. ">El‐Refaey 1995</a> used mifepristone 600 mg and <a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a> used mifepristone 200 mg. Both used misoprostol 800 µg orally or vaginally after 48 hours (<a href="./references#CD002855-bbs2-0029" title="El-RefaeyH , RajasekarD , AbdallaM , CalderL , TempletonA .Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. New England Journal of Medicine1995;332:983-7. ">El‐Refaey 1995</a>), and at least 24 hours (<a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a>), after mifepristone. <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a> used 200 mg oral mifepristone followed by oral (every three hours) or vaginal (every six hours) misoprostol 400 µg (no more than four doses). </p> <p>Misoprostol administered orally probably led to more failure in complete abortion than the vaginal route (RR 2.38, 95% CI 1.46 to 3.87; I<sup>2</sup> = 39%; 3 RCTs, 1704 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0037" title="">Analysis 6.1</a>; <a href="./full#CD002855-tbl-0005">summary of findings Table 5</a>), and might lead to more nausea (RR 1.14, 95% CI 1.03 to 1.26; I<sup>2</sup> = 0%; 2 RCTs, 1380 women; low‐certainty evidence; <a href="./references#CD002855-fig-0038" title="">Analysis 6.2</a>; <a href="./full#CD002855-tbl-0005">summary of findings Table 5</a>) and more diarrhoea (RR 1.80 95% CI 1.49 to 2.17; I<sup>2</sup> = 0%, 2 RCTs, 1379 women; <a href="./references#CD002855-fig-0038" title="">Analysis 6.2</a>). Unexpectedly, vomiting occurred more often in the vaginal group in one study, and reporting error cannot be excluded (<a href="./references#CD002855-bbs2-0063" title="SchaffEA , FieldingSL , WesthoffC .Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception2001;64(2):81-5. ">Schaff 2001</a>). Only <a href="./references#CD002855-bbs2-0055" title="QianJ , JingX , WuS , ZhengS , LiY , RenM , et al.Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy between 8 and 16 weeks of gestation. Zhonghua Fu Chan Ke Za Zhi2015;50(7):505-9. ">Qian 2015</a> reported bleeding volume and conceptus passing time but without differences between groups. </p> <p>Three studies used different doses orally and vaginally and we could not combine them in meta‐analysis (<a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>; <a href="./references#CD002855-bbs2-0023" title="CreininMD , PymarHC , SchwartzJL .Mifepristone 100 mg in abortion regimens. Obstetrics and Gynecology2001;98(3):434-9. ">Creinin 2001a</a>; <a href="./references#CD002855-bbs2-0065" title="ShannonC , WiebeE , JacotF , GuilbertE , DunnS , SheldonW , et al.Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG2006;113:621–8. ">Shannon 2006</a>). We meta‐analysed the comparison of 400 µg oral misoprostol versus 800 µg of vaginal misoprostol in comparison 2: dose of prostaglandin (<a href="./references#CD002855-fig-0009" title="">Analysis 2.1</a>; <a href="./references#CD002855-bbs2-0004" title="ArvidssonC , HellborgM , Gemzell-DaniellsonK .Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:87-91. ">Arvidsson 2005</a>; <a href="./references#CD002855-bbs2-0065" title="ShannonC , WiebeE , JacotF , GuilbertE , DunnS , SheldonW , et al.Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG2006;113:621–8. ">Shannon 2006</a>), so we did not meta‐analyse this route comparison again. One study (<a href="./references#CD002855-bbs2-0073" title="TangOS , LeeSW , HoPC .A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. Human Reproduction (Oxford, England)2002;17(11):2865-8. ">Tang 2002</a>), used a combined regimen oral/vaginal in one group and repeated oral misoprostol doses in another group, and these data were therefore not included in the meta‐analysis. </p> </section> <section id="CD002855-sec-0076"> <h5 class="title">Comparison 7: route of administration of misoprostol ‐ buccal versus vaginal</h5> <p>We included two studies with 479 women using 200 mg of oral mifepristone followed by 800 µg of misoprostol given buccally or vaginally for this comparison (<a href="./references#CD002855-bbs2-0031" title="GargG , TakkarN , SehgalA .Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions. Journal of Obstetrics and Gynaecology of India2015;65(2):111-6. [DOI: https://dx.doi.org/10.1007/s13224-014-0605-5]">Garg 2015</a>; <a href="./references#CD002855-bbs2-0048" title="MiddletonT , SchaffE , FieldingSL , ScahillM , ShannonC , WestheimerE , et al.Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception2005;72:328-32. ">Middleton 2005</a>). Misoprostol administered buccally might lead to lower failure in abortion than vaginally administered misoprostol (RR 0.71, 95% CI 0.34 to1.46; I<sup>2</sup> = 0%; 2 RCTs, 479 women; <a href="./references#CD002855-fig-0041" title="">Analysis 7.1</a>). </p> <p>There were more women with diarrhoea in the buccal compared to the vaginal group (RR 1.51, 95% CI 1.12 to 2.03; 2 RCTs, 479 women; <a href="./references#CD002855-fig-0042" title="">Analysis 7.2</a>). </p> <p>From evidence from one study (<a href="./references#CD002855-bbs2-0031" title="GargG , TakkarN , SehgalA .Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions. Journal of Obstetrics and Gynaecology of India2015;65(2):111-6. [DOI: https://dx.doi.org/10.1007/s13224-014-0605-5]">Garg 2015</a>), it was uncertain whether misoprostol administered buccally was better than misoprostol administered vaginally on need for surgical evacuation (RR 0.33, 95% CI 0.01 to 7.81; 1 study, 50 women; <a href="./references#CD002855-fig-0043" title="">Analysis 7.3</a>) and women's dissatisfaction with the procedure (RR 0.20, 95% CI 0.01 to 3.97; 1 RCT, 50 women; <a href="./references#CD002855-fig-0044" title="">Analysis 7.4</a>). </p> </section> <section id="CD002855-sec-0077"> <h5 class="title">Comparison 8: route of administration of misoprostol ‐ buccal versus oral</h5> <p>We included one study with 847 women in this comparison (<a href="./references#CD002855-bbs2-0097" title="WinikoffB , DzubaIG , CreininMD , CrowdenWA , GoldbergAB , GonzalesJ , et al.Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstetrics and Gynecology2008;112(6):1303-10. ">Winikoff 2008</a>). Misoprostol administered buccally probably leads to lower failure in complete abortion than the oral route (RR 0.62, 95% CI 0.40 to 0.96; 847 women; <a href="./references#CD002855-fig-0045" title="">Analysis 8.1</a>) for all gestational ages and for women at more than 49 days' gestation (RR 0.37, 95% CI 0.18 to 0.73, 429 women; <a href="./references#CD002855-fig-0045" title="">Analysis 8.1</a>); and might reduce failure to achieve complete abortion slightly for women at 49 days' gestation or less (RR 0.72, 95% CI 0.25 to 2.04, 418 women; <a href="./references#CD002855-fig-0045" title="">Analysis 8.1</a>). </p> <p>Misoprostol administered buccally might slightly reduce overall ongoing pregnancy (RR 0.31, 95% CI 0.09 to 1.08; 847 women; <a href="./references#CD002855-fig-0046" title="">Analysis 8.2</a>) and for women at 49 days' gestation or less (RR 0.64, 95% CI 0.11 to 3.80; 418 women; <a href="./references#CD002855-fig-0046" title="">Analysis 8.2</a>), while it might reduce ongoing pregnancy for women with more than 49 days' gestation (RR 0.18, 95% CI 0.04 to 0.78, 429 women; <a href="./references#CD002855-fig-0046" title="">Analysis 8.2</a>) compared to oral misoprostol. </p> <p>Misoprostol administered buccally probably leads to more nausea (RR 1.10, 95% CI 1.01 to 1.19, 830 women; <a href="./references#CD002855-fig-0047" title="">Analysis 8.3</a>), while it might result in similar dissatisfaction with the procedure (RR 1.21, 95% CI 0.76 to 1.91, 835 women; <a href="./references#CD002855-fig-0048" title="">Analysis 8.4</a>) compared to oral misoprostol. </p> </section> <section id="CD002855-sec-0078"> <h5 class="title">Comparison 9: route of administration of misoprostol ‐ sublingual versus vaginal</h5> <p>We included three studies with 3543 women in this comparison (<a href="./references#CD002855-bbs2-0034" title="HamodaH , AshokPW , FlettGM , TempletonA .A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG2005;112:1102–8. ">Hamoda 2005</a>; <a href="./references#CD002855-bbs2-0074" title="TangOS , ChanCC , NgEH , Lee SW and HoPC .A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Human Reproduction (Oxford, England)2003;18:2315-8. ">Tang 2003</a>; <a href="./references#CD002855-bbs2-0084" title="vonHertzenH , HuongNT , PiaggioG , BayalagM , CabezasE , FangAH , et al, WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG2010;117(10):1186-96. [DOI: https://dx.doi.org/10.1111/j.1471-0528.2010.02636.x]">von Hertzen 2010</a>). Misoprostol administered sublingually probably slightly reduced failure to achieve complete abortion (RR 0.68, 95% CI 0.22 to 2.11; I<sup>2</sup> = 59%; 2 RCTs, 3229 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0049" title="">Analysis 9.1</a>; <a href="./full#CD002855-tbl-0006">summary of findings Table 6</a>), number of needed surgical evacuations (RR 0.80, 95% CI 0.18 to 3.53; 1 study, 327 women; <a href="./references#CD002855-fig-0050" title="">Analysis 9.2</a>), ongoing pregnancy (RR 0.67, 95% CI 0.13 to 3.47; I<sup>2</sup> = 43%; 2 RCTs, 3229 women; <a href="./references#CD002855-fig-0051" title="">Analysis 9.3</a>), but might slightly increase dissatisfaction with the procedure (RR 1.67, 95% CI 0.80 to 3.50; I<sup>2</sup> = 64%; 2 RCTs, 3303 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0052" title="">Analysis 9.4</a>; <a href="./full#CD002855-tbl-0006">summary of findings Table 6</a>) compared to misoprostol administered vaginally. In one study women received additional doses of misoprostol if abortion was incomplete at follow‐up and the results were not presented for the intended method used and were therefore not totaled (<a href="./references#CD002855-bbs2-0034" title="HamodaH , AshokPW , FlettGM , TempletonA .A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG2005;112:1102–8. ">Hamoda 2005</a>). </p> <p>Misoprostol administered sublingually probably slightly increased nausea (RR 1.11, 95% CI 0.93 to 1.33; I<sup>2</sup> = 78%; 3 RCTs, 3543 women; moderate‐certainty evidence; <a href="./references#CD002855-fig-0053" title="">Analysis 9.5</a>; <a href="./full#CD002855-tbl-0006">summary of findings Table 6</a>), vomiting (RR 1.21, 95% CI 0.88 to 1.66; I<sup>2</sup> = 87%; 3 RCTs, 3543 women; <a href="./references#CD002855-fig-0053" title="">Analysis 9.5</a>), and diarrhoea (RR 1.83, 95% CI 1.33 to 2.50; I<sup>2</sup> = 79%; 3 RCTs, 3543 women; <a href="./references#CD002855-fig-0053" title="">Analysis 9.5</a>) than the vaginal route. Furthermore, <a href="./references#CD002855-bbs2-0074" title="TangOS , ChanCC , NgEH , Lee SW and HoPC .A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Human Reproduction (Oxford, England)2003;18:2315-8. ">Tang 2003</a> reported that more women in the sublingual group experienced side effects: nausea (RR 1.67, 95% CI 1.21 to 2.29) and vomiting (RR 2.93, 95% CI 1.69 to 5.06). <a href="./references#CD002855-bbs2-0034" title="HamodaH , AshokPW , FlettGM , TempletonA .A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG2005;112:1102–8. ">Hamoda 2005</a> did not use an ITT analysis; loss to follow‐up was identical in both groups (n = 13). </p> </section> <section id="CD002855-sec-0079"> <h5 class="title">Comparison 10: route of administration of misoprostol ‐ sublingual versus oral</h5> <p>We included two studies with 564 women for this comparison, that used 200 mg of oral mifepristone followed by 400 µg of misoprostol (<a href="./references#CD002855-bbs2-0027" title="DahiyaK , MannS , NandaS .Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion. Archives of Gynecology and Obstetrics2011;284(1):59-63. [DOI: https://dx.doi.org/10.1007/s00404-010-1590-2]">Dahiya 2011</a>; <a href="./references#CD002855-bbs2-0056" title="RaghavanS , ComendantR , DigolI , UngureanuS , FriptuV , BrackenH , et al.Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol. Contraception2009;79:84-90. ">Raghavan 2009</a>). </p> <p>Misoprostol administered sublingually probably reduced failure to achieve complete abortion compared to the oral group (RR 0.26, 95% CI 0.10 to 0.68; I<sup>2</sup> = 0%; 2 RCTs, 564 women; <a href="./references#CD002855-fig-0054" title="">Analysis 10.1</a>), especially for women at 49 days' gestation or less (RR 0.28, 95% CI 0.08 to 0.99; 1 study, 422 women; <a href="./references#CD002855-fig-0054" title="">Analysis 10.1</a>). </p> <p>It was uncertain whether misoprostol administered sublingually could reduce ongoing pregnancy (RR 0.36, 95% CI 0.01 to 8.50, 1 study, 93 women; <a href="./references#CD002855-fig-0055" title="">Analysis 10.2</a>) or need for surgical evacuation (RR 0.36, 95% CI 0.08 to 1.67, 1 study, 93 women; <a href="./references#CD002855-fig-0056" title="">Analysis 10.3</a>) compared to the oral group. </p> <p>Misoprostol administered sublingually might slightly increase women's dissatisfaction with the procedure compared to misoprostol administered orally (RR 1.96, 95% CI 0.94 to 4.09, 1 study, 471 women; <a href="./references#CD002855-fig-0057" title="">Analysis 10.4</a>). </p> <p>It was uncertain whether misoprostol administered sublingually was different from oral misoprostol on side effects including nausea (RR 0.62, 95% CI 0.27 to 1.41; I<sup>2</sup> = 78%; 2 RCTs, 564 women; <a href="./references#CD002855-fig-0058" title="">Analysis 10.5</a>), vomiting, and diarrhoea. </p> </section> <section id="CD002855-sec-0080"> <h5 class="title">Comparison 11: route of administration of misoprostol ‐ sublingual versus buccal</h5> <p>We included two studies with 640 women in this comparison (<a href="./references#CD002855-bbs2-0014" title="ChaiJ , WongCY , HoPC .A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception2013;87(4):480-5. [DOI: https://dx.doi.org/10.1016/j.contraception.2012.09.022]">Chai 2013</a>; <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a>). Both studies compared oral mifepristone 200 mg, <a href="./references#CD002855-bbs2-0014" title="ChaiJ , WongCY , HoPC .A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception2013;87(4):480-5. [DOI: https://dx.doi.org/10.1016/j.contraception.2012.09.022]">Chai 2013</a> compared misoprostol 800 µg sublingually or buccally 48 hours later and <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a> used misoprostol 400 µg sublingually or buccally 24 hours later. </p> <p>Misoprostol administered sublingually may slightly increase failure to achieve complete abortion (RR 1.43, 95% CI 0.64 to 3.23; I<sup>2</sup> = 0; 2 studies, 640 women; <a href="./references#CD002855-fig-0059" title="">Analysis 11.1</a>), need for surgical evacuation (RR 1.72, 95% CI 0.75 to 3.96; I<sup>2</sup> = 0%; 2 RCTs, 640 women; <a href="./references#CD002855-fig-0060" title="">Analysis 11.2</a>), and ongoing pregnancy (RR 2.59, 95% CI 0.88 to 7.61; I<sup>2</sup> = 0%; 2 RCTs, 640 women; <a href="./references#CD002855-fig-0061" title="">Analysis 11.3</a>), when compared with buccal administration. </p> <p>It was uncertain whether misoprostol administered sublingually reduced vomiting (RR 1.33, 95% CI 1.01 to 1.77; I<sup>2</sup> = 0%; 2 RCTs, 640 women; <a href="./references#CD002855-fig-0062" title="">Analysis 11.4</a>), nausea (RR 1.06, 95% CI 0.88 to 1.27; I<sup>2</sup> = 19%; 2 RCTs, 640 women; <a href="./references#CD002855-fig-0062" title="">Analysis 11.4</a>), diarrhoea (RR 2.19, 95% CI 0.56 to 8.51; I<sup>2</sup> = 80%; 2 RCTs, 640 women; <a href="./references#CD002855-fig-0062" title="">Analysis 11.4</a>), and abdominal pain (RR 1.10, 95% CI 0.79 to 1.52; I<sup>2</sup> = 92%; 2 RCTs, 640 women; <a href="./references#CD002855-fig-0062" title="">Analysis 11.4</a>) compared to buccal administration. </p> <p>Misoprostol administered buccally might reduce women's dissatisfaction with the procedure when compared with sublingual administration as reported by <a href="./references#CD002855-bbs2-0057" title="RaghavanS , ComendantR , DigolI , UngureanuS , DondiucI , TurcanuS , et al.Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial. Contraception2010;82(6):513-9. [DOI: https://dx.doi.org/10.1016/j.contraception.2010.05.013]">Raghavan 2010</a> (RR 2.54, 95% CI 1.14 to 5.66; 550 women; <a href="./references#CD002855-fig-0063" title="">Analysis 11.5</a>). </p> <p>The haemoglobin level (MD 0.00, 95% CI −0.40 to 0.40; 1 study, 90 women; <a href="./references#CD002855-fig-0064" title="">Analysis 11.6</a>) were similar between groups, but passing time of conceptus might be less in the sublingual group (MD −0.88, 95% CI −2.44 to 0.68; 1 study, 90 women; <a href="./references#CD002855-fig-0065" title="">Analysis 11.7</a>), as reported by <a href="./references#CD002855-bbs2-0014" title="ChaiJ , WongCY , HoPC .A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception2013;87(4):480-5. [DOI: https://dx.doi.org/10.1016/j.contraception.2012.09.022]">Chai 2013</a>. </p> </section> <section id="CD002855-sec-0081"> <h5 class="title">Comparison 12: single versus split dose of prostaglandin</h5> <p>We included one study with 154 women in this comparison (<a href="./references#CD002855-bbs2-0028" title="El-RefaeyH , TempletonA .Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure. British Journal of Obstetrics and Gynaecology1994;101:792-6. ">El‐Refaey 1994</a>). Administration of 800 µg of misoprostol as a single dose might slightly reduce failure in complete abortion compared to two doses of 400 µg, two hours apart (RR 0.70, 95% CI 0.21 to 2.39; 1 study, 154 women; <a href="./references#CD002855-fig-0066" title="">Analysis 12.1</a>). It was uncertain whether side effects following misoprostol administered as single dose were different from the split‐dose group. </p> </section> <section id="CD002855-sec-0082"> <h5 class="title">Comparison 13: single versus continuous misoprostol</h5> <p>We included two studies for this comparison (<a href="https://revman.cochrane.org/396502338401649943" target="_blank">Tang 2002</a>; <a href="./references#CD002855-bbs2-0081" title="HonkanenH , PiaggioG , Von HertzenH , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women’s perceptions. BJOG2004;111:715-25. Von HertzenH , HonkanenH , PiaggioG , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG2003;110:808-18. ">von Hertzen 2003</a>). Honkanen reported on the same study as <a href="./references#CD002855-bbs2-0081" title="HonkanenH , PiaggioG , Von HertzenH , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women’s perceptions. BJOG2004;111:715-25. Von HertzenH , HonkanenH , PiaggioG , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG2003;110:808-18. ">von Hertzen 2003</a>, but on different outcomes. <a href="https://revman.cochrane.org/396502338401649943" target="_blank">Tang 2002</a> and <a href="./references#CD002855-bbs2-0081" title="HonkanenH , PiaggioG , Von HertzenH , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women’s perceptions. BJOG2004;111:715-25. Von HertzenH , HonkanenH , PiaggioG , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG2003;110:808-18. ">von Hertzen 2003</a> compared oral misoprostol 400 µg twice daily continued for seven days after either an initial oral (group A) or vaginal 800 µg (group B) and single vaginal dose (group C) among 150 women. All women had received mifepristone 200 mg 48 hours prior to misoprostol. </p> <p>Misoprostol all administered orally (group A) probably increased failure to achieve complete abortion compared to the vaginal and continuous oral misoprostol group (RR 1.48; 95% CI 1.01 to 2.16; I<sup>2</sup> = 0%; 2 RCTs, 1581 women; <a href="./references#CD002855-fig-0068" title="">Analysis 13.1</a>) and might increase ongoing pregnancy (<a href="./references#CD002855-fig-0072" title="">Analysis 13.5</a>); probably induced more diarrhoea compared to the vaginal and continuous oral group (RR 1.83, 95% CI 1.11 to 3.01, 1 study, 1481 women; group B; <a href="./references#CD002855-fig-0069" title="">Analysis 13.2</a>) and single vaginal group (RR 2.09, 95% CI 1.24 to 3.53, group C; <a href="./references#CD002855-fig-0069" title="">Analysis 13.2</a>). The all‐oral group (A) probably experienced less nausea (<a href="./references#CD002855-fig-0070" title="">Analysis 13.3</a>), and less vomiting (<a href="./references#CD002855-fig-0071" title="">Analysis 13.4</a>). </p> </section> <section id="CD002855-sec-0083"> <h5 class="title">Comparison 14: mifepristone alone versus combined regimen mifepristone/prostaglandin</h5> <p>We included three studies for this comparison (<a href="./references#CD002855-bbs2-0011" title="CameronIT , MichieAF , BairdDT .Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (gemeprost). Contraception1986;34(5):459-68. ">Cameron 1986</a>; <a href="./references#CD002855-bbs2-0072" title="SwahnML , UgocsaiG , BygdemanM , KovacsL , BelseyEM , Van LookPF .Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy. Human Reproduction (Oxford, England)1989;4(1):21-8. ">Swahn 1989</a>; <a href="./references#CD002855-bbs2-0099" title="ZhengSR .RU486 (mifepristone): clinical trials in China. Acta Obstetricia et Gynecologica Scandinavica. Supplement1989;149:19-23. ">Zheng 1989</a>). </p> <p>It was uncertain whether the combination regimen could reduce the failure to achieve complete abortion compared to mifepristone alone (RR of failure 3.25, 95% CI 0.81 to 13.09; I<sup>2</sup> = 83%; 3 RCTs, 273 women; <a href="./references#CD002855-fig-0073" title="">Analysis 14.1</a>; very low‐certainty evidence; <a href="./full#CD002855-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD002855-sec-0084"> <h5 class="title">Comparison 15: prostaglandin alone versus a combined regimen (all)</h5> <p>We included 19 studies in this comparison and 18 (3471 women) of these in meta‐analyses of different comparison subgroups. We evaluated publication bias as low by examining funnel plots <a href="#CD002855-fig-0004">Figure 4</a>. Misoprostol combined with letrozole (<a href="./references#CD002855-bbs2-0001" title="AbbasalizadehF , SahhafF , Sadeghi-ShabestariP , Mirza-Aghazadeh-AttariM , Naghavi-BehzadM .Comparison between effect of letrozole plus misoprostol and misoprostol alone in terminating non-viable first trimester pregnancies: a single blind randomized trial. Journal of Family and Reproductive Health2018;12(1):27-33. ">Abbasalizadeh 2018</a>; <a href="./references#CD002855-bbs2-0003" title="AllamehZ , GoharianM , EslamianM .Share effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. International Journal of Gynaecology and Obstetrics2020;151(2):214-8. ">Allameh 2020</a>; <a href="./references#CD002855-bbs2-0007" title="Behroozi-LakT , Derakhshan-AydenlooS , BroomandF .Evaluation of effect of letrozole prior to misoprostol in comparison with misoprostol alone in success rate of induced abortion. Journal of Gynecology Obstetrics and Human Reproduction2018;47(3):113-7. [DOI: https://dx.doi.org/10.1016/j.jogoh.2017.11.002]">Behroozi Lak 2018</a>; <a href="./references#CD002855-bbs2-0038" title="JavadiEH , MohammadiM , BarikaniA .Induction of abortion in the first trimester by misoprostol or misoprostol with letrozole. Biotechnology and Health Sciences2015;2(3):e29562. ">Javadi 2015</a>; <a href="./references#CD002855-bbs2-0042" title="LeeVC , NgEH , YeungWS , HoPC .Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial. Obstetrics and Gynecology2011;117(2 Pt 1):317-23. [DOI: https://dx.doi.org/10.1097/AOG.0b013e3182073fbf]">Lee 2011</a>; <a href="./references#CD002855-bbs2-0077" title="TorkyHA , MarieH , ElDesoukyES , GebreelS , RaslanO , MoussaAA , et al.Letrozole vs. placebo pretreatment in the medical management of first trimester missed miscarriage: a randomized controlled trial. Geburtshilfe und Frauenheilkunde2018;78(1):63-9. [DOI: https://dx.doi.org/10.1055/s-0043-122499]">Torky 2018</a>), or estradiol valerate (<a href="./references#CD002855-bbs2-0076" title="TeimooriB , EsmaeilpoorM , AshkezariAK , FarzanehF .Comparison of induction abortion in the first trimester using misoprostol alone and misoprostol with estrogen priming. International Journal of Women’s Health and Reproduction Sciences2019;7(3):404. ">Teimoori 2019</a>), were added in the current review. <a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a>, compared methotrexate combined with 400 µg misoprostol vaginal with misoprostol 400 µg sublingual; we did not include 400 µg vaginal in the meta‐analysis, but presented data in Additional <a href="#CD002855-tbl-0011">Table 1</a>. One study used additional doses of prostaglandin and did not specify which women received them (<a href="./references#CD002855-bbs2-0036" title="JainJK , MeckstrothKR , ParkM , Mishell DR Jr.A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception1999;60(6):353-6. ">Jain 1999</a>). </p> <div class="figure" id="CD002855-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 15 prostaglandin alone vs combined regimen (all), outcome 15.1 failure to achieve complete abortion" data-id="CD002855-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 15 prostaglandin alone vs combined regimen (all), outcome 15.1 failure to achieve complete abortion </p> </div> </div> </div> <p>The studies consistently demonstrated that compared to a combination regimen, misoprostol alone might be less effective in achieving complete abortion (RR 2.39, 95% CI 1.89 to 3.02; I<sup>2</sup> = 64%, 18 RCTs, 3471 women; low‐certainty evidence; <a href="./references#CD002855-fig-0074" title="">Analysis 15.1</a>; <a href="./full#CD002855-tbl-0008">summary of findings Table 8</a>). Sensitivity analysis, excluding <a href="./references#CD002855-bbs2-0036" title="JainJK , MeckstrothKR , ParkM , Mishell DR Jr.A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception1999;60(6):353-6. ">Jain 1999</a>, also showed similar results (RR 2.45, 95% CI 1.92 to 3.14; I<sup>2</sup> = 64%; 17 RCTs, 3321 women; <a href="./references#CD002855-fig-0074" title="">Analysis 15.1</a>). Subgroup analysis based on gestational week also showed higher failure of complete abortion in the misoprostol‐alone group. Misoprostol combined with letrozole might reduce failure to achieve complete abortion (RR 2.29, 95% CI 1.62 to 3.24; I<sup>2</sup> = 54%; 6 RCTs, 1008 women; <a href="./references#CD002855-fig-0074" title="">Analysis 15.1</a>). </p> <p>Time to pass conceptus was shorter in the combination group (SMD 0.43, 95% CI 0.05 to 0.80; I<sup>2</sup> = 86%; 6 RCTs, 988 women; <a href="./references#CD002855-fig-0075" title="">Analysis 15.2</a>), fewer women needing surgical evacuation (RR 2.90, 95% CI 2.26 to 3.73; I<sup>2</sup> = 0%; 7 RCTs, 1307 women; <a href="./references#CD002855-fig-0076" title="">Analysis 15.3</a>), less use of additional uterotonics (RR 2.05, 95% CI 1.26 to 3.34; I<sup>2</sup> = 26%; 3 RCTs, 592 women; <a href="./references#CD002855-fig-0077" title="">Analysis 15.4</a>), and fewer women with ongoing pregnancy (RR 3.63, 95% CI 1.18 to 11.16; I<sup>2</sup> = 75%; 5 RCTs, 1353 women; <a href="./references#CD002855-fig-0078" title="">Analysis 15.5</a>). However, women receiving misoprostol alone might experience more diarrhoea compared to the combined regimen (RR 1.26, 95% CI 1.11 to 1.43; I<sup>2</sup> = 26%; 11 RCTs, 2342 women; <a href="./references#CD002855-fig-0079" title="">Analysis 15.6</a>), which might be caused by the higher dosage used in the misoprostol‐alone group; but might experience slightly less nausea (RR 0.90, 95% CI 0.74 to 1.10; I<sup>2</sup> = 77%; 12 RCTs, 2722 women; low‐certainty evidence; <a href="./references#CD002855-fig-0079" title="">Analysis 15.6</a>; <a href="./full#CD002855-tbl-0008">summary of findings Table 8</a>). No difference was found for vomiting, pelvic infection and abdominal pain. </p> <p>Prostaglandin administered alone might slightly increase women's dissatisfaction with the procedure (RR 1.65, 95% CI 0.75 to 3.64; I<sup>2</sup> = 90%; 5 RCTs, 1485 women; low‐certainty evidence; <a href="./references#CD002855-fig-0080" title="">Analysis 15.7</a>; <a href="./full#CD002855-tbl-0008">summary of findings Table 8</a>), but might slightly reduce the need for blood transfusion (RR 0.33, 95% CI 0.03 to 3.13; 1 study, 300 women; low‐certainty evidence; <a href="./references#CD002855-fig-0081" title="">Analysis 15.8</a>; <a href="./full#CD002855-tbl-0008">summary of findings Table 8</a>). Prostaglandin alone might shorten the number of bleeding days (<a href="./references#CD002855-fig-0082" title="">Analysis 15.9</a>) and improve haemoglobin level (<a href="./references#CD002855-fig-0083" title="">Analysis 15.10</a>) compared to the combination regimens. </p> </section> </section> <section id="CD002855-sec-0085"> <h4 class="title">Single regimen</h4> <section id="CD002855-sec-0086"> <h5 class="title">Comparison 16: prostaglandin alone: route of administration</h5> <p>We included 11 studies in this comparison group, with 4667 women (<a href="./references#CD002855-bbs2-0002" title="AbdelshafyA , AwwadH , Abo-GamraA , AlanwarA , ElkotbAM , ShahinM , et al.Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2019;24(2):134-9. [DOI: https://dx.doi.org/10.1080/13625187.2019.1569224]">Abdelshafy 2019</a>; <a href="./references#CD002855-bbs2-0039" title="CleeveA , ByamugishaJ , Gemzell-DanielssonK , Mbona TumwesigyeN , AtuhairweS , FaxelidE , et al.Women's acceptability of misoprostol treatment for incomplete abortion by midwives and physicians - secondary outcome analysis from a randomized controlled equivalence trial at district level in Uganda. PloS One2016;11(2):e0149172. [DOI: https://dx.doi.org/10.1371/journal.pone.0149172]Klingberg-AllvinM , CleeveA , AtuhairweS , TumwesigyeNM , FaxelidE , ByamugishaJ , et al.Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet2015;385(9985):2392-8. [DOI: https://dx.doi.org/10.1016/S0140-6736(14)61935-8]">Klingberg Allvin 2015</a>; <a href="./references#CD002855-bbs2-0046" title="MarwahS , GuptaS , BatraNP , BhasinV , SarnaV , KaurN .A comparative study to evaluate the efficacy of vaginal vs oral prostaglandin E1 analogue (misoprostol) in management of first trimester missed abortion. Journal of Clinical and Diagnostic Research2016;10(5):QC14-8. [DOI: https://dx.doi.org/10.7860/JCDR/2016/18178.7891]">Marwah 2016</a>; <a href="./references#CD002855-bbs2-0049" title="MizrachiY , DekaloA , GluckO , MirembergH , DafnaL , FeldsteinO , et al.Single versus repeat doses of misoprostol for treatment of early pregnancy loss-a randomized clinical trial. Human Reproduction (Oxford, England)2017;32(6):1202-7. [DOI: https://dx.doi.org/10.1093/humrep/dex074]">Mizrachi 2017</a>; <a href="./references#CD002855-bbs2-0050" title="NgBK , AnnamalaiR , LimPS , Aqmar SurayaS , Nur AzurahAG , Muhammad Abdul JamilMY .Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of Gynecology and Obstetrics2015;291(1):105-13. [DOI: https://dx.doi.org/10.1007/s00404-014-3388-0]">Ng 2015</a>; <a href="./references#CD002855-bbs2-0054" title="ParitakulP , PhupongV .Comparative study between oral and sublingual 600 micro g misoprostol for the treatment of incomplete abortion. Journal of Obstetrics and Gynaecology Research2010;36(5):978-83. [DOI: https://dx.doi.org/10.1111/j.1447-0756.2010.01264.x]">Paritakul 2010</a>; <a href="./references#CD002855-bbs2-0066" title="SheldonWR , DurocherJ , DzubaIG , SayetteH , MartinR , VelascoMC , et al.Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception2019;99(5):272-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2019.02.002]">Sheldon 2019</a>; <a href="./references#CD002855-bbs2-0070" title="SonsanohA , ChullapramT .Comparison of sublingual and vaginal misoprostol for termination of early pregnancy failure: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2014;22(3):128. ">Sonsanoh 2014</a>; <a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a>; <a href="./references#CD002855-bbs2-0075" title="TanhaFD , FeiziM , ShariatM .Sublingual versus vaginal misoprostol for the management of missed abortion. Journal of Obstetrics and Gynaecology Research2010;36(3):525-32. [DOI: 10.1111/j.1447-0756.2010.01229.x]">Tanha 2010</a>; <a href="./references#CD002855-bbs2-0082" title="vonHertzenH , PiaggioG , HuongN , ArustamyanK , CabezasE , GomezM , et al, on behalf of the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet2007;369:1938-46. ">von Hertzen 2007</a>), five studies compared sublingual versus vaginal administration, one sublingual versus buccal, two sublingual versus oral, two oral versus vaginal, one repeat versus single dose, and two studies had different administration models (home versus hospital; nurse versus doctor). One study had three arms that compared misoprostol sublingually, orally or vaginally (<a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a>). The dosage of misoprostol among the studies ranged from 400 µg to 2400 µg. Except for two studies (<a href="./references#CD002855-bbs2-0066" title="SheldonWR , DurocherJ , DzubaIG , SayetteH , MartinR , VelascoMC , et al.Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception2019;99(5):272-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2019.02.002]">Sheldon 2019</a>; <a href="./references#CD002855-bbs2-0082" title="vonHertzenH , PiaggioG , HuongN , ArustamyanK , CabezasE , GomezM , et al, on behalf of the WHO Research Group on Post-Ovulatory Methods of Fertility Regulation.Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet2007;369:1938-46. ">von Hertzen 2007</a>), the others included women with missed or incomplete abortion. The follow‐up duration ranged from two days to 30 days. </p> <p>Misoprostol alone provided vaginally may reduce the failure to achieve complete abortion compared to misoprostol provided orally (RR 3.68, 95% CI 1.56 to 8.71; I<sup>2</sup> =0%; 2 RCTs, 216 women; low‐certainty evidence; <a href="./references#CD002855-fig-0084" title="">Analysis 16.1</a>; <a href="./full#CD002855-tbl-0009">summary of findings Table 9</a>). Misoprostol alone provided sublingually may reduce failure to achieve complete abortion compared with the vaginal route (RR 0.69, 95% CI 0.37 to 1.28; I<sup>2</sup> =87%; 5 RCTs, 2705 women; low‐certainty evidence; <a href="./references#CD002855-fig-0084" title="">Analysis 16.1</a>; <a href="./full#CD002855-tbl-0010">summary of findings Table 10</a>), may also reduce failure compared to the oral route (RR 0.58, 95% CI 0.11 to 2.99; I<sup>2</sup> =66%; 2 RCTs, 173 women; <a href="./references#CD002855-fig-0084" title="">Analysis 16.1</a>); but may slightly increase failure compared to the buccal route (RR 1.11, 95% CI 0.71 to 1.74; 1 study, 401 women; <a href="./references#CD002855-fig-0084" title="">Analysis 16.1</a>). A repeat dose of misoprostol may result in more failure to achieve complete abortion compared to a single dose (RR 1.30, 95% CI 0.78 to 2.15; 1 study, 180 women; <a href="./references#CD002855-fig-0084" title="">Analysis 16.1</a>; <a href="./references#CD002855-bbs2-0049" title="MizrachiY , DekaloA , GluckO , MirembergH , DafnaL , FeldsteinO , et al.Single versus repeat doses of misoprostol for treatment of early pregnancy loss-a randomized clinical trial. Human Reproduction (Oxford, England)2017;32(6):1202-7. [DOI: https://dx.doi.org/10.1093/humrep/dex074]">Mizrachi 2017</a>). </p> <p>We included two studies with different administration models of misoprostol: nurse‐administered versus doctor‐administered (<a href="./references#CD002855-bbs2-0039" title="CleeveA , ByamugishaJ , Gemzell-DanielssonK , Mbona TumwesigyeN , AtuhairweS , FaxelidE , et al.Women's acceptability of misoprostol treatment for incomplete abortion by midwives and physicians - secondary outcome analysis from a randomized controlled equivalence trial at district level in Uganda. PloS One2016;11(2):e0149172. [DOI: https://dx.doi.org/10.1371/journal.pone.0149172]Klingberg-AllvinM , CleeveA , AtuhairweS , TumwesigyeNM , FaxelidE , ByamugishaJ , et al.Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet2015;385(9985):2392-8. [DOI: https://dx.doi.org/10.1016/S0140-6736(14)61935-8]">Klingberg Allvin 2015</a>), and at home versus in hospital (<a href="./references#CD002855-bbs2-0050" title="NgBK , AnnamalaiR , LimPS , Aqmar SurayaS , Nur AzurahAG , Muhammad Abdul JamilMY .Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of Gynecology and Obstetrics2015;291(1):105-13. [DOI: https://dx.doi.org/10.1007/s00404-014-3388-0]">Ng 2015</a>). Misoprostol alone administered by a doctor might reduce failure to achieve complete abortion compared to nurse administration (RR 3.84, 95% CI 2.16 to 6.83; 1 study, 1010 women; <a href="./references#CD002855-fig-0084" title="">Analysis 16.1</a>). However, home versus hospital administration might have similar effectiveness in achieving complete abortion (RR 1.00, 95% CI 0.37 to 2.72; 1 study, 154 women; <a href="./references#CD002855-fig-0084" title="">Analysis 16.1</a>). </p> <p>It was uncertain whether misoprostol alone administered sublingually was different from misoprostol alone administered vaginally on blood transfusion (RR 5.00, 95% CI 0.24 to 102.96; 1 RCT, 220 women; very low‐certainty evidence; <a href="./references#CD002855-fig-0085" title="">Analysis 16.2</a>; <a href="./full#CD002855-tbl-0010">summary of findings Table 10</a>), ongoing pregnancy (RR 0.57, 95% CI 0.21 to 1.51; 2 RCTs, 340 women; <a href="./references#CD002855-fig-0086" title="">Analysis 16.3</a>; <a href="./references#CD002855-bbs2-0070" title="SonsanohA , ChullapramT .Comparison of sublingual and vaginal misoprostol for termination of early pregnancy failure: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2014;22(3):128. ">Sonsanoh 2014</a>; <a href="./references#CD002855-bbs2-0075" title="TanhaFD , FeiziM , ShariatM .Sublingual versus vaginal misoprostol for the management of missed abortion. Journal of Obstetrics and Gynaecology Research2010;36(3):525-32. [DOI: 10.1111/j.1447-0756.2010.01229.x]">Tanha 2010</a>). It was also uncertain whether misoprostol administered sublingually was different from misoprostol administered buccally on ongoing pregnancy (RR 1.11, 95% CI 0.50 to 2.45, 1 RCT, 401 women; <a href="./references#CD002855-fig-0086" title="">Analysis 16.3</a>) and additional uterotonics (RR 1.89, 95% CI 0.77 to 4.63; 1 RCT, 401 women; <a href="./references#CD002855-fig-0087" title="">Analysis 16.4</a>; <a href="./references#CD002855-bbs2-0066" title="SheldonWR , DurocherJ , DzubaIG , SayetteH , MartinR , VelascoMC , et al.Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception2019;99(5):272-7. [DOI: https://dx.doi.org/10.1016/j.contraception.2019.02.002]">Sheldon 2019</a>). </p> <p>Surgical evacuation was probably lower (sublingual versus vaginal: RR 0.47, 95% CI 0.26 to 0.85; I<sup>2</sup> = 68%; 3 RCTs, 540 women; nurse versus doctor: RR 3.84, 95% CI 2.16 to 6.83; 1 study, 1010 women; <a href="./references#CD002855-fig-0088" title="">Analysis 16.5</a>), and women's dissatisfaction with the procedure was probably lower (sublingual versus vaginal: RR 0.14, 95% CI 0.07 to 0.29; 1 study, 220 women; low‐certainty evidence; <a href="./full#CD002855-tbl-0010">summary of findings Table 10</a>; nurse versus doctor: RR 2.18, 95% CI 1.40 to 3.41; 1 study, 1010 women; <a href="./references#CD002855-fig-0093" title="">Analysis 16.10</a>) in the sublingual‐ or doctor‐administered groups, compared with the vaginal‐ or nurse‐administered groups, respectively. </p> <p>Nausea (RR 1.16, 95% CI 1.02 to 1.32; <a href="./references#CD002855-fig-0089" title="">Analysis 16.6</a>) and vomiting (RR 1.35, 95% CI 1.08 to 1.68; 1 study, 1010 women; <a href="./references#CD002855-fig-0090" title="">Analysis 16.7</a>) might occur much more frequently in the nurse‐administered group than when the doctor administered the therapy (<a href="./references#CD002855-bbs2-0039" title="CleeveA , ByamugishaJ , Gemzell-DanielssonK , Mbona TumwesigyeN , AtuhairweS , FaxelidE , et al.Women's acceptability of misoprostol treatment for incomplete abortion by midwives and physicians - secondary outcome analysis from a randomized controlled equivalence trial at district level in Uganda. PloS One2016;11(2):e0149172. [DOI: https://dx.doi.org/10.1371/journal.pone.0149172]Klingberg-AllvinM , CleeveA , AtuhairweS , TumwesigyeNM , FaxelidE , ByamugishaJ , et al.Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet2015;385(9985):2392-8. [DOI: https://dx.doi.org/10.1016/S0140-6736(14)61935-8]">Klingberg Allvin 2015</a>). </p> <p>More women experienced diarrhoea (RR 1.73, 95% CI 1.41 to 2.12; I<sup>2</sup> = 25%; 5 RCTs, 2725 women; <a href="./references#CD002855-fig-0091" title="">Analysis 16.8</a>) and abdominal pain (RR 1.38, 95% CI 0.49 to 3.86; I<sup>2</sup> = 98%; 3 RCTs, 459 women; <a href="./references#CD002855-fig-0092" title="">Analysis 16.9</a>) in the sublingual group, compared with the vaginal route. However, the heterogeneity was high for the abdominal pain among studied, which might be induced by <a href="./references#CD002855-bbs2-0071" title="SouiziB , AkramiR , BorzoeeF , SahebkarM .Comparison of the efficacy of sublingual, oral, and vaginal administration of misoprostol in the medical treatment of missed abortion during first trimester of pregnancy: a randomized clinical trial study. Journal of Research in Medical Sciences2020;25:72. ">Souizi 2020</a> reporting higher ratio of abdominal pain, and the other two studies just counted severe pain (<a href="./references#CD002855-bbs2-0070" title="SonsanohA , ChullapramT .Comparison of sublingual and vaginal misoprostol for termination of early pregnancy failure: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2014;22(3):128. ">Sonsanoh 2014</a>; <a href="./references#CD002855-bbs2-0075" title="TanhaFD , FeiziM , ShariatM .Sublingual versus vaginal misoprostol for the management of missed abortion. Journal of Obstetrics and Gynaecology Research2010;36(3):525-32. [DOI: 10.1111/j.1447-0756.2010.01229.x]">Tanha 2010</a>), When misoprostol was administered vaginally, compared to oral administration, less time was needed to expel the products of conception (SMD 0.71, 95% CI 0.31 to 1.12; 1 study, 100 women; <a href="./references#CD002855-fig-0095" title="">Analysis 16.12</a>; <a href="./references#CD002855-bbs2-0046" title="MarwahS , GuptaS , BatraNP , BhasinV , SarnaV , KaurN .A comparative study to evaluate the efficacy of vaginal vs oral prostaglandin E1 analogue (misoprostol) in management of first trimester missed abortion. Journal of Clinical and Diagnostic Research2016;10(5):QC14-8. [DOI: https://dx.doi.org/10.7860/JCDR/2016/18178.7891]">Marwah 2016</a>). However, sublingual administration was faster to achieve complete abortion than the vaginal route (SMD −1.10, 95% CI −1.34 to −0.87; I<sup>2</sup> = 0%; 2 RCTs, 320 women; <a href="./references#CD002855-fig-0095" title="">Analysis 16.12</a>; <a href="./references#CD002855-bbs2-0002" title="AbdelshafyA , AwwadH , Abo-GamraA , AlanwarA , ElkotbAM , ShahinM , et al.Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2019;24(2):134-9. [DOI: https://dx.doi.org/10.1080/13625187.2019.1569224]">Abdelshafy 2019</a>; <a href="./references#CD002855-bbs2-0070" title="SonsanohA , ChullapramT .Comparison of sublingual and vaginal misoprostol for termination of early pregnancy failure: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2014;22(3):128. ">Sonsanoh 2014</a>). Bleeding time was similar between sublingual and vaginal groups (SMD −0.22, 95% CI −0.50 to 0.06; 1 study, 200 women; <a href="./references#CD002855-fig-0094" title="">Analysis 16.11</a>), and between different misoprostol administration models (<a href="./references#CD002855-fig-0094" title="">Analysis 16.11</a>). The reduction of haemoglobin (<a href="./references#CD002855-bbs2-0050" title="NgBK , AnnamalaiR , LimPS , Aqmar SurayaS , Nur AzurahAG , Muhammad Abdul JamilMY .Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of Gynecology and Obstetrics2015;291(1):105-13. [DOI: https://dx.doi.org/10.1007/s00404-014-3388-0]">Ng 2015</a>), and the actual level of haemoglobin (<a href="./references#CD002855-bbs2-0002" title="AbdelshafyA , AwwadH , Abo-GamraA , AlanwarA , ElkotbAM , ShahinM , et al.Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. European Journal of Contraception &amp; Reproductive Health Care2019;24(2):134-9. [DOI: https://dx.doi.org/10.1080/13625187.2019.1569224]">Abdelshafy 2019</a>), were each reported by one study (<a href="./references#CD002855-fig-0096" title="">Analysis 16.13</a>). Less reduction was observed in the sublingual or home group, compared with vaginal or hospital group. </p> </section> <section id="CD002855-sec-0087"> <h5 class="title">Comparison 17: mifepristone single dose, high dose versus low dose</h5> <p>We included one study with 101 women in this comparison (<a href="./references#CD002855-bbs2-0008" title="BirgersonL , OdlindV .The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception1988;38(4):391-400. ">Birgerson 1988</a>). Low‐dose (140 mg) mifepristone may have similar effectiveness to high‐dose (700 mg) mifepristone for failure to achieve complete abortion (RR 1.32, 95% CI 0.74 to 2.38; <a href="./references#CD002855-fig-0097" title="">Analysis 17.1</a>). However, the low‐dose group might experience much more nausea, but similar vomiting, compared to the high‐dose group. </p> </section> </section> <section id="CD002855-sec-0088"> <h4 class="title">Combined regimen: methotrexate/prostaglandin</h4> <section id="CD002855-sec-0089"> <h5 class="title">Comparison 18: timing of prostaglandin</h5> <p>We included three studies in the review for this comparison (<a href="./references#CD002855-bbs2-0012" title="CarbonellJL , VelazcoA , VarelaL , CabezasE , FernandezC , SanchezC .Misoprostol 3, 4, or 5 days after methotrexate for early abortion. Contraception1997;56:169-74. ">Carbonell 1997b</a>; <a href="./references#CD002855-bbs2-0013" title="CarbonellJL , VarelaL , VelazcoA , CabezasE , FernandezC , SanchezC .Oral methotrexate and vaginal misoprostol for early abortion. Contraception1998;57:83-8. ">Carbonell 1998</a>; <a href="./references#CD002855-bbs2-0020" title="CreininMD , VittinghoffE , GalbraithS , KlaisleC .A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. American Journal of Obstetrics and Gynecology1995;173:1578-84. ">Creinin 1995</a>), and data from two studies were included in the meta‐analysis (<a href="./references#CD002855-bbs2-0012" title="CarbonellJL , VelazcoA , VarelaL , CabezasE , FernandezC , SanchezC .Misoprostol 3, 4, or 5 days after methotrexate for early abortion. Contraception1997;56:169-74. ">Carbonell 1997b</a>; <a href="./references#CD002855-bbs2-0013" title="CarbonellJL , VarelaL , VelazcoA , CabezasE , FernandezC , SanchezC .Oral methotrexate and vaginal misoprostol for early abortion. Contraception1998;57:83-8. ">Carbonell 1998</a>). It was uncertain whether misoprostol given on day seven after methotrexate might have a similar effect to misoprostol given on day three in failure to achieve complete abortion (RR 0.14, 95% CI 0.02 to 1.10; 1 study, 86 women; <a href="./references#CD002855-fig-0099" title="">Analysis 18.1</a>), but misoprostol might slightly reduce failure to achieve complete abortion on day five compared to day three (RR 0.72, 95% CI 0.36 to 1.45; I<sup>2</sup> = 0%; 2 RCTs, 387 women; <a href="./references#CD002855-fig-0099" title="">Analysis 18.1</a>), on day five compare to day four (RR 0.75, 95% CI 0.38 to 1.49; I<sup>2</sup> = 0%; 2 RCTs, 394 women; <a href="./references#CD002855-fig-0099" title="">Analysis 18.1</a>), and on day four compared to day three (RR 0.97, 95% CI 0.52 to 1.80; I<sup>2</sup> = 0%; 2 RCTs, 393 women). </p> </section> <section id="CD002855-sec-0090"> <h5 class="title">Comparison 19: route of methotrexate ‐ intramuscular versus oral</h5> <p>One study (100 women) compared intramuscular versus oral administration of methotrexate (<a href="./references#CD002855-bbs2-0094" title="WiebeER .Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. American Journal of Obstetrics &amp; Gynecology1999;181:149-52. ">Wiebe 1999b</a>). It was uncertain whether methotrexate given intramuscularly was different from methotrexate given orally on failure to achieve complete abortion (RR 2.04, 95% CI 0.51 to 8.07; <a href="./references#CD002855-fig-0100" title="">Analysis 19.1</a>) or on side effects (nausea: RR 0.52, 95% CI 0.22 to 1.25; vomiting: RR 4.89, 95% CI 0.57 to 42.21; diarrhoea: RR 1.22, 95% CI 0.18 to 8.34; <a href="./references#CD002855-fig-0101" title="">Analysis 19.2</a>). </p> </section> <section id="CD002855-sec-0091"> <h5 class="title">Comparison 20: dose of methotrexate</h5> <p>Two studies (40 women) were eligible to be included in the review (<a href="./references#CD002855-bbs2-0021" title="CreininMD .Oral methotrexate and vaginal misoprostol for early abortion. Contraception1996;54:15-8. ">Creinin 1996a</a>; <a href="./references#CD002855-bbs2-0022" title="CreininMD , KrohnMA .Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. American Journal of Obstetrics and Gynecology1997;177:1444-9. ">Creinin 1997</a>). Both studies had a very small sample size (10 women in each group); they used differently dosed regimens and we therefore presented them separately. It was uncertain whether the different dosage of methotrexate were similarly effective in failure to achieve complete abortion (<a href="./references#CD002855-fig-0102" title="">Analysis 20.1</a>). </p> </section> <section id="CD002855-sec-0092"> <h5 class="title">Comparison 21: route of prostaglandin (misoprostol)</h5> <p>One study with 309 women (<a href="./references#CD002855-bbs2-0095" title="WiebeER , TroutonK .Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion. Contraception2004;70:463-6. ">Wiebe 2004</a>), compared buccal versus vaginal administration of misoprostol three to six days after methotrexate. Women received additional misoprostol but it was unclear how many or in which treatment group. The vaginal route might be more effective in achieving complete abortion than the buccal route (RR of failure 1.43, 95% CI 1.08 to 1.90; <a href="./references#CD002855-fig-0103" title="">Analysis 21.1</a>). Women administered misoprostol vaginally after methotrexate might experience similar nausea, vomiting and diarrhoea as via the buccal route (<a href="./references#CD002855-fig-0104" title="">Analysis 21.2</a>). </p> </section> </section> <section id="CD002855-sec-0093"> <h4 class="title">Tamoxifen versus methotrexate (combined with prostaglandin)</h4> <p>One study compared methotrexate to tamoxifen, both followed by misoprostol. The study was conducted in two phases: phase one used low‐dose tamoxifen (40 mg) and phase two used high‐dose tamoxifen (160 mg). We have therefore referred to this study as <a href="./references#CD002855-bbs2-0093" title="WiebeER .Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception1999;59:265-70. ">Wiebe 1999a</a> (low dose) and <a href="./references#CD002855-bbs2-0094" title="WiebeER .Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. American Journal of Obstetrics &amp; Gynecology1999;181:149-52. ">Wiebe 1999b</a> (high dose). </p> <section id="CD002855-sec-0094"> <h5 class="title">Comparison 22: low‐dose tamoxifen (40 mg)</h5> <p>Women administered low‐dose tamoxifen (40 mg) might experience slightly increased failure to achieve complete abortion (RR 2.04, 95% CI 0.86 to 4.84; 198 women; <a href="./references#CD002855-fig-0105" title="">Analysis 22.1</a>), reduced nausea (RR 0.56, 95% CI 0.33 to 0.97; 198 women; <a href="./references#CD002855-fig-0106" title="">Analysis 22.2</a>); similar vomiting (RR 1.70, 95% CI 0.42 to 6.92; 198 women; <a href="./references#CD002855-fig-0106" title="">Analysis 22.2</a>) and diarrhoea (RR 1.53, 95% CI 0.26 to 8.96; 198 women; <a href="./references#CD002855-fig-0106" title="">Analysis 22.2</a>) compared to methotrexate (<a href="./references#CD002855-bbs2-0093" title="WiebeER .Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception1999;59:265-70. ">Wiebe 1999a</a>). </p> </section> <section id="CD002855-sec-0095"> <h5 class="title">Comparison 23: high‐dose tamoxifen (160 mg)</h5> <p>Women administered high‐dose tamoxifen (160 mg) might also experience slightly increased failure to achieve complete abortion (RR 1.96, 95% CI 0.93 to 4.15; 200 women; <a href="./references#CD002855-fig-0107" title="">Analysis 23.1</a>), reduced nausea (RR 0.78, 95% CI 0.54 to 1.10; 200 women; <a href="./references#CD002855-fig-0108" title="">Analysis 23.2</a>); similar vomiting (RR 0.65, 95% CI 0.28 to 1.53; 200 women; <a href="./references#CD002855-fig-0108" title="">Analysis 23.2</a>) and diarrhoea (RR 1.23, 95% CI 0.34 to 4.43; 200 women; <a href="./references#CD002855-fig-0108" title="">Analysis 23.2</a>) compared to methotrexate (<a href="./references#CD002855-bbs2-0094" title="WiebeER .Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. American Journal of Obstetrics &amp; Gynecology1999;181:149-52. ">Wiebe 1999b</a>). </p> </section> </section> <section id="CD002855-sec-0096"> <h4 class="title">Combined regimen mifepristone/prostaglandin versus mifepristone/prostaglandin plus tamoxifen </h4> <section id="CD002855-sec-0097"> <h5 class="title">Comparison 24</h5> <p>We included one study with 932 women (<a href="./references#CD002855-bbs2-0098" title="WuYM , LiY , FanHM , ZhuXJ , ZhengS , WangS , et al.Clinical study of mifepristone in combination with tamoxifen and 15-methyl-PGF2alpha methylester for termination of early pregnancy. Sheng Zhi Yi Xue Za Zhi1993;4:224-7. ">Wu 1993</a>); the combined regimen without tamoxifen might lead to higher failure to achieve complete abortion (RR 1.29, 95% CI 0.82 to 2.02; <a href="./references#CD002855-fig-0109" title="">Analysis 24.1</a>). </p> </section> </section> <section id="CD002855-sec-0098"> <h4 class="title">Other comparisons</h4> <p><a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a> compared mifepristone 25 mg a day over seven days (total dose of 250 mg) followed by oral misoprostol 200 mg a day over three days (total dose of 1200 µg) to mifepristone 150 mg on day one followed by oral misoprostol 600 µg on day three. The doses and regimens in the two groups make it difficult to draw any meaningful conclusion from this comparison. <a href="./references#CD002855-bbs2-0040" title="KoopersmithTB , MishellDR .The use of misoprostol for termination of early pregnancy. Contraception1996;53:237-42. ">Koopersmith 1996</a> compared misoprostol alone to misoprostol/tamoxifen and misoprostol/laminaria. The sample size was very small, which precludes drawing any meaningful conclusions from this study. We included these two studies in the additional tables. Additionally, <a href="./references#CD002855-bbs2-0009" title="BlanchardK , Tara ShochetT , CoyajicK , NgocN , WinikoffB .Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception2005;72:91-7. ">Blanchard 2005</a> used various doses, routes and timings of misoprostol administered alone in a very small sample of women. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002855-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002855-sec-0099"></div> <p>The literature on different medical abortion methods is vast, but contains relatively few RCTs that compare the different regimens. The studies included in this review were all conducted after the mifepristone/misoprostol regimen was licensed for sale in the UK and France and sought to determine if a lower dose and less costly regimen could be as effective as the licensed one. <a href="./references#CD002855-bbs2-0232" title="GrimesDA .Medical abortion in early pregnancy: a review of the evidence. Obstetrics and Gynecology1997;89:790-6.">Grimes 1997</a> and <a href="./references#CD002855-bbs2-0223" title="BygdemanM , DanielssonKG .Options for early therapeutic abortion. Drugs2002;62(17):2459-70.">Bygdeman 2002</a> in their reviews mentioned the different aspects to be considered when using medical abortion methods. Medical methods used are mostly combined regimens and many different types of combinations are described. To facilitate synthesising the data, studies were grouped into comparisons, as listed above (see <a href="#CD002855-sec-0035">Data synthesis</a>). The focus was mainly on primary outcomes, such as effectiveness, complications, side effects and acceptability. </p> <p>Meta‐analysis was complicated by the use of different pharmaceutical agents, different doses and different routes of application; therefore, most meta‐analyses contain only a small number of reasonably comparable studies. The review also focused on unwanted effects. </p> <section id="CD002855-sec-0100"> <h3 class="title" id="CD002855-sec-0100">Summary of main results</h3> <p>These data support that the most common combined regimen (mifepristone/misoprostol) is an effective and safe method for pregnancy termination in the first trimester. The effect of mifepristone is not decreased by lowering the dose from previously recommended 600 mg to 200 mg when combined with at least 400 µg of misoprostol. In earlier studies, it was demonstrated that the linear dose‐response effect of mifepristone does not occur in doses above 100 mg (<a href="./references#CD002855-bbs2-0219" title="BeaulieuEE .RU 486 (Mifepristone) - A short overview of its mechanisms of action and clinical uses at the end of 1996. In: Annals New York Academy of Sciences. New York Academy of Sciences, 1997:47-58.">Beaulieu 1997</a>). A combination regimen with a prostaglandin is more effective than use of prostaglandin alone. Similarly, mifepristone alone is less effective than when combined with prostaglandin. </p> <p>Different prostaglandins have been used for medical abortion, but misoprostol has superior attributes; misoprostol is at least as effective as gemeprost and is less costly, does not require refrigeration and offers different routes of administration. Of the different routes of misoprostol administration, vaginal appears to be superior to oral administration in terms of efficacy in the meta‐analysis and majority of studies, and has fewer side effects when compared to oral, buccal or sublingual routes. </p> <p>Medical abortion administered by doctors in hospital seems as effective as that managed by women themselves at home, however, might be better administered by a doctor than a nurse within the healthcare system. However, the certainty of the evidence is low, and more data are needed to confirm this finding. </p> <p>In regards to the role of gestational age, when comparing abortions at seven weeks' gestational age or less to those at seven weeks or more, there was insufficient data to evaluate whether effects differed according to gestational age in any of the included analyses. </p> <p>Methotrexate, combined with a prostaglandin, has been used in some studies with an effectiveness of mostly greater than 90%. We did not identify any new studies for the current, updated review that compared mifepristone/prostaglandin with methotrexate/prostaglandin. Letrozole used prior to misoprostol might increase the efficacy of misoprostol in achieving complete abortion for women with missed abortion. </p> <p>An important aspect of this review is the overall very low rate of major complications reported among the various medical abortion regimens. The most severe complication is the need for blood transfusion (see table <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>). The reported self‐limiting side effects of medical abortion regimens are mainly due to the prostaglandins (nausea, vomiting, diarrhoea, abdominal pain). The dose, route and type of prostaglandin used may influence the occurrence of side effects, as higher doses and oral administration are associated with an increase in nausea and vomiting. </p> </section> <section id="CD002855-sec-0101"> <h3 class="title" id="CD002855-sec-0101">Overall completeness and applicability of evidence</h3> <p>The included studies have addressed the objectives of the review. The generalisability of these results to some settings may be limited, as most studies considered in the review had strict inclusion criteria: intrauterine pregnancy was confirmed by ultrasound, emergency back‐up facilities were available and follow‐up was high. Fortunately, an increasing number of studies are focusing on the provision of medical abortion outside these particular constructs. We have included studies relating to medical abortion administered by women themselves at home or by nurses in hospital in the current update of the review. Additional barriers to the introduction of medical abortion may include the relatively high cost and need for registration of mifepristone. </p> <p>Acceptability of medical abortion methods is often associated with the success of the abortion, and may decrease with higher gestational ages (<a href="./references#CD002855-bbs2-0235" title="HonkanenH , vonHertzenH .Users' perspectives on medical abortion in Finland. Contraception2002;65(6):419-23.">Honkanen 2002</a>; <a href="./references#CD002855-bbs2-0081" title="HonkanenH , PiaggioG , Von HertzenH , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women’s perceptions. BJOG2004;111:715-25. Von HertzenH , HonkanenH , PiaggioG , BartfaiG , ErdenetungalagR , Gemzell-DanielssonK , et al.WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. BJOG2003;110:808-18. ">von Hertzen 2003</a>; <a href="./references#CD002855-bbs2-0250" title="WinikoffB , IrvingS , CoyajiK , CaberasE , BilianX , SujuanG , et al.Safety, efficacy and acceptability of medical abortion in China, Cuba and India: a comparative trial of mifepristone - misoprostol versus surgical abortion. American Journal of Obstetrics and Gynecology1997;176:431-7.">Winikoff 1997</a>). Whether acceptability of different application routes is linked to age, parity or cultural differences is not well established. The difference in time intervals between mifepristone and methotrexate and the administration of prostaglandin, or their use outside the healthcare setting may also play a role in the acceptability of one method over the other. </p> <p>Other comparisons, such as the combination of tamoxifen/prostaglandin have not been evaluated extensively enough to draw firm conclusions. Some outcomes such as number of days of bleeding with the procedure, pain, time to return of menstruation, cost or acceptability have not been assessed sufficiently (<a href="./references#CD002855-bbs2-0246" title="SjöströmS , Kopp KallnerH , SimeonovaE , MadestamA , Gemzell-DanielssonK .Medical abortion provided by nurse-midwives or physicians in a high resource setting: a cost-effectiveness analysis. PLoS One2016;11(6):e0158645.">Sjöström 2016</a>). </p> </section> <section id="CD002855-sec-0102"> <h3 class="title" id="CD002855-sec-0102">Quality of the evidence</h3> <p>Overall, the certainty of the evidence is low to moderate. The methodology of included studies was adequate for most included studies, especially for the randomisation method. We included 99 RCTs in the current review relating to different interventions and different inclusion criteria of women; therefore the consistency of evidence should be evaluated for each subgroup but not for the whole review. All the included studies directly assessed the primary outcome of this review, complete abortion rate, using different methods. However, some studies also included a few women in the second trimester, and not all the included studies detailed the results of reported side effects. The sample size was adequate for most included studies to address the research objectives. </p> </section> <section id="CD002855-sec-0103"> <h3 class="title" id="CD002855-sec-0103">Potential biases in the review process</h3> <p>The risk of bias within the evidence was moderately high (<a href="#CD002855-fig-0002">Figure 2</a>; <a href="#CD002855-fig-0003">Figure 3</a>; <a href="./references#CD002855-sec-0123" title="">Characteristics of included studies</a>). Not all studies described their random sequence generation or allocation concealment methods, few studies reported blinding, and most studies randomly assigned only limited numbers of women. </p> <p>Heterogeneity, especially clinical heterogeneity, was high in the included studies, including different dosage and type, different route, different interval, and different duration of follow‐up. </p> <p>We believe that we identified all relevant studies. However, attempted contact with primary authors of 10 records for full texts was unsuccessful. Imputation of individual values for attrition was undertaken by us. Subjective judgements are involved in the assessment of risk of bias. This potential limitation is minimised by following the procedures in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002855-bbs2-0234" title="HigginsJP , AltmanDG , Sterne JA editor(s).Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/PDF/v5.2/chapter-08.">Higgins 2017</a>), with review authors independently assessing studies and resolving any disagreement through discussion, and if required involving a third review author in the decision. </p> </section> <section id="CD002855-sec-0104"> <h3 class="title" id="CD002855-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>Medical abortion for the first trimester has also been systematically reviewed by the following systematic reviews. </p> <p>Being consistent with the results of the current review, other systematic reviews found that the combined regimen of mifepristone and misoprostol is more effective than misoprostol alone; misoprostol provided vaginally is better compared to oral administration; and adverse events are rare (<a href="./references#CD002855-bbs2-0214" title="AbubekerFA , LavelanetA , RodriguezMI , KimC .Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review. BMC Womens Health2020;20(1):142.">Abubeker 2020</a>; <a href="./references#CD002855-bbs2-0215" title="Al WattarBH , MurugesuN , TobiasA , ZamoraJ , KhanKS .Management of first-trimester miscarriage: a systematic review and network meta-analysis. Human Reproduction Update2019;25(3):362-74.">Al Wattar 2019</a>; <a href="./references#CD002855-bbs2-0236" title="KappN , EckersbergerE , LavelanetA , RodriguezMI .Medical abortion in the late first trimester: a systematic review. Contraception2019;99(2):77-86.">Kapp 2018</a>). <a href="./references#CD002855-bbs2-0217" title="BaijuN , AcharyaG , D'AntonioF , BergRC .Effectiveness, safety and acceptability of self-assessment of the outcome of first-trimester medical abortion: a systematic review and meta-analysis. BJOG2019;126(13):1536-44.">Baiju 2019</a> also found no significant difference in complete abortion rates between self‐assessment and routine clinic follow‐up. Therefore, the option of expulsion at home after misoprostol has been taken is also advised to women before 10 gestational weeks (<a href="./references#CD002855-bbs2-0244" title="Schmidt-HansenM , PandeyA , LohrPA , NevillM , TaylorP , HaslerE , et al.Expulsion at home for early medical abortion: a systematic review with meta-analyses. Acta Obstetricia et Gynecologica Scandinavica2020;100(4):727-35. [CENTRAL: 10.1111/aogs.14025]">Schmidt‐Hansen 2020</a>). Early medical abortion with mifepristone 200 mg followed by misoprostol is also effective and safe (<a href="./references#CD002855-bbs2-0241" title="RaymondEG , ShannonC , WeaverMA , WinikoffB .First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review. Contraception2013;87(1):26-37.">Raymond 2013</a>). But the evidence is also limited for the inconsistency among included studies. </p> <p>However, being inconsistent with the present review, other systematic reviews found that incomplete abortion is equally effective and acceptable when performed by non‐doctor providers as doctors (<a href="./references#CD002855-bbs2-0247" title="SjöströmS , DragomanM , FønhusMS , GanatraB , Gemzell-DanielssonK .Effectiveness, safety, and acceptability of first-trimester medical termination of pregnancy performed by non-doctor providers: a systematic review. BJOG2017;124(13):1928-40.">Sjöström 2017</a>). <a href="./references#CD002855-bbs2-0218" title="BarnardS , KimC , ParkMH , NgoTD .Doctors or mid-level providers for abortion. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD011242. [CENTRAL: CD011242] [DOI: 10.1002/14651858.CD011242.pub2]">Barnard 2015</a> found no difference between mid‐level providers (such as midwives, nurses and other non‐physician providers) and doctors for first trimester abortion. There was no difference in complete abortion between vaginal misoprostol with expectant care for women with incomplete abortion before 13 weeks' gestation <a href="./references#CD002855-bbs2-0237" title="KimC , BarnardS , NeilsonJP , HickeyM , VazquezJC , DouL .Medical treatments for incomplete miscarriage. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD007223. [CENTRAL: CD007223] [DOI: 10.1002/14651858.CD007223.pub4]">Kim 2017</a>. The efficacy of letrozole prior to misoprostol is controversial in <a href="./references#CD002855-bbs2-0239" title="NashCM , PhilpL , ShahP , MurphyKE .Letrozole pretreatment prior to medical termination of pregnancy: a systematic review. Contraception2018;97(6):504-9.">Nash 2018</a>. A 24‐hour time interval between mifepristone and buccal misoprostol administration is slightly less effective than a 24‐hour to 48‐hour interval (<a href="./references#CD002855-bbs2-0225" title="ChenMJ , CreininMD .Mifepristone with buccal misoprostol for medical abortion: a systematic review. Obstetrics and Gynecology2015;126(1):12-21.">Chen 2015b</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002855-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of updated process" data-id="CD002855-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram of updated process</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002855-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Review authors' judgements about each risk of bias item presented as percentages across all studies" data-id="CD002855-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Review authors' judgements about each risk of bias item presented as percentages across all studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 15 prostaglandin alone vs combined regimen (all), outcome 15.1 failure to achieve complete abortion" data-id="CD002855-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison 15 prostaglandin alone vs combined regimen (all), outcome 15.1 failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined regimen mifepristone/prostaglandin: dose of mifepristone, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Combined regimen mifepristone/prostaglandin: dose of mifepristone, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined regimen mifepristone/prostaglandin: dose of mifepristone, Outcome 2: Side effects" data-id="CD002855-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Combined regimen mifepristone/prostaglandin: dose of mifepristone, Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined regimen mifepristone/prostaglandin: dose of mifepristone, Outcome 3: Time until passing of conceptus &gt; 3 to 6 hours" data-id="CD002855-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Combined regimen mifepristone/prostaglandin: dose of mifepristone, Outcome 3: Time until passing of conceptus &gt; 3 to 6 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined regimen mifepristone/prostaglandin: dose of mifepristone, Outcome 4: Ongoing pregnancy" data-id="CD002855-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Combined regimen mifepristone/prostaglandin: dose of mifepristone, Outcome 4: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 2: Surgical evacuation" data-id="CD002855-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 2: Surgical evacuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 3: Ongoing pregnancy" data-id="CD002855-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 3: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 4: Nausea" data-id="CD002855-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 4: Nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 5: Vomiting" data-id="CD002855-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 5: Vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 6: Diarrhoea" data-id="CD002855-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 6: Diarrhoea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 7: Abdominal pain" data-id="CD002855-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 7: Abdominal pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 8: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Combined regimen mifepristone/prostaglandin: dose of prostaglandin, Outcome 8: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combined regimen mifepristone/prostaglandin: type of prostaglandin, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Combined regimen mifepristone/prostaglandin: type of prostaglandin, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combined regimen mifepristone/prostaglandin: type of prostaglandin, Outcome 2: Side effects" data-id="CD002855-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Combined regimen mifepristone/prostaglandin: type of prostaglandin, Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combined regimen mifepristone/prostaglandin: type of prostaglandin, Outcome 3: Ongoing pregnancy" data-id="CD002855-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Combined regimen mifepristone/prostaglandin: type of prostaglandin, Outcome 3: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combined regimen mifepristone/prostaglandin: type of prostaglandin, Outcome 4: Time until passing of conceptus &gt; 3 to 6 hours" data-id="CD002855-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Combined regimen mifepristone/prostaglandin: type of prostaglandin, Outcome 4: Time until passing of conceptus &gt; 3 to 6 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 2: Side effects" data-id="CD002855-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 3: Surgical evacuation" data-id="CD002855-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 3: Surgical evacuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 4: Ongoing pregnancy" data-id="CD002855-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 4: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 5: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 5: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 6: Time until passing of conceptus" data-id="CD002855-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 6: Time until passing of conceptus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 7: Days of bleeding" data-id="CD002855-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 7: Days of bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 8: Additional uterotonics used" data-id="CD002855-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Combined regimen mifepristone/prostaglandin: timing of prostaglandin, Outcome 8: Additional uterotonics used </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 2: Surgical evacuation" data-id="CD002855-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 2: Surgical evacuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 3: Ongoing pregnancy" data-id="CD002855-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 3: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 4: Side effects" data-id="CD002855-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 4: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 5: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 5: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 6: Additional uterotonics used" data-id="CD002855-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 6: Additional uterotonics used </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 7: Days of bleeding" data-id="CD002855-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 7: Days of bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 8: Blood transfusion" data-id="CD002855-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Combined regimen mifepristone/prostaglandin: administration strategy, Outcome 8: Blood transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal, Outcome 2: Side effects" data-id="CD002855-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal, Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal, Outcome 3: Bleeding volume" data-id="CD002855-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal, Outcome 3: Bleeding volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal, Outcome 4: Time until passing of conceptus" data-id="CD002855-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal, Outcome 4: Time until passing of conceptus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal, Outcome 2: Side effects" data-id="CD002855-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal, Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal, Outcome 3: Surgical evacuation" data-id="CD002855-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal, Outcome 3: Surgical evacuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal, Outcome 4: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal, Outcome 4: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral, Outcome 2: Ongoing pregnancy" data-id="CD002855-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral, Outcome 2: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral, Outcome 3: Side effects" data-id="CD002855-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral, Outcome 3: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral, Outcome 4: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral, Outcome 4: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 2: Surgical evacuation" data-id="CD002855-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 2: Surgical evacuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 3: Ongoing pregnancy" data-id="CD002855-fig-0051" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 3: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 4: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0052" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 4: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 5: Side effects" data-id="CD002855-fig-0053" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal, Outcome 5: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0054" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 2: Ongoing pregnancy" data-id="CD002855-fig-0055" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 2: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 3: Surgical evacuation" data-id="CD002855-fig-0056" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 3: Surgical evacuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 4: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0057" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 4: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 5: Side effects" data-id="CD002855-fig-0058" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral, Outcome 5: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0059" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 2: Surgical evacuation" data-id="CD002855-fig-0060" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 2: Surgical evacuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 3: Ongoing pregnancy" data-id="CD002855-fig-0061" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 3: Ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 4: Side effects" data-id="CD002855-fig-0062" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 4: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 5: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0063" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 5: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-011.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 6: Haemoglobin level" data-id="CD002855-fig-0064" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-011.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 6: Haemoglobin level </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-011.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 7: Time until passing of conceptus" data-id="CD002855-fig-0065" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-011.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11: Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal, Outcome 7: Time until passing of conceptus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-011.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Combined regimen mifepristone/prostaglandin: single vs split dose of prostaglandin, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0066" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Combined regimen mifepristone/prostaglandin: single vs split dose of prostaglandin, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Combined regimen mifepristone/prostaglandin: single vs split dose of prostaglandin, Outcome 2: Side effects" data-id="CD002855-fig-0067" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Combined regimen mifepristone/prostaglandin: single vs split dose of prostaglandin, Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0068" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 2: Diarrhoea" data-id="CD002855-fig-0069" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 2: Diarrhoea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 3: Nausea" data-id="CD002855-fig-0070" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 3: Nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 4: Vomiting" data-id="CD002855-fig-0071" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 4: Vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 5: Ongoing pregnancy at follow‐up" data-id="CD002855-fig-0072" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin, Outcome 5: Ongoing pregnancy at follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Mifepristone alone vs combined regimen mifepristone/prostaglandin, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0073" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Mifepristone alone vs combined regimen mifepristone/prostaglandin, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0074" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 2: Time until passing of conceptus" data-id="CD002855-fig-0075" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 2: Time until passing of conceptus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 3: Surgical evacuation" data-id="CD002855-fig-0076" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 3: Surgical evacuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 4: Additional uterotonics used" data-id="CD002855-fig-0077" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 4: Additional uterotonics used </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 5: Ongoing pregnancy" data-id="CD002855-fig-0078" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 5: Ongoing pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 6: Side effects" data-id="CD002855-fig-0079" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.6</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 6: Side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 7: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0080" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.7</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 7: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 8: Blood transfusion" data-id="CD002855-fig-0081" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.8</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 8: Blood transfusion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 9: Days of bleeding" data-id="CD002855-fig-0082" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.9</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 9: Days of bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-015.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 10: Haemoglobin level" data-id="CD002855-fig-0083" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-015.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.10</div> <div class="figure-caption"> <p>Comparison 15: Prostaglandin alone vs combined regimen (all), Outcome 10: Haemoglobin level </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-015.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0084" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 2: Blood transfusion" data-id="CD002855-fig-0085" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 2: Blood transfusion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 3: Ongoing pregnancy" data-id="CD002855-fig-0086" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 3: Ongoing pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 4: Additional uterotonics used" data-id="CD002855-fig-0087" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 4: Additional uterotonics used </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 5: Surgical evacuation" data-id="CD002855-fig-0088" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 5: Surgical evacuation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 6: Nausea" data-id="CD002855-fig-0089" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 6: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 7: Vomiting" data-id="CD002855-fig-0090" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.7</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 7: Vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 8: Diarrhoea" data-id="CD002855-fig-0091" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.8</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 8: Diarrhoea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 9: Abdominal pain" data-id="CD002855-fig-0092" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.9</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 9: Abdominal pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 10: Women's dissatisfaction with the procedure" data-id="CD002855-fig-0093" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.10</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 10: Women's dissatisfaction with the procedure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 11: Days of bleeding" data-id="CD002855-fig-0094" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.11</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 11: Days of bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 12: Time until passing of conceptus" data-id="CD002855-fig-0095" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.12</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 12: Time until passing of conceptus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-016.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Prostaglandin alone: route of administration, Outcome 13: Haemoglobin level" data-id="CD002855-fig-0096" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-016.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.13</div> <div class="figure-caption"> <p>Comparison 16: Prostaglandin alone: route of administration, Outcome 13: Haemoglobin level </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-016.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Mifepristone alone: high dose vs low dose, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0097" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Mifepristone alone: high dose vs low dose, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Mifepristone alone: high dose vs low dose, Outcome 2: Side effects" data-id="CD002855-fig-0098" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Mifepristone alone: high dose vs low dose, Outcome 2: Side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Combined regimen methotrexate/prostaglandin: timing of prostaglandin, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0099" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Combined regimen methotrexate/prostaglandin: timing of prostaglandin, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Combined regimen methotrexate/prostaglandin: methotrexate intramuscular vs oral, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0100" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: Combined regimen methotrexate/prostaglandin: methotrexate intramuscular vs oral, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Combined regimen methotrexate/prostaglandin: methotrexate intramuscular vs oral, Outcome 2: Side effects" data-id="CD002855-fig-0101" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: Combined regimen methotrexate/prostaglandin: methotrexate intramuscular vs oral, Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Combined regimen methotrexate/prostaglandin: dose of methotrexate, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0102" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: Combined regimen methotrexate/prostaglandin: dose of methotrexate, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Combined regimen methotrexate/prostaglandin: route of prostaglandin (misoprostol), Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0103" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: Combined regimen methotrexate/prostaglandin: route of prostaglandin (misoprostol), Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Combined regimen methotrexate/prostaglandin: route of prostaglandin (misoprostol), Outcome 2: Side effects" data-id="CD002855-fig-0104" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: Combined regimen methotrexate/prostaglandin: route of prostaglandin (misoprostol), Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Tamoxifen vs methotrexate (combined with prostaglandin): low‐dose tamoxifen (40 mg), Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0105" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: Tamoxifen vs methotrexate (combined with prostaglandin): low‐dose tamoxifen (40 mg), Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Tamoxifen vs methotrexate (combined with prostaglandin): low‐dose tamoxifen (40 mg), Outcome 2: Side effects" data-id="CD002855-fig-0106" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: Tamoxifen vs methotrexate (combined with prostaglandin): low‐dose tamoxifen (40 mg), Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Tamoxifen vs methotrexate (combined with prostaglandin): high‐dose tamoxifen (160 mg), Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0107" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: Tamoxifen vs methotrexate (combined with prostaglandin): high‐dose tamoxifen (160 mg), Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-023.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Tamoxifen vs methotrexate (combined with prostaglandin): high‐dose tamoxifen (160 mg), Outcome 2: Side effects" data-id="CD002855-fig-0108" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-023.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-023.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23: Tamoxifen vs methotrexate (combined with prostaglandin): high‐dose tamoxifen (160 mg), Outcome 2: Side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-023.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002855-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/urn:x-wiley:14651858:media:CD002855:CD002855-CMP-024.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: Combined regimen mifepristone/prostaglandin vs mifepristone/prostaglandin and tamoxifen, Outcome 1: Failure to achieve complete abortion" data-id="CD002855-fig-0109" src="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-024.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_t/tCD002855-CMP-024.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24: Combined regimen mifepristone/prostaglandin vs mifepristone/prostaglandin and tamoxifen, Outcome 1: Failure to achieve complete abortion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/media/CDSR/CD002855/image_n/nCD002855-CMP-024.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mifepristone (600 mg) plus prostaglandin versus mifepristone (200 mg) plus prostaglandin for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mifepristone (600 mg) combined with prostaglandin compared to mifepristone (200 mg) combined with prostaglandin for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> mifepristone (600 mg) combined with prostaglandin<br/><b>Comparison:</b> mifepristone (200 mg) combined with prostaglandin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with mifepristone (200 mg) combined with prostaglandin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with mifepristone (600 mg) combined with prostaglandin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.87 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3494<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000<br/>(75 to 114) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.95 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2432<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>459 per 1000<br/>(428 to 491) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency of intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mifepristone (600 mg) plus prostaglandin versus mifepristone (200 mg) plus prostaglandin for first trimester abortion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Misoprostol 800 µg plus mifepristone 200 mg versus misoprostol 400 µg plus mifepristone 200 mg for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Misoprostol (800 µg) compared to misoprostol (400 µg) for first trimester abortion as combined with mifepristone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> misoprostol 800 µg combined with mifepristone 200 mg<br/><b>Comparison:</b> misoprostol 400 µg combined with mifepristone 200 mg </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with misoprostol 400 µg combined with mifepristone 200 mg</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with misoprostol 800 µg combined with mifepristone 200 mg</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.51 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4424<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/>(48 to 73) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.94 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4424<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>479 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000<br/>(450 to 503) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.60 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4420<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/>(49 to 76) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency of intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Misoprostol 800 µg plus mifepristone 200 mg versus misoprostol 400 µg plus mifepristone 200 mg for first trimester abortion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Medical abortion self‐administered at home compared to administered in hospital for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Medical abortion self‐administered at home compared to administered in hospital for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> at home or hospital outpatient<br/><b>Intervention:</b> self‐administered at home<br/><b>Comparison:</b> administered in hospital </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with hospital‐administered</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with self‐administered at home</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.63<br/>(0.68 to 3.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2263<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(34 to 199) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/>(0.74 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1532<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>258 per 1000<br/>(175 to 380) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.63<br/>(0.95 to 2.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2155<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(48 to 140) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/>(0.01 to 8.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>731<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 22) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded two levels due to risk of bias, as unclear randomisation method, no allocation concealment, no blinding.<br/><sup>d</sup>Downgraded one level due to imprecision, as the 95% confidence intervals is wide and overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Medical abortion self‐administered at home compared to administered in hospital for first trimester abortion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Medical abortion administered by nurses compared to by doctors for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Medical abortion administrated by nurses compared to by doctors for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> administrated by nurses<br/><b>Comparison:</b> administrated by doctors </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with administrated by doctors</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with administrated by nurses</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.69<br/>(1.39 to 5.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3056<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(35 to 133) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.70<br/>(0.16 to 44.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1988<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(1 to 266) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1068<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded one level due to imprecision, as the 95% confidence interval is wide and overlaps no effect.<br/><sup>d</sup>Downgraded two levels due to risk of bias, as no blinding and attrition. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Medical abortion administered by nurses compared to by doctors for first trimester abortion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Oral misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Oral misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> oral mifepristone and oral misoprostol<br/><b>Comparison:</b> oral mifepristone and vaginal misoprostol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vaginal misoprostol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral misoprostol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.38<br/>(1.46 to 3.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1704<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000<br/>(63 to 168) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(1.03 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1380<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>482 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>549 per 1000<br/>(496 to 607) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Oral misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sublingual misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Sublingual misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> oral mifepristone and sublingual misoprostol<br/><b>Comparison:</b> oral mifepristone and vaginal misoprostol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vaginal misoprostol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with sublingual misoprostol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/>(0.22 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3229<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/>(19 to 180) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.93 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3543<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>595 per 1000<br/>(499 to 713) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.67<br/>(0.80 to 3.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3303<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<br/>(52 to 230) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to inconsistency of intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sublingual misoprostol compared to vaginal misoprostol for first trimester abortion in combined regimen mifepristone/prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mifepristone alone compared to mifepristone/prostaglandin for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Mifepristone alone compared to mifepristone/prostaglandin for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> mifepristone alone<br/><b>Comparison:</b> mifepristone/prostaglandin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with mifepristone/prostaglandin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with mifepristone alone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.25<br/>(0.81 to 13.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>273<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>451 per 1000<br/>(113 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded one level due to imprecision, as the 95% confidence interval is wide and overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mifepristone alone compared to mifepristone/prostaglandin for first trimester abortion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Prostaglandin alone compared to combined regimen for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Prostaglandin alone compared to combined regimen for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> prostaglandin alone<br/><b>Comparison:</b> combined regimen </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with combined regimen</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prostaglandin alone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.39<br/>(1.89 to 3.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3471<br/>(18 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>323 per 1000<br/>(255 to 408) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.74 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2722<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>412 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000<br/>(305 to 453) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.65<br/>(0.75 to 3.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1485<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>209 per 1000<br/>(95 to 461) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/>(0.03 to 3.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/>(1 to 63) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded one level due to imprecision and small sample size, as the 95% confidence interval is wide and overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Prostaglandin alone compared to combined regimen for first trimester abortion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Oral misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women undergoing first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> oral misoprostol alone<br/><b>Comparison:</b> vaginal misoprostol alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vaginal misoprostol alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral misoprostol alone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.68<br/>(1.56 to 8.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>216<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000<br/>(83 to 462) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.21<br/>(0.92 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>216<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1000<br/>(261 to 456) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.25<br/>(0.65 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/>(156 to 574) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to imprecision and small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002855-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sublingual misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Sublingual misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> first trimester abortion<br/><b>Setting:</b> hospital outpatient<br/><b>Intervention:</b> sublingual misoprostol alone<br/><b>Comparison:</b> vaginal misoprostol alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vaginal misoprostol alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with sublingual misoprostol alone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure to achieve complete abortion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/>(0.37 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2705<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1000<br/>(74 to 254) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.61<br/>(0.78 to 3.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2505<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>226 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1000<br/>(176 to 753) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Women's dissatisfaction with the procedure</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.14<br/>(0.07 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a, c</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>464 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/>(32 to 134) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00 <br/>(0.24 to 102.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220 <br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝ <br/>Very low <sup>a, d</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 <br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias, as no allocation concealment, no blinding.<br/><sup>b</sup>Downgraded one level due to inconsistency of intervention.<br/><sup>c</sup>Downgraded one level due to imprecision and small sample size.<br/><sup>d</sup> Downgraded two levels due to imprecision and small sample size, as the 95% confidence interval is wide and overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sublingual misoprostol alone compared to vaginal misoprostol alone for first trimester abortion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002855-tbl-0011"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other studies included in the review</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0015" title="ChenLY , HuLS , ChenXY , MingZS .Clinical study on the synergistic effect of medical abortion of missed abortion with Shenghua decoction Jiawei prescription. Journal of Jiangxi Univeristy of TCM2015;27(3):39. ">Chen 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 1‐3: antibiotic and oestrogen. After gestational sac passed out: oxytocin, 20 U, IM </p> <p>Day 3: mifepristone 150 mg, oral</p> <p>Day 4: misoprostol 600 µg, vaginal</p> <p>Group 1: Shenghua decoction from day 1 to 2 weeks after gestational sac passed out</p> <p>Group 2: Shenghua decoction from day 4 to 2 weeks after gestational sac passed out</p> <p>Group 3: without Shenghua decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding duration</p> <p>Time until passing of conceptus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0043" title="LiCL , ChenDJ , SongLP , WangY , ZhangZF , LiuMX , et al.Effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy: a dose-ranging randomized controlled trial. Reproductive Sciences2015;22(6):706-11. [DOI: https://dx.doi.org/10.1177/1933719114557897]">Li 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 1: oral mifepristone from 150‐50 mg</p> <p>Day 2: 200 µg of oral misoprostol</p> <p>Group 1: 6 pills of mifepristone (150 mg)</p> <p>Group 2: 5 pills of mifepristone plus 1 pill of placebo (125 mg)</p> <p>Group 3: 4 pills of mifepristone plus 2 pills of placebo (100 mg)</p> <p>Group 4: 3 pills of mifepristone plus 3 pills of placebo (75 mg)</p> <p>Group 5: 2 pills of mifepristone plus 4 pills of placebo (50 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 24/500</p> <p>Group 2: 27/500</p> <p>Group 3: 25/500</p> <p>Group 4: 22/500</p> <p>Group 5: 28/500</p> <p>Ongoing pregnancy</p> <p>Group 1: 18/500</p> <p>Group 2: 20/500</p> <p>Group 3: 18/500</p> <p>Group 4: 19/500</p> <p>Group 5: 25/500</p> <p>Nausea</p> <p>Group 1: 211/500</p> <p>Group 2: 203/500</p> <p>Group 3: 197/500</p> <p>Group 4: 109/500</p> <p>Group 5: 84/500</p> <p>Vomiting</p> <p>Group 1: 64/500</p> <p>Group 2: 62/500</p> <p>Group 3: 55/500</p> <p>Group 4: 43/500</p> <p>Group 5: 32/500</p> <p>Diarrhoea</p> <p>Group 1: 50/500</p> <p>Group 2: 50/500</p> <p>Group 3: 37/500</p> <p>Group 4: 29/500</p> <p>Group 5: 24/500</p> <p>Abdominal pain</p> <p>Group 1: 394/500</p> <p>Group 2: 380/500</p> <p>Group 3: 354/500</p> <p>Group 4: 299/500</p> <p>Group 5: 119/500</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0045" title="LiaoA , HanXJ , WuSY , XiaoDZ , XiongCL , WuXR .Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;116:211-6. ">Liao 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: mifepristone given: 50 mg, then 12 h later 25 mg, then 12 h later 50 mg, and finally, 12 h later, 25 mg mifepristone. 24 h after, 600 µg misoprostol oral (total: 150 mg) </p> <p>Group 2: mifepristone given 30 mg, then 15 mg every 12 h for 3 doses. 24 h after last dose, 600 µg misoprostol given oral (total: 75 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 11/240<br/>Group 2: 9/240 </p> <p>Ongoing pregnancy</p> <p>Group 1: 2/240<br/>Group 2: 1/240 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0085" title="WangZH .Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy. Zhonghua Fu Chan Ke Za Zhi2000;35(9):554-7. ">Wang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1:</p> <p>Day 1: mifepristone 50 mg/oral/12‐hourly, 2 doses, day 2‐7: mifepristone 25 mg oral/day</p> <p>Day 3: misoprostol 600 µg/oral, day 4‐6: misoprostol 200 µg/day</p> <p>Group 2:</p> <p>Day 1: mifepristone 50 mg, followed by 25 mg/12‐hourly/4 times</p> <p>Day 3: misoprostol 600 µg, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 18/1118</p> <p>Group 2: 59/494</p> <p>Ongoing pregnancy</p> <p>Group 1: 2/1118</p> <p>Group 2: 6/494</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0087" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multi-centre, randomized comparison between two treatment regimens. Human Reproduction (Oxford, England)1989;4(6):718-25. ">WHO 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: mifepristone 25 mg/twice daily for 3 days (total 150 mg) and sulprostone 0.25 mg IM on morning of 3rd day </p> <p>Group 2: mifepristone 25 mg /twice daily for 4 days (total 200 mg) and sulprostone 0.25 mg IM on morning of fourth day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion<br/>Group 1: 15/125<br/>Group 2: 13/126 </p> <p>Ongoing pregnancy</p> <p>Group 1: 3/125<br/>Group 2: 3/126 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0088" title="WHO Task Force on Post-Ovulatory Methods for Fertility Regulation.Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility1991;56:32-40. ">WHO 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: mifepristone 25 mg/12‐hourly, 5 doses (total 125 mg) and gemeprost 1 mg vaginally 60 h after the start of the treatment </p> <p>Group 2: mifepristone 600 mg single dose and gemeprost 1 mg vaginally 60 h after the start of the treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 12/181</p> <p>Group 2: 15/187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002855-bbs2-0096" title="WiebeER , TroutonKJ , LimaR .Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. International Journal of Gynecology and Obstetrics2006;95:286-7. ">Wiebe 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1: methotrexate 50 mg/m<sup>2</sup> followed by &gt;/72 h by 400 µg misoprostol vaginal </p> <p>Group 2: misoprostol 400 µg sublingual and 400 µg misoprostol vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to achieve complete abortion</p> <p>Group 1: 62/149<br/>Group 2: 57/149 </p> <p>Nausea</p> <p>Group 1: 53/49<br/>Group 2: 54/149 </p> <p>Vomiting</p> <p>Group 1: 17/149<br/>Group 2: 21/149 </p> <p>Diarrhoea</p> <p>Group 1: 16/149<br/>Group 2: 41/149 </p> <p>Surgical abortion</p> <p>Group 1: 9/149<br/>Group 2: 18/149 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>IM:</b> intramuscular </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other studies included in the review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/full#CD002855-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: dose of mifepristone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 600 mg vs 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.87, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 200 mg vs 100 mg (&gt; 49 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.61, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 600 mg vs 200 mg with gemeprost 1 mg vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.72, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 200 mg vs 100 mg (≤ 49 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.47, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.95, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.58, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Time until passing of conceptus &gt; 3 to 6 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.69, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: dose of mifepristone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: dose of prostaglandin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Combined dosage comparison: gemeprost 1 mg versus 0.5 mg with different dosage of mifepristone </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.31, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Misoprostol 800 µg vs 400 µg all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.51, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Misoprostol 800 µg vs 400 µg ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.79, 6.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Misoprostol 800 µg vs 400 µg &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.26, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Misoprostol vaginal 800 µg vs oral 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.59, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Misoprostol 800 µg vs 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.44, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.26, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Misoprostol 800 µg vs 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.26, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Misoprostol vaginal 800 µg vs oral 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Misoprostol 800 µg vs 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.94, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Misoprostol vaginal 800 µg vs oral 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Misoprostol 800 µg vs 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.77, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Misoprostol vaginal 800 µg vs oral 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.32, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Misoprostol 800 µg vs 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.43, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Misoprostol vaginal 800 µg vs oral 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.59, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Misoprostol 800 µg vs 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.89, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Misoprostol 800 µg vs 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Misoprostol vaginal 800 µg vs oral 400 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.89, 1.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: dose of prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: type of prostaglandin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Gemeprost vs misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.28, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 PGF2α vs misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.44, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.06, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [1.35, 5.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.28, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Time until passing of conceptus &gt; 3 to 6 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: type of prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: timing of prostaglandin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Day 3 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.05, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Day 3 vs day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.95, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Day 2 vs day 1 (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.61, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 Day 2 vs day 1 (≤ 49 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.5 Day 2 vs day 1 (&gt; 49 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.09, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.6 Day 2 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.25, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.7 Day 1 vs day 0 (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.46, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.8 Day 1 vs day 0 (≤ 49 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.38, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.9 Day 1 vs day 0 (&gt; 49 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.42, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Nausea day 3 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.96, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Nausea day 3 vs day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Nausea day 2 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.98, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.4 Nausea day 2 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.58, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.5 Vomiting day 3 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.86, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.6 Vomiting day 3 vs day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.83, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.7 Vomiting day 2 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.8 Vomiting day 2 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.9 Diarrhoea day 3 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.99, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.10 Diarrhoea day 3 vs day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.95, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.11 Diarrhoea day 2 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.09, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.12 Diarrhoea day 2 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.42, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.13 Nausea day 1 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.14 Vomiting day 1 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.82, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.15 Diarrhoea day 1 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.60, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.16 Abdominal pain day 1 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Day 3 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.78, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Day 3 vs day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.92, 3.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Day 2 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.68, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Day 2 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.19, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.5 Day 1 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.36, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Day 3 vs day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.51, 4.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Day 3 vs day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.72, 10.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Day 2 vs day 1 (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.45, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.4 Day 1 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.07, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.80, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Time until passing of conceptus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐1.27, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Day 1 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐1.27, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Days of bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.64, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Day 1 vs day 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.64, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Additional uterotonics used <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: timing of prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: administration strategy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Home vs hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.68, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Nurse vs doctor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [1.39, 5.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Home vs hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.37, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Nurse vs doctor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [1.67, 6.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.74, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.97, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.80, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.4 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.95, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Home vs hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.95, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Nurse vs doctor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.16, 44.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Additional uterotonics used <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Days of bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.25, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 Home vs hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.2 Nurse vs doctor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: administration strategy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [1.46, 3.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.03, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.51, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.49, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Bleeding volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.00 [‐2.94, 18.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Time until passing of conceptus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.71, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol oral vs vaginal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.34, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.97, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.89, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.12, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol buccal vs vaginal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Failure to achieve complete abortion (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Failure to achieve complete abortion ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.25, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 Failure to achieve complete abortion &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.18, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.09, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Ongoing pregnancy ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.11, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Ongoing pregnancy &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.01, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.94, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.94, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.76, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol buccal vs oral</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.22, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.18, 3.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.13, 3.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.80, 3.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.1 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.33, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.2 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.93, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.3 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.88, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.4 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs vaginal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.10, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.3 &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.01, 8.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.08, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.94, 4.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.27, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.25, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.3 Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.09, 1.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs oral</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.64, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.30, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.3 &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.18, 11.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.75, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.88, 7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.3 &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [0.16, 83.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.1 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.01, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.2 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.88, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.56, 8.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.4 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.79, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.14, 5.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.6 Haemoglobin level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.40, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.7 Time until passing of conceptus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐2.44, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: misoprostol sublingual vs buccal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: single vs split dose of prostaglandin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.21, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin: single vs split dose of prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 All oral vs vaginal and continuous oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.01, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 All oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.83, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.3 Vaginal and continuous oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.54, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.4 All oral vs vaginal &amp; continuous oral ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.57, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.5 All oral vs vaginal and continuous oral &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.00, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.6 All oral vs single vaginal ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.60, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.7 All oral vs single vaginal &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.8 Vaginal and continuous oral vs single vaginal ≤ 49days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.50, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.9 Vaginal and continuous oral vs single vaginal &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.43, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 All oral vs vaginal and continuous oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.11, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.2 All oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.24, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.3 Vaginal and continuous oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.63, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 All oral vs vaginal and continuous oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.65, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.2 All oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.72, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.3 Vaginal and continuous oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.87, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.1 All oral vs vaginal and continuous oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.49, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.2 All oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.53, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.3 Vaginal and continuous oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.68, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 Ongoing pregnancy at follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5.1 All oral vs vaginal and continuous oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5.2 All oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5.3 Vaginal and continuous oral vs single vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin:single vs continuous prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Mifepristone alone vs combined regimen mifepristone/prostaglandin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [0.81, 13.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Mifepristone alone vs combined regimen mifepristone/prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Prostaglandin alone vs combined regimen (all)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.89, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.2 All without Jain 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.92, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.3 With letrozole combined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.62, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.4 ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.65 [2.65, 8.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.5 &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [1.48, 3.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.6 With methotrexate combined regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.74, 5.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.7 With estradiol valerate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.25 [2.19, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Time until passing of conceptus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.05, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [2.26, 3.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 Additional uterotonics used <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.26, 3.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.5 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5.1 All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [1.18, 11.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5.2 ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.12 [3.07, 33.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5.3 &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [0.86, 12.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.6 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.1 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.11, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.2 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.3 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.4 Pelvic infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.14, 6.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.5 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.90, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.7 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.75, 3.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.8 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.9 Days of bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.13 [‐1.69, ‐0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.10 Haemoglobin level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.75, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Prostaglandin alone vs combined regimen (all)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Prostaglandin alone: route of administration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 Misoprostol oral vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [1.56, 8.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.2 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.37, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.3 Misoprostol sublingual vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.05, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.4 Misoprostol sublingual vs buccal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.71, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.5 Misoprostol repeat vs single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.78, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.6 Administration model of misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.56, 7.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.7 ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.56, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.8 &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.18, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.1 Misoprostol sublingual vs buccal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.50, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.2 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.21, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.3 &gt; 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.4 ≤ 49 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.4 Additional uterotonics used <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4.1 Misoprostol sublingual vs buccal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.5 Surgical evacuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.1 Misoprostol sublingual vs buccal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.80, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.2 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.3 Misoprostol sublingual vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.60, 8.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.4 Misoprostol repeat vs single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.78, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.5 Misoprostol nurse vs doctor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.84 [2.16, 6.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.6 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.1 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.78, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.2 Misoprostol sublingual vs buccal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.92, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.3 Misoprostol sublingual vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.50, 7.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.4 Misoprostol oral vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.92, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.5 Misoprostol repeat vs single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.00, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.6 Administration model of misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.02, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.7 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7.1 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.22, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7.2 Misoprostol sublingual vs buccal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.00, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7.3 Misoprostol sublingual vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.60, 8.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7.4 Misoprostol repeat vs single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.31, 10.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7.5 Misoprostol nurse vs doctor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.08, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.8 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.1 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.41, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.2 Misoprostol sublingual vs buccal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.99, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.3 Misoprostol sublingual vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.17, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.4 Misoprostol oral vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.60, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.5 Misoprostol repeat vs single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.71, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.6 Administration model of misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.00, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.9 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9.1 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.49, 3.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9.2 Misoprostol sublingual vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.96, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9.3 Misoprostol oral vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.48, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9.4 Administration model of misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.55, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.10 Women's dissatisfaction with the procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.1 Misoprostol sublingual vs buccal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.2 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.3 Misoprostol sublingual vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.4 Misoprostol oral vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.5 Misoprostol nurse vs doctor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.11 Days of bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.11.1 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.11.2 Administration model of misoprostol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.12 Time until passing of conceptus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.12.1 Misoprostol sublingual vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.34, ‐0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.12.2 Misoprostol sublingual vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.34, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.12.3 Misoprostol oral vs vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.31, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.13 Haemoglobin level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Prostaglandin alone: route of administration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Mifepristone alone: high dose vs low dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.74, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.19, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.07, 1.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Mifepristone alone: high dose vs low dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Combined regimen methotrexate/prostaglandin: timing of prostaglandin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.1 Misoprostol day 7 vs day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.2 Misoprostol day 5 vs day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.36, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.3 Misoprostol day 5 vs day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.38, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.4 Misoprostol day 4 vs day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.52, 1.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Combined regimen methotrexate/prostaglandin: timing of prostaglandin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Combined regimen methotrexate/prostaglandin: methotrexate intramuscular vs oral</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.51, 8.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.22, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [0.57, 42.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.18, 8.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Combined regimen methotrexate/prostaglandin: methotrexate intramuscular vs oral</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Combined regimen methotrexate/prostaglandin: dose of methotrexate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.1 methotrexate 60 mg vs 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.2 methotrexate 50 mg vs 25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Combined regimen methotrexate/prostaglandin: dose of methotrexate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Combined regimen methotrexate/prostaglandin: route of prostaglandin (misoprostol)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.84, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.94, 2.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Combined regimen methotrexate/prostaglandin: route of prostaglandin (misoprostol)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Tamoxifen vs methotrexate (combined with prostaglandin): low‐dose tamoxifen (40 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.86, 4.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.33, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.42, 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.26, 8.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Tamoxifen vs methotrexate (combined with prostaglandin): low‐dose tamoxifen (40 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Tamoxifen vs methotrexate (combined with prostaglandin): high‐dose tamoxifen (160 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.93, 4.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.54, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.28, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.34, 4.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Tamoxifen vs methotrexate (combined with prostaglandin): high‐dose tamoxifen (160 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002855-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin vs mifepristone/prostaglandin and tamoxifen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.1 Failure to achieve complete abortion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Combined regimen mifepristone/prostaglandin vs mifepristone/prostaglandin and tamoxifen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002855.pub5/references#CD002855-tbl-0035">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002855.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002855-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002855-note-0022">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD002855-note-0021">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD002855-note-0020">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD002855-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD002855-note-0017">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD002855-note-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002855-note-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002855-note-0016">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002855\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002855\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002855\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002855\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002855\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002855.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002855.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002855.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002855.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002855.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728042709"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002855.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728042713"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002855.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebac16e72f498',t:'MTc0MDcyODA0My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 